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ABSTRACT 
 Mitogen Activated Protein Kinases (MAPKs)  have been implicated in cellular 
signal transduction leading to cellular growth and differentiation in skeletal muscle following 
exercise.  This dissertation provides a review of the published literature describing the role and 
actions of the MAPK pathways particularly the ERK1/2 and p38 pathways in response to exercise 
and to nutritional supplements.  Two separate but related investigations were conducted. The first 
sought to elucidate the effect of various permutations of acute resistance exercise programming 
using a high concentric velocity (high power) back squat exercise on the mitogen activated 
protein kinases ERK1/2 and p38. The second investigation examined the effect of 8 weeks of 
resistance training with and without a multi-ingredient caffeinated pre-workout supplement on the 
same two MAPK pathways (p38 and ERK1/2), and other performance variables. Taken together 
these two studies show the response of ERK1/2 and p38 to resistance exercise programing 
variables and resistance exercise training status.  This information taken in light of the previous 
research has significant implications for strength and conditioning coaches, trainers, and 
therapists  who are seeking to increase muscular strength and hypertrophy for any number of 
reasons. 
RESEARCH ABSTRACT FOR STUDY 1 
PURPOSE: The purpose of this study was to determine the effect of  three different high power 
back squat protocols and the associated muscular power production on the MAPKs, ERK1/2 and 
p38. Power fatigue across sets was also considered METHODS: Nine recreationally trained 
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males (21.4±1.67 years, 202.9±21.4 lbs.), completed each of three speed squat protocols 
in randomized order. The three testing protocols consisted of 5 sets of 10 repetitions at 
30% of 1RM; 5 sets of 5 repetitions at 70% of 1RM; and 5 sets of 3 repetitions at 90% of 
1RM. Average and peak power measurements were obtained by Tendo Weightlifting 
Analyzer for 7 of the subjects.  Resting and post exercise blood lactate and muscle 
biopsies were taken. Western blot analysis was completed for ERK1/2 and p38 as well as 
their phosphorylaed counterparts.  RESULTS: Blood lactate increased similarly between 
the three testing protocols. Analysis of power measures identified a significant main 
effect for load (F=10.23, p= 0.004), but not for set, p >0.05). The average power was 
lower for the 90% protocol than for the 30% protocol (F= 28.96, p<0.01).  A significant 
interaction (F= 4.98, p< 0.001) was found differentiating the power production between 
the  highest and lowest loads.  This study did not show any increase in the ratio of 
ERK1/2 phosphorylation following exercise. And only a relative difference in 38 was 
found between the exercise protocols (F2,16) = 5.514, p=0.015). CONCLUSIONS: 
Resistance load appears to affect power fatigue across five sets of resistance exercise.  
The heaviest load had the highest power fatigue, while the light and  moderate  loads did 
not show any evidence of power fatigue. This study found no change in the ERK1/2 or 
p38 phosphorylation following any of the protocols. The exercise modality, training 
status of the subjects, and/or the timing may account for these findings.  
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RESEARCH ABSTRACT FOR STUDY 2 
PURPOSE: The purpose of this study was to examine the  acute and training  effects with and 
without a multi-ingredient high caffeine pre-workout supplement on squat and bench press 
power, vertical jump, and the mitogen activated protein kinase (MAPK) pathways (ERK1/2 and 
p38). METHODS: Twenty four of thirty physically active collegiate (19.5±0.269 yr) males 
completed this double blind placebo controlled investigation. Subjects in the Experimental group 
(EXP) (n=14) consumed a multi-ingredient, high caffeine (450mg) pre-exercise supplement 10-
15 minutes before each training session. Subjects in the Control group (CON) (n=10) drank a 
non-caloric placebo at the same times. Both groups completed an eight week resistance training 
program (3days/wk). Squat and bench press power and vertical jump were measured before and 
after the 8 weeks of resistance training. Muscle biopsies were also taken before and after the first 
and last workouts of the training program. Separate repeated measures ANOVAs were performed 
to test for differences between EXP and CON groups for power as well as total, phosphorylated 
and the relative ratio of phosphorylated to total ERK1/2 and p38. RESULTS: Squat power 
measurements showed a significant group by time interaction (F1/22 =4.857, p=0.038). Vertical 
Jump and bench press power did increase with training, but did not differ between groups. Not 
only did ERK phosphorylation and the ratio of phophorylation increase after exercise (F (1,22) = 
4.854, p = 0.38; F(1,22) = 5.159, p=0.033) but there was evidence that the ERK1/2 exercise 
response was is reduced after weeks of training (F(1,22) = 6.607, p=0.017). P38 was increased 
following training, but there was no effect of exercise bout on the phosphorylation on p38 in this 
study.  DISCUSSION: Only one of the three power measurements, squat power, was benefited by 
the supplementation. EXP group than the CON group, the supplement did not affect any ERK1/2 
or p38 measures.  Eight weeks of pre-workout supplementation may provide some muscle 
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performance benefit when combined with resistance exercise training.  This study supports 
previous findings that ERK1/2 phosphorylation following exercise is blunted by exercise training.   
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CHAPTER 1: INTRODUCTION  
 Muscle cells are capable of responding to diverse environmental stimuli. Chronic 
responses to such stimuli cause muscle cells to adapt over time. The metabolic, mechanical, 
environmental, and hormonal trigger coordinated cellular signaling pathways that ultimately alter 
gene expression within the cell. The differential gene activation dependent on these stimuli allow 
for the up or down regulation of  the genes that will be most crucial for adaptation and resistance 
to the same cellular perturbation or condition if it were experienced again in the future. To state 
the same more concisely, the altered gene expression (termed adaptation) that is observed in 
response to a cellular stress or stimuli, must be linked by some cellular mechanism.  Thus, 
cellular signaling pathways and interactions are critical mechanisms responsible for the 
adaptation response.    
 Mitogen activated protein kinase (MAPK) pathways have been implicated as one 
of many contributors to the cellular responses following resistance training. The MAPKs are a 
family of ubiquitous proteins, prevalent in mammalian cells. These MAPK signaling pathways  
transmit cellular signals via phosphorylation of  threonine,  and tyrosine residues (reviewed in 
Widegren, Ryder, & Zierath, 2001). Within the ‘classical’ MAPK pathways there are four 
primary parallel MAPK signaling pathways that are affected by different upstream kinase 
cascades (Widegren et al., 2001). As you can see in the Figure 1 below, these pathways appear to 
be entirely separate independent of other signaling cascades, however this is not necessarily the 
case as will be discussed more completely in chapter two .   
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Figure 1. Simplified MAPK Cascade based upon the review by Widegren (2001). The 
Stars  highlight the two pathways that are the focus in this paper.  
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Many extracellular and intracellular stimuli  for MAPK activation have been identified. 
These include hormones, cytokines, mechanotransduction, and metabolic disturbances (Li et al., 
2005; Martineau & Gardiner, 2001; Widegren et al., 1998; Wright, 2007; Yan, Li, & Akimoto, 
2007). Once activated, the MAPK proteins will activate or modify one or many other downstream 
protein kinases, gene promoters for example,  altering gene expression within the cell (M Gibala, 
2009).  The MAPK pathways, together, have important regulatory functions in almost every 
aspect of the myocyte activity. These include cellular proliferation, differentiation in stem cells as 
well as hypertrophy, mitochondrial biogenesis of differentiated myocytes. Each of these will be 
discussed in greater detail in chapter 2 of this work.  
Because the MAPK pathways are crucially involved in the some of the most important 
cellular functions in skeletal muscle, they are also considered a therapeutic target particularly for 
the treatment muscle wasting diseases and the age related loss of strength and muscle mass 
(Williamson, Gallagher, Harber, Hollon, & Trappe, 2003), as well as cancer and inflammatory 
diseases (Malemud, 2007).  MAPK pathways also affect muscle size and strength relating to 
athletic performance (Bassel-Duby & Olson, 2006). In addition to skeletal muscle hypertrophy, 
the MAPK pathways appear to be involved in the progression of insulin resistance and diabetes in 
the skeletal muscle (Cusi et al., 2000; Hawley, 2004; McGee & Hargreaves, 2004; Vichaiwong et 
al., 2009). Finally, the MAPK pathways represent a point of convergence and mechanism of 
control complementary to many other signaling pathways.  The medical, performance, and basic 
research related implications of the MAPK pathways are not mutually exclusive and there are 
many potential benefits to understanding the MAPK pathways more fully.    
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STATEMENT OF THE PROBLEM 
 MAPKs are shown to respond to a wide variety of exercise and contraction types 
and it is likely that these stimuli affect the MAPK pathways by multiple mechanisms. What 
remains to be elucidated is the differential changes in the ERK1/2 pathway in human skeletal 
muscle following different types of resistance training. Also it is known that the MAPK pathways 
respond to a wide variety of stimuli related to nutrition and dietary supplementation. Lastly the 
response of these pathways to consistent resistance training has not been clearly elucidated. 
RATIONALE FOR THE INVESTIGATIONS 
 While MAPKs especially ERK phosphorylation and activity increases following 
resistance exercise, there is very little research examining the exact relationships between this, the  
training status, and resistance exercise prescription variables.  A more complete understanding of 
the relationship between resistance exercise and resistance exercise training would allow a more 
precise and efficient application of resistance exercise for sporting populations, the general 
population, and the elderly. It is likely that a more thorough understanding of the cellular 
response to exercise would be of the greatest benefit to those for whom muscle hypertrophy is 
most crucial, such as is the case in elderly individuals who are frequently limited in daily function 
and self-care because of muscle atrophy. The therapeutic application of resistance exercise  for 
such individuals is necessary to preserve function, maintain independence,  and  retain quality of 
life.   
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STATEMENT OF THE PURPOSES 
INVESTIGATION I:  
 The purpose of this study was to determine the MAPK (ERK1/2 and p38) 
responses to three different protocols of maximal power back squat and elucidate the role of 
muscular power in resistance training on the changes in these MAPKs.  
INVESTIGATION II:   
 The purpose of this study was to examine the effects of resistance exercise and a 
high-caffeine, multi-ingredient pre-workout supplement on the phosphorylation of p38 and ERK 
proteins before and after 8 weeks of training. In order to clearly delineate the contribution of the 
exercise and the supplement plus exercise a double blind placebo controlled training design was 
utilized.   
STATEMENT OF HYPOTHESES 
INVESTIGATION I: THE EFFECT OF  THREE DIFFERENT HIGH POWER SQUAT PROTOCOLS ON MAPK 
EXPRESSION AND  PHOSPHORYLATION 
1. Acute bouts of resistance exercise will increase the phosphorylation of  
ERK1/2. 
2. A dose response relationship will exist between the muscular power of the 
resistance exercise and the relative changes in phosphorylation of the 
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MAPKs (ERK1/2, and p38).  Muscular power is most likely to be highest in 
the low or moderate intensity loads 
3. Within the context of this study’s high power resistance exercise protocols 
MAPK p38 will be activated to a greater extend in the exercise protocol with 
the highest volume (total number of repetitions) but not intensity of work as 
measured by the load or relative load used.  The p38 protein is unlikely to be 
related to power output.  
INVESTIGATION II: THE EFFECT OF EIGHT WEEKS OF RESISTANCE TRAINING WITH AND WITHOUT 
PRE-WORKOUT SUPPLEMENTATION ON MAPK EXPRESSION AND PHOSPHORYLATION. 
1. Acute bouts of resistance exercise will increase the phosphorylation of  ERK 
1/2.   
2. Habituation to a total body resistance exercise bout  via regular resistance 
training will assuage relative MAPK responses to exercise at the same 
relative intensity. 
3.  The pre-exercise supplement will produce a MAPK response to an acute 
bout of resistance exercise that is different than the placebo based upon the 
possible actions of one or more of the ingredients of the supplement. 
RATIONALE FOR THE  SCOPE OF THE INVESTIGATIONS 
PHILOSOPHICAL RATIONALE FOR APPLIED RESEARCH 
 While basic scientists have at their ready a wide range of research tools and 
techniques to undertake the complete biochemical study of the MAPK or any other cellular 
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signaling pathway, the studies presented here take a decidedly applied approach to the problem at 
hand.  Basic molecular and biochemical analysis of the cellular signaling process is vital to the 
advancement of our understanding in this area, but without a robust body of more applied studies 
the implications of such basic research remains theoretical.  The assumption that whole muscle in 
a biologically complex human being, having an endocrine, immune, and  neruoregulatory 
systems, would respond identically to analogous but not identical stimuli (bicycling vs. vacuum 
induced cyclical stretch)  is abhorrently arrogant and demonstrably false. 
 The proposed studies were not undertaken to produce new evidence of the 
mechanistic actions of the MAPK  pathways, this research was undertaken in an effort to 
corroborate the previously identified  basic observations in live whole humans undertaking 
resistance exercise as they might their ‘native habitat’.  The exercise programs used in this study 
are substantially similar to those that athletes or avid exercisers might complete and performed in 
a setting more similar to the typical gym. Thus this research was designed to be more externally 
valid than previous resistance training investigations on the same topic.  
CHAPTER 2: REVIEW OF LITERATURE 
INTRODUCTION 
 The mitogen activated protein kinase (MAPKs) pathways have been implicated 
as one of cellular responses following resistance training and many other exercise and nutritional 
stimuli. The MAPKs are a family of ubiquitous proteins, prevalent in mammalian cells including 
skeletal muscle. These MAPK signaling pathways  transmit cellular signals via phosphorylation 
(reviewed in Widegren et al., 2001). There are four parallel MAPK signaling pathways that are 
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affected by different upstream kinase cascades, (shown in figure 1 in chapter 1), (Widegren et al., 
2001). While the pathways work in conjunction with one another and there is evidence of 
crosstalk between these pathways (Widegren et al., 2001), it is thought that each is particularly 
sensitive to different stimuli (Widegren et al., 1998) and that associated scaffolding proteins, 
proteins that physically link kinases within a cascade.  Similarly the role of the MAPK proteins as 
regulators of muscle specific gene promoters, (Aziz, Liu, & Dilworth, 2010).  
 Many extracellular and intracellular prompts for MAPK activation have been 
identified. These include hormones, cytokines, reactive oxygen species, mechanotransduction, 
and metabolic disturbances, to list a few. (Li et al., 2005; Makanae, Kawada, Sasaki, Nakazato, & 
Ishii, 2013; Martineau & Gardiner, 2001; Widegren et al., 1998; Wright, 2007; Yan et al., 2007). 
Once activated, the MAPK proteins will differentially affect other downstream protein kinases 
and gene promoters,  altering gene expression within the cell (M Gibala, 2009).  The MAPK 
pathways, together, have important regulatory functions in cellular hypertrophy, differentiation, 
mitochondrial biogenesis and apoptosis.  
 Because the MAPK pathways are crucially involved in the some of the most 
important cellular functions, they are also considered a therapeutic target particularly for the 
treatment of muscle wasting diseases and the age related loss of strength and muscle mass 
(Williamson et al., 2003), as well as cancer and inflammatory diseases (Malemud, 2007).  MAPK 
pathways also affect muscle size and strength relating to athletic performance (Bassel-Duby & 
Olson, 2006). In addition to skeletal muscle hypertrophy, the MAPK pathways appear to be 
involved in the progression of insulin resistance and diabetes in the skeletal muscle (Cusi et al., 
2000; Hawley, 2004; McGee & Hargreaves, 2004; Vichaiwong et al., 2009). Finally, the MAPK 
pathways represent a point of convergence and mechanism of control complementary to many 
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other signaling pathways.  The therapeutic, sport performance, and basic research related 
implications of the MAPK pathways are not mutually exclusive and there are many potential 
benefits to understanding the MAPK pathways more fully.    
 Among the many signaling stimuli that the MAPKs are associated with, the 
cyclic adenosine mono-phosphate (cAMP) and GTP-binding protein coupled receptors (GPCR) 
present a particularly interesting scenario. GPCRs and cAMP are upregulated by exercise and 
various nutraceuticals, which are herbal other chemical substances that affect various tissues 
beyond the expected role of foods.   These cellular receptors are also common therapeutic drug 
targets.  Thus a better understanding of this pathway is an important first step in developing more 
effective and targeted therapeutic interventions and drugs to combat muscle wasting diseases or 
any of the other conditions where the MAPKs might play a role.  
 The purpose of the following review is threefold.  In the first section a general 
overview of the MAPK signaling cascades as they are understood to occur in skeletal muscle 
Special emphasis will be placed upon the p38 and ERK1/2 pathways.  In the second section a 
more thorough review of the literature related to the role of these same two MAPK pathways in 
important skeletal muscle differentiation, hypertrophy, senescence regulation, and insulin 
resistance.   The third portion of this review will examine the relationship of the MAPK signaling 
cascades to various forms of exercise, nutritional and orthomolecular compounds.    Finally in the 
conclusion I will present the argument that there is sufficient basic science evidence to support 
further research into the nutritional and exercise interventions to affect the p38 and ERK1/2 
pathways in humans.  
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SECTION I: THE MITOGEN ACTIVATED PROTEIN KINASES SIGNALLING CASCADES 
 The mitogen activated protein kinases are actually at least four parallel signaling 
cascades that have a common scheme of action.  There are actually many total MAPKs in 
mammalian cells that can be grouped into four/five functional families. One family includes the  
extracellular related protein kinases (ERK1 and ERK2), collectively ERK1/2. A second 
extracellular related protein kinase of a much larger size, ERK 5, is prevalent in mammalian cells. 
In addition to the ERK1/2 MAPKs, there are two common isoforms of the c-Jun NH2 Terminal 
kinase (JNK1 and JNK2), collectively JNK1/2.  Lastly, there is the p38 protein so named for its 
38kD size.   
 Each of these MAPKs is activated by upstream mitogen activated protein kinase 
kinases (MAPKKs or MKK).  Each parallel branch of the MAPKs has one or more specific MKK 
associated with it.  MKKs are themselves protein kinases that act to activate MAPKs via dual 
phosphorylation on both tyrosine and threonine residues (Garrington & Johnson, 1999). The 
MKKs are also activated by phosphorylation by upstream mitogen activated protein kinase kinase 
kinases (MAPKKK or MKKK).  The MKKK are capable of phosphorylating MKKs on serine 
and threonine residues.  Again each of the MAPK cascade families has a specific MKKK 
associated with it.  Lastly upstream of the MKKKs are a variety of GTP binding proteins and 
other low molecular weight proteins that could be considered MKKKKs (Garrington & Johnson, 
1999).  GTP related proteins such as Ras and Cdc42 are the proteins responsible for linking 
receptor activity to the MAPK pathways.  
  The activity of these GTP related proteins may be aided by scaffold proteins that 
help to bring the selected G-protein subunits and kinases of a pathway together (Garrington & 
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Johnson, 1999; Mayor, Jurado-Pueyo, Campos, & Murga, 2007). Combined, the specificity of 
scaffold proteins, MKKKKs and MKKKs and MKKs and MAPKs create a very complex system 
of specific signaling (Raman, Chen, & Cobb, 2007). A problem in defining the precise MKKKK 
and GTP-binding and especially the scaffold protein interactions is that the majority of this 
research is performed in saccharomyces cerevisiae or isolated cells and these interactions may 
not clearly represent the complexities of a multicellular organism responding to more complex 
and varied stimuli simultaneously.  Studies in human and animal models have demonstrated 
general activation patterns of the MAPK, especially within the three most studied MAPK 
signaling pathways in skeletal muscle, p38, JNK1/2 and ERK1/2.  
MAPKS A JUNCTION CHECKPOINT IN SIGNAL CASCADES 
 Collectively, the MAPKs appear to be junctions for several major signaling 
pathways within the cell.  Some of the cellular pathways associated with MAPK changes are, 
mechanical deformation or mechanotransduction (Boppart, Burkin, & Kaufman, 2006; Boppart, 
Hirshman, Sakamoto, Fielding, & Goodyear, 2001; Martineau & Gardiner, 2001), beta-adrenergic 
signaling (Crespo, Cachero, Xu, & Gutkind, 1995; Frost, Nystrom, & Lang, 2004; Zheng et al., 
2000), calcineurin signaling (Rauch & Loughna, 2008), calcium-calmodulin signaling (Xu et al., 
2002) cytokine signaling (de Alvaro, Teruel, Hernandez, & Lorenzo, 2004) and many others. 
These varied cellular signals all seem to activate one or more of the MAPK proteins.   
 Because the MAPK pathways are perfectly positioned to propagate signal 
transduction to a variety of stimuli, the MAPKs are also a good candidate mechanism of trans-
pathway regulatory action. The MAPK family ERK1/2, for example, has been shown to be a 
major regulator of tuberous sclerosis complex (TSC) which in turn regulates mammalian target of 
rapamycin (mTOR) (Kwiatkowski & Manning, 2005).  Therefore, ERK in particular can 
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influence or modify signals of nutrient and energy availability in mTOR, a known regulator of 
protein synthesis.   Similarly p38 has been shown to regulate the important skeletal muscle gene  
‘master regulator’ MyoD, as well as play a critical role in the PGC-1 signalling pathway that is 
associated with insulin sensitivity, energy availability, and mitochondrial biogenesis.    
 The upstream, and downstream targets of the different isoforms varies in 
response to its activating stimuli, the cell type or stage of the cell cycle, and possibly hundreds of 
other factors with the cell (Aziz et al., 2010; Guttridge, 2004; Liu et al., 2012). Thus contrary to 
the simplified classical model of the MAPK cascades that is depicted in Figure 1 (in chapter 1),  
the complexity of the signaling cascades of ERK1/2 and p38 cannot be understated..  Figure 2 
below demonstrates that complexity for just one aspect of p38 function.  Figure 2 shows a 
proposed mechanism by which MyoD which was previously thought to act in an MAPK 
independent mechanism is now believed to be reliant on p38 for its demethylation and activation 
of the skeletal muscle specific genes in differentiating skeletal muscle cells (Aziz et al., 2010). 
In the figure p38 not only phosphorylates MEF2d, but it is done as part of a complexed 
protein structure. Part B of figure 2 demonstrates the MAPKs are not true linear signaling 
cascades, but the amount of crosstalk is significant(Junttila, Li, & Westermarck, 2008). 
Finally part C of figure 2 shows that these cascades do respond to more than one 
upstream signal, and that there is significant crosstalk not only among MAPK pathways, 
but as shown in the case of ERK1/2, there is crosstalk with other signaling pathways 
(Berki, Boldizsar, Szabo, Talaber, & Varecza, 2001). This evidence Thus this single 
example of one of p38’s known roles shows that the previously held simplified model of 
separate, true, and linear cascades for the MAPKs is incorrect.  
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Figure 2a. Proposed model of p38 action in activation of  repressed muscle specific genes 
during differentiations. The complexed protein shown in A above is proposed to activate 
a demethylation enzyme. Modeled after proposed interatctions presented in Aziz et al. 
(2010). Figure 2b.Demonstrates crosstalk within the MAPK cascades and the multiple 
and overlapping downstream targets proposed for these cascades. The figure is base upon 
the work of Junttila et al. (2008).  
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JNK PATHWAY 
 The first of the four pathways to be examined here is the JNK pathways. JNK 
MAPKs were originally identified as stress activated protein kinases. There are actually three 
JNK isoforms but only JNK1 and  JNK2 are fund in muscle (Krishna & Narang, 2008). The 
MAPKKs responsible for JNK activation are the mitogen activated protein kinase kinase 4 and 7 
(MKK4 and MKK7) and the MKKKs associated with JNK are MEKK1-4 (Krishna & Narang, 
2008).  Additionally the JNKs are activated by the upstream kinases RAC1/2, Cdc 2, and  SEK1. 
JNK becomes maximally activated when phosphorylated on both threonine and tyrosine residues.   
 Like other MAPKs the activation of JNK can result in downstream changes in 
gene expression as well as modification of other kinases. More than 50 possible JNK substrates 
have been identified, though little research has been performed to clarify most of these 
interactions (Bogoyevitch, Ngoei, Zhao, Yeap, & Ng, 2010).  JNK is capable of phosphorylating 
transcription factors like c-jun, jun D, jun B, and ATF-2 (reviewed in Krishna & Narang, 2008). 
One of the most often studied JNK associated events is the upregulation of the AP-1 promoted 
genes (Krishna & Narang, 2008). JNK has been shown to play a critical role in cytokine 
signaling, especially in response to TNF-α (Borer, 2003)  and are involved in cytokine production 
(Frost et al., 2004).  JNK has also been linked to carbohydrate metabolism and insulin (Hirosumi 
et al., 2002; Moxham, Tabrizchi, Davis, & Malbon, 1996), epinephrine (Napoli et al., 1998), and 
cell apoptosis (Krishna & Narang, 2008). Also, JNK is activated by several forms of exercise and 
muscle overload (Boppart et al., 1999; Carlson, Fan, Gordon, & Booth, 2001; Goodyear, Chang, 
Sherwood, Dufresne, & Moller, 1996). Over-expression of JNK in mice also increased the 
phosphorylation of several other proteins including ERK 1/2 and its downstream target p90, AKT 
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and its downstream target p70, and Glycogen synthase kinase 3, (Fujii et al., 2004).  This is 
further evidence of th junctional role of MAPKs. 
ERK 1/2  
 The ERK 1/2 pathway was both the first identified and most researched among 
all the MAPK pathways (Krishna & Narang, 2008).  This pathway has gained a great deal of 
attention because it responds strongly to many types of exercise as well as growth factors 
(Krishna & Narang, 2008). The common activation pathways for ERK1/2 include MEK1 and 
MEK2 as well as MKK and Raf MKKKs. Upstream of this are small G-proteins like Ras.  Of all 
the MAPKs, ERK has the greatest amount of evidence for transport to the nucleus upon activation 
(Krishna & Narang, 2008).  ERK does have substrates at the cell membrane, in the cytoplasm, 
and within the nucleus, however.  Some of the many substrates include phospholipase 2, MEF-2, 
c-myc, and CREB (Krishna & Narang, 2008).   
The genes and protein substrates activated by ERK are involved in a wide variety of cellular 
activities including cell differentiation (Al-Khalili, Kramer, Wretenberg, & Krook, 2004), growth,  
survival (Aronson et al., 1998), and apoptosis (Krishna & Narang, 2008).  More specifically ERK 
is activated by insulin (Napoli et al., 1998), various forms of exercise (Martineau & Gardiner, 
2001; Osman, Hancock, Hunt, Ivy, & Mandarino, 2001; Yu, Blomstrand, Chibalin, Krook, & 
Zierath, 2001), as well as GPCRs (Krishna & Narang, 2008).   
THE P38 PATHWAY 
 The p38 MAPK pathway shares commonalities with both the JNK and ERK 
pathways.  There are four isoforms of p38 (α, β, γ, and δ) and these isoforms appear to be 
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selectively phosphorylated by different upstream MKKs (Krishna & Narang, 2008). MEK3 and 
MEK6 are the most traditionally associated with p38, but the MKKs in the JNK pathway (MKK4 
and MKK7) also activate some forms of p38, thus accounting for the crosstalk between these two 
pathways. MAPK p38 has been shown to respond to MTK1, AKL, ASK1, and TAK1, all 
MKKKs.  Lastly, the same G proteins in the ERK pathways (Ras, Raf) can activate p38 as well.   
 When activated, p38 may translocate to the nucleus, but like ERK there appear to 
be a variety of p38 substrates at the membrane, in the cytoplasm, and in the nucleus (Krishna & 
Narang, 2008). Many transcription factors are phosphorylated and activated by p38 including: 
ATF-1, ATF-2, Sap1, p53, MEF2A and NFAT.  PGC-1α, a transcriptional co-activator associated 
with mitochondrial genes, also seems to be activated by p38 (Knutti, Kressler, & Kralli, 2001).  
Other evidence calls into question any direct interaction between p38 and PGC-1α, but instead 
demonstrates that p38 activity removes the PGC-1α repressor p160 myb (Fan et al., 2004; Knutti 
et al., 2001).  
 Physiological activation of p38 has been shown for growth factors , interleukins, 
and insulin like growth factor (Krishna & Narang, 2008).  MAPK p38 has been implicated as a 
major mechanism in skeletal muscle atrophy signaling (Glass, 2005). Increased levels of p38 
phosphorylation (Kim et al., 2009) or activity (Zhang, Chen, & Fan, 2007) have been shown to 
exert transcriptional control over atrogin 1,  also called muscle atrophy F-box (MAFbx), and 
Muscle specific ring finger 1 (MuRF-1).   The p38 induced increases in MAFbx and MuRF-1 
have been observed with disuse atrophy (Zhang et al., 2007), cast immobilization (Kim et al., 
2009), and TNF-induced atrophy, (Li et al., 2005). It is also been observed in serum starved cell 
cultures (Kim et al., 2009), and reactive oxygen species (Li et al., 2005).  Because the FOX-O 
transcription factor has also been shown to be responsible for MuRF-1 and atrogen-1 
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transcription, one hypothesis is that p38 directly activates FOXO (Li et al., 2005).  
 This proves again the xomplexity as p38 is both associated with cellular 
differentiation in skeltal muscle as well as atraophy in other circumstances.  
ERK 5  
 Little is known about the contribution of ERK 5 (also known as BigMAPK)  in 
skeletal muscle (Kramer & Goodyear, 2007). Both ERK5 and MAPK/ERK kinase 5, its upstream 
kinase, have been found in significant quantities in the skeletal muscle (Zhou, Bao, & Dixon, 
1995). Its contribution to the skeletal response to exercise has not been clearly established, but it 
is known that during the differentiation of myoblast to fused myotubes, the relative expression of 
ERK5 does not change (Al-Khalili et al., 2004) .  Future research may elaborate its involvement 
or lack there-of in the signaling mechanisms within skeletal muscle.  
SECTION II. PRIMARY  IMPLICATIONS FOR P38 AND ERK1/2 SIGNALLING IN 
MUSCLE DIFFERENTITAION, GROWTH, AND HYPERTOROPHY. 
EMBRYONIC STEM CELL AND SKELETAL MUSCLE SATELLITE CELL DIFFERENTIATION 
 Differentiation is a complex, vital, and often irreversible cellular activity and is 
controlled by combination of signaling cascades. To put the regulation of muscle into perspective 
consider that there are at least 5 separate signaling cascades that affect muscle size either by 
stimulating hypertrophy or atrophy, (Guttridge, 2004).  For a simplified overview of the most 
completely understood of those pathways see the review by Guttridge (Guttridge, 2004). 
Arguably the MyoD signaling is of greatest interest here.  MyoD is considered the ‘master 
regulator’ or skeletal muscle gene products (Aziz et al., 2010).  MyoD expression and function 
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seems to be a defining characteristic of functional muscle cells so its expression during the 
cellular differentiation process is a crital component (Aziz et al., 2010; Liu et al., 2012).The 
MAPK proteins especially p38 are known to play a crucial role in the differentiation and 
development of myoblasts and myocites (Aziz et al., 2010; Knight et al., 2012; Liu et al., 2012).   
In this section, evidence of the mechanisms by which p38 and ERK1/2 are involved in the 
regulation of muscle hypertrophy will be considered.  
 Durring myocyte differentiation mesodermal stem cells are the precursors to 
myocytes. The mesodermal cells exit the cell cycle and differentiate into mononuclear 
monoblasts.  This process is regulated by the muscle regulatory factors ( MRFs) a family which 
includes MyoD, Myf5, myogenin and MRF4 (Liu et al., 2012).  This differentiation is also 
controlled tightly by the p38 protein kinase signaling pathways.  Fascinatingly, it appears that 
several of the isoforms of p38 play a unique and separate roles in this process.  The p38γ isoforms 
has been shown to prevent the cell from exiting the cell cycle and becoming a differentiated cell 
(Gillespie et al., 2009). Newer research clearly shows that the asymmetric cell division in the 
proliferation phase is associated with the Par Complex activation of p38α/β occurs in one 
daughter cell while myoginin and MyoD initiate the differentiation in the other daughter cell 
(Troy et al., 2012). The p38α isoform, on the other hand, is required for differentiation to occur 
(Liu et al., 2012). Specifically p38α has been shown to regulate several muscle specific genes, 
chromatin remodeling enzymes, and also the expression of at least one of the MRF family 
proteins, as myogenenin in reduced in p38α knockdown cells. (Liu et al., 2012). Up-regulating 
myogenein leads to a down regulation of genes involved in progression of cell differentiation, 
therefore p38α and p38γ appear to regulate opposite outcomes for the cell. Stated more simply 
p38α either initiates or supports the exit from the cell cycle and differentiation into a myocyte 
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(Liu et al., 2012), while the p38γ isoform prevents the differentiation (Gillespie et al., 2009).  It 
has also been observed that loss of both p38γ and α  within a cell produce irreversible 
quinescence, (Jones et al., 2005). 
  In an effort to further understand the binding homology differences between 
p38α and γ isoforms and to understand more fully the opposing roles these proteins play in the 
differentiation, Knight et al. (2012), found that though the binding domains are 75% identical (H. 
Wang, Xu, Xiao, Jiang, & Wu, 2008), It is in fact there localization, and not their substrate 
specificity that determines the oppositional roles of these two isoforms.  Specifically p38α 
appears to increase substantially in the cytoplasm during the differentiation process, and that p38γ 
cannot fulfill the cytosolic role of p38α (Knight et al., 2012). A second observation that helps to 
explain the contradictory roles of p38 in the differentiation process, is that both p38α and γ 
appeared to produces different outcomes based upon the stage of the cell cycle, cell phenotype,  
and/or another regulatory mechanism yet to be discovered (Jones et al., 2005; Knight et al., 
2012).   I It is likely that future research will clarify that many mechanisms are responsible for 
additional modification of the p38 protein kinase activity.    
 While differentiation of the stem cell into a myoblast through the aforementioned 
mechanisms, p38α has an additional role as well in the fusion of the myoblasts into the functional 
multi-nucleated myocyte as well (Liu et al., 2012).  This second role is equally essential for 
normal muscle development.   Liu et al. (2012) dramatically demonstrated that the p38α 
knockdown cells were able to differentiate when myogenein was over expressed to compensate, 
but that myoblast fusion into myocytes was not possible without adequate levels of p38α.  Further 
investigation into this showed that p38α regulates several genes previously shown to be important 
for myoblast fusion.  Liu et al. found that tetraspanin CD53 was likely the primary protein 
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involved in this fusion process as it is not only up-regulated  during fusion but also localizes to 
the site of the fusion along the membrane (Liu et al., 2012). Furthermore, a tetraspanin CD 53 
knockdown mouse model had significantly reduced muscle size (Liu et al., 2012).  
 Clearly p38 has a critical role in the differentiation process of skeletal muscle in 
mammalian cells as well as fusion of myoblasts.  It is no great leap therefore to see that it must 
play a significant role in muscle hypertrophy as a regulator and essential part of the satellite cell 
differentiation and fusion to the existing myofibers. The role of ERK1/2 in the proliferation and 
differentiation is only just becoming more clear.  There is far less known about the role of 
ERK1/2 on cellular differentiation than p38.  What is known is that ERK1/2 and MEK1/2 
phosphorylation increased as well as cellular differentiation and myogenesis when the antagonist 
protein kinase Cθ isoform was knocked down (Marino et al., 2013).  Contradictory findings from 
Feng et al. (2013), on the other hand show that inhibition of ERK1/2 enhanced myoblast 
differentiation so long as the ERK1/2 was available for early myogenic processes. This study also 
demonstrated that a microRNA secquence miR-133 was tied into a negative feedback loop with 
ERK1/2 and its phosphorylation (Feng et al., 2013).  miR-133 is known to regulate protein at the 
post transcription level. A possible interpretation of these findings and a way to resolve the 
apparent conflict with the Marino et al. research would suggest that ERK1/2 is necessary for 
proliferation of the undifferentiated cells, but that differentiation can only occur when ERK1/2 
and its phosphorylation are decreased or alternately by the modifying actions of the ERK1/2 
activity antagonist miR-133 (Feng et al., 2013; Marino et al., 2013). 
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A POSSIBLE ROLE FOR ERK1/2 AND P38 IN G PROTIEN RECEPTOR SIGNALLING 
    The class of membrane receptors that associate with GTP-binding proteins (G 
proteins) are often identified as G protein coupled receptors (GPCRs). There are many types of 
GPCRs that have been further classified into adenosine, adrenergic, angiotensin II,  endothelin  
receptor types,  and other families based on homology and function (Borer, 2003). GPCR super 
family  all contain seven membrane spanning segments, where the extracellular portion is 
associated with agonist binding specificity and the intracellular of the protein is associated with G 
protein specificity (reviewed in Lynch & Ryall, 2008).   Each of these categories has multiple 
receptor subtypes and isoforms.   
 GPCR are by definition associated with G-proteins and use some specific G-
protein for signal transduction.  In addition to the wide variety of GPCRs and their agonist 
binding specificities, there are also G protein specificities for each receptor type. G-proteins are 
heterotrimeric proteins with subunits identified as α, β and γ. Both the α and γ subunits are 
attached to the membrane by a covalently linked lipid tail in most cases. The α subunit also has a 
GTP/GDP binding and hydrolysis site as well.  
  In the inactive state, the trimeric G protein is associated with GDP.  Cytosolic 
interaction with an activated GPCR causes the trimeric G protein to release GDP and associate 
with GTP instead.  The α subunit will undergo a conformational change following GTP binding 
that can (but not always) cause the alpha subunit to dissociate from the βγ complex. Both the α 
and the βγ subunits can play a role in the signaling pathways. 
 G-proteins are varied in their structure and function. Based upon the target specificity, the G 
proteins are further classified as Gs, Gi, Gq/11, and G12/13, (Post & Brown, 1996).  Each receptor 
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type is likely to recruit predominantly one type of G protein.  Beta adrenergic signaling 
predominantly couples with Gαx and Gαi subunits to activate  adenylyl  cyclase and α2 adrenergic 
receptors recruit primarily Gαq/11 (reviewed in Lynch & Ryall, 2008).  Further complexity arises 
in this system with at least 27α, 7β, and 12γ subtypes that can form in any combination (Lynch & 
Ryall, 2008). Thus, although the family of beta receptors may all appear to be similar, they will 
have a combination of agonist specificity and G protein specificity, resulting in different 
catecholamines activating different receptors and having different effects within different cell 
types.  
Beta-agonist Stimulated Transduction 
 There is a great deal of research demonstrating that β-agonists induce 
hypertrophy and/or repair of cardiac, smooth, and skeletal muscle (Beitzel, Sillence, & Lynch, 
2007; Izevbigie & Bergen, 2000; Lynch & Ryall, 2008; Ryall et al., 2008; Zheng et al., 2000).  
There are three subtypes of β-adrenergic receptors that are expressed in varying quantities in 
different tissues.  Of these subtypes, the β1 and β2 appear to be most plentiful in skeletal muscle 
(Lynch & Ryall, 2008) and the β2 receptors appear to be the primary stimulators of cAMP 
(Roberts & Summers, 1998).  cAMP itself is not the only possible activator of downstream 
kinases however.  Both the Gα and Gβγ  are capable of activating various signaling proteins 
upstream of the MAPKs. First, the role of cAMP in MAPK signaling will be explored, followed 
by possible direct G-protein signaling. 
Gαs is the G protein subunit that is responsible for the activation of adenylyl  cyclase, causing the 
conversion of ATP into cAMP.  cAMP then interacts with various cell proteins to begin the 
kinase signaling cascades, including the MAPKs.  Specifically cAMP can interact with an 
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exchange protein directly activated by cAMP (EPAC) or one of several other activators of Rap-1 
(Goldsmith & Dhanasekaran, 2007).  From there the Rap-1 will signal one of the Raf isoforms, 
and from there the cascade continues to MEK1/2 and ERK1/2 (Goldsmith & Dhanasekaran, 
2007).  This direct pathway leading to ERK activation may not hold true for all cell types, in 
other instances the ERK activation observed following GPCR activation is mediated by protein 
kinase A (PKA)  . The specific activation mechanism of ERK in skeletal muscle has not yet been 
determined.     
The activation of p38 by Gαs is likely to be caused by a PKA mediated pathway as well.   Beta 
adrenergic induced phosphorylation of p38 is not direct, but is instead PKA dependent in 
cardiomyocytes (Zheng et al., 2000), but the exact proteins connecting PKA activation to MKK3 
and MKK6 (upstream of p38), have not been identified (Goldsmith & Dhanasekaran, 2007).  In 
PKA dependent ERK1/2 phosphorylation, the upstream protein Ras is likely involved. Thus, both 
ERK1/2 and p38 may be activated in a PKA dependent manner, while more direct cAMP 
signaling is possible in some cell types, though it has not been clearly established for skeletal 
muscle. JNK does not apparently respond to Gαs signaling (Goldsmith & Dhanasekaran, 2007).  
The inhibitory Gi class of G-proteins are also able to stimulate ERK1/2 through the involvement 
of phospholipase C (Goldsmith & Dhanasekaran, 2007).  There is however no evidence that p38 
can be activated in this manner.  Instead Gi inhibits adenylyl cyclase activity and would 
theoretically then inhibit PKC stimulation of p38 as well as ERK1/2.  
β-adrenergic receptor activity may also play an important role in the muscle repair and 
hypertrophy following injury, (Beitzel et al., 2007; Ryall et al., 2008).  Ryall et al. (Ryall et al., 
2008)  found that a single injection of formoterol resulted in significantly higher strength at seven 
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days without any detrimental cardiac hypertrophy. Moreover Beitzel and colleagues (Beitzel et 
al., 2007) found that there was a threefold increase in receptor density following injury, which 
increased the ability of regenerating muscle to respond to beta agonists.  In that study, the 
receptor density in fenoterol (an agonist) treated animals did decrease, but the cAMP levels 
following isoproterenol were only reduced in the fast twitch extensor digitorum longus muscle of 
the rats (Beitzel et al., 2007) indicating a muscle type specificity. Elevated adenylyl cyclase 
activity and cAMP production may also be the mechanism by which the β-agonist is able to 
increase the rate of injury repair.  Thus, the next piece of the puzzle is to understand the signaling 
that is occurring downstream of cAMP. There have been no specific mechanisms of action 
determined with regard to muscle injury and repair.  
 
ESTROGEN, ESTROGEN –RELATED RECEPTOR,  AND VITAMIN D RECEPTOR SIGNALING 
  Estradiol and its estrogen receptors (α and β subtypes) are important regulators of 
cellular activity including activation of Elk-1transcription factor and the cAMP response element 
binding protein (CREB) that are known to increase or decrease downstream transcription (Ronda 
et al., 2007).  Similarly while the vitamin D receptor differs significantly in homology, it does 
share many similarities in the downstream signaling pathways with the estrogen signaling axis 
(Ronda et al., 2007). Estrogen signaling is dependent upon both the ERK1/2 and the p38 MAPKs, 
as well as protein kinase C and src (Ronda, Buitrago, & Boland, 2010). Similarly it has been 
shown that there are significant anti-apoptotic effects of estradiol are mediated by p38 (Ronda, 
Vasconsuelo, & Boland, 2010). While estradiol does interact with both of its receptor types, there 
may be additional mechanisms by which the steroid hormone alters cellular signaling that are yet 
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to be elucidated. It has been noted that activation of both the estrogen (Hatae, Takami, Lin, 
Honda, & Inoue, 2009) and the vitamin D receptor (Thota et al., 2014) up-regulates the synthesis 
and the translocation of estrogen receptors to the cell membrane in various cell types. It appears 
that this rapid increase in estrogen receptor number occurs by an ERK1/2 dependent mechanism 
(Hatae et al., 2009).  The up-regulation of estrogen receptors may create a positive feedback 
mechanism by which cells become increasingly sensitive to estrogen signals. While there are a 
host of similarities between the estrogen receptor and the vitamin D receptors, the  unique role of 
vitamin D signaling is discussed more completely in the ‘nutrition: vitamins’ section later in the 
paper. 
 The Estrogen-related receptors are named for their close structural similarities to 
the estrogen receptors, but do not bind estradiol, in fact its physiologically significant ligand has 
not been clearly established (Murray & Huss, 2011). Even so this receptor appears to regulate 
myocyte differentiation as well as a host of metabolism related genes via an ERK1/2 dependent 
mechanism (Barker et al., 2014).  
   
TESTOSTERONE STIMULATED MUSCLE HYPERTROPHY 
 While the exact mechanism remains unknown, administration of testosterone to 
rats resulted in an increase in p38 phosphorylation and was linked to the resultant muscle 
hypertrophy by concomitant administration with a p38 inhibitor (Brown, Hikim, Kovacheva, & 
Sinha-Hikim, 2009).  This may be related to its role in the activation of differentiation of satellite 
cells as it was also associated with up-regulated Notch1 and Notch2 proteins, which are thought 
to be transmembrane receptors related to proliferation and differentiation (Brown et al., 2009).   
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OBESITY, INSULIN RESISTANCE AND TYPE II DIABETES 
 Because of the treatment potential, involved one of the most exciting areas of 
research is the role of p38 in insulin resistance. Koistinen (2003) showed that there was 
significantly higher basal p38 phosphorylation in insulin resistant skeletal muscle obtained from 
type II diabetics. This may indicate that p38 plays some role in the maladaptive physiologic 
changes. Similar changes to p38 phosphorylation state have also been observed in diabetic 
adipocytes as well (Carlson, Koterski, Sciotti, Poccard, & Rondinone, 2003). At this time it 
appears that the changes in p38 do not cause the muscle to take on the insulin resistant 
characteristics (Koistinen et al., 2003). The up-regulated p38 levels may instead be the result of 
poor energy availability within the cells such as the reduced availability of glucose within the cell 
(Koistinen et al., 2003).  Hirosumi, (2002) clearly shows that many members of the MAPK 
family respond to cytokines that may be elevated in the diabetic or insulin resistant condition. 
Thus the unregulated p38 levels may also be more directly caused by the inflammatory markers 
associated with diabetes and insulin resistance.    
 In addition to aberrant basal phosphorylation levels, Koistinen (2003) also found 
that in vitro exposure of normal and insulin resistant muscle to insulin produced divergent 
changes. Whereas normal muscle showed an increase in p38 phosphorylation following insulin 
exposure, the insulin resistant muscle actually saw a significant drop in phophorylation from its 
elevated basal condition.   More recent evidence takes this a step further showing that exercise 
training can not only lower basal phosphorylation levels in the insulin resistant muscle 
(Vichaiwong et al., 2009), but that increased phosphorylation of p38 was associated with 
increased GLUT 4 transporter protein mRNA post exercise (Hussey, McGee, Garnham, 
McConell, & Hargreaves, 2012).  This may indicate that the elevated p-p38 in insulin resistant 
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skeletal muscle is not maladaptive but instead a reactive and positive adaptation given the 
reduced function of the insulin regulated glucose transport. 
 What is known definitively is that p38γ is tightly associated with the PGC-1α a 
major regulator of gene products associated with substrate utilization including mitochondrial 
biogenesis as more completely described in the review article by Lira, Benton, Yan, and Bonen, 
(2010).   Because of this potentially therapeutic effects the relationship of p38 to insulin resistant 
skeletal muscle and exercise should be investigated further.  
 While p38 is the MAPK typically associated with insulin resistance there is also 
evidence that the ratio of phosphorylated to total ERK2 is lower in obese rats than their lean 
counterparts (Osman et al., 2001). Furthermore, seven weeks of exercise training for these rats 
restored some of the ERK2 activity both at rest and following insulin administration (Osman et 
al., 2001).   
SECTION III: EXERCISE AND NUTRITIONAL MODULATORS OF P38 AND ERK1/2 
SIGNALLING 
EXERCISE, CONTRACTION, AND STRETCH 
 Traditional endurance training, long duration moderate intensity (Benziane et al., 
2008), as well as short bouts of intense interval exercise  have been shown to increase the 
activation of p38 and this has been associated circumstantially (M. Gibala et al., 2009) and 
causally (Little, Safdar, Cermak, Tarnopolsky, & Gibala, 2010) with up-regulated expression of 
Proliferator Activated Receptor-γ Coactivator-1α (PGC-1α). For a more complete review of the 
relationship between p38 and PGC-1α see Lira et al. (Lira et al., 2010).  It should also be noted 
that there is evidence that exercise not only affects the ERK1/2 and p38 pathways of the 
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exercising muscle, but p38 of non-exercised limbs also seems to respond indicating that there 
may be both local and systemic pathways of activation (Widegren et al., 1998) .  
 Muscular contraction has been shown to activate both p38 and ERK1/2 in some 
(Galpin, Fry, Chiu, Thomason, & Schilling, 2012; Moore, Atherton, Rennie, Tarnopolsky, & 
Phillips, 2011; Ryder et al., 2000), but not all (Terzis et al., 2010)  studies. Furthermore, the type 
of contraction or other modifications to the resistance training or contraction protocols may all be  
contributing to the skeletal muscle adaptations and the MAPK signaling response to exercise as it 
has in other signaling pathways (Terzis et al., 2010). Hulmi et al. (2012) found that a hypertrophy 
protocol, high volume and moderate intensity), produced significantly greater increases in 
ERK1/2 phophorylation over a maximal strength (low volume, high intensity) protocol while 
Terzis et al. (2010) did not see a significant change in ERK1/2 in any of their protocols. These 
two studies were in agreement that p38 was equally increased in all exercise protocols indicating 
that it is not differentially activated by modifications to the resistance training protocol (Hulmi et 
al., 2012; Terzis et al., 2010).    
 In addition to the volume and intensity, power, rate of force development and 
frequency may also have a role.  Type II muscle fibers had had markedly higher phosphorylation 
of p38 following lengthening contractions (Tannerstedt, Apro, & Blomstrand, 2009; Wretman, 
Widegren, Lionikas, Westerblad, & Henriksson, 2000).  Thus activities that produce a greater rate 
of force development, and those that require recruitment of a greater number of type II muscle 
fibers would produce greater whole muscle changes in p38 phosphorylation.  Franchi et al.  
(2014) found that the morphological characteristics of the muscle, fascicle length and the 
pennation angle, were differently affected by either concentric or eccentric exercise training. 
These differences were circumstantially associated with MAPK activation in the eccentric group 
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but not in the concentric group (Franchi et al., 2014). Lastly, the frequency of training appears to 
affect the activation of several signaling pathways in rats (Coffey et al., 2007). Frequent training 
bouts with incomplete recovery between bouts increased the p38 activity likely in association 
with increased cytokine signaling or phosphorylation of AMPK and may suppress IGF-1 and Akt 
associated hypertrophic activity. ERK1/2 was not tested in this study (Coffey et al., 2007).  Much 
further research is necessary to fully elucidate the roles each resistance training variable has on 
the cellular response to the exercise.  
 . 
 Aging 
 Age appears to also influence the MAPK response to exercise and muscle 
contraction.  In comparison to young adult skeletal muscle muscle from aged rats demonstrated a 
much blunted increase in ERK1/2 phosphorylation immediately following contraction 
(Parkington, LeBrasseur, Siebert, & Fielding, 2004). There were however no differences 6 hours 
after the contraction, nor where there any differences between the young and old muscle’s 
expression or phosphorylation of ERK1/2 in the basal state (Parkington et al., 2004).   This 
stunted signaling was found to be true in both the tibialis anterior and in the plantaris muscles 
(Parkington et al., 2004).  This does however conflict with a previous study in humans that 
showed a significantly higher phosphorylation of both ERK1/2 and p38 in the basal state of older 
subjects (Williamson et al., 2003).  
 A second discrepancy is that Williamson et al. (2003), showed a decrease in 
ERK1/2 and p38 phosphorylation following resistance exercise.  From these two studies it can be 
concluded that ERK1/2 phosphorylation does not increase as much or is in fact decreased 
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following exercise in aged muscle, but the contradictory findings regarding differences in p38 
signalling are hard to resolve between these two studies (Parkington et al., 2004; Williamson et 
al., 2003).  These studies explored the immediate and intermediate timed effects of exercise on 
ERK1/2 and p38.  When measured 24 hours after the exercise bout ERK1/2 phosporylation was 
significantly increased compared to young subjects while p38 phosporylation was not different 
between the age groups (Kosek & Bamman, 2008).  Kosek & Bamman followed up with 16 
weeks of resistance training 3 times per week, and tested the response to exercise after the 16 
weeks as well.  Interestingly the older men had much elevated p38 phosphorylation after 16 
weeks of training compared to the initial exercise bout (Kosek & Bamman, 2008).  Kosek & 
Bamman (2008) like Parkington (2004) attributed this to “overstress” of the muscle of the aged 
individuals, but in this case they were referring to chronic overstress and not acute overstress 
though that notion was not well supported.    
Training Status 
 It is known that exercise training produces diminishing returns over time. What is 
not well understood is the molecular signaling changes that account for this ceiling effect.  The 
role of training status in MAPK activation is a fascinating area that has only just begun to be 
studied.  An early study by Yu et al. (2003) found that there was greater MAPK activation in 
untrained vs trained male after intervals of cycling.  This seems to indicate that the blunted 
response to exercise with training is accompanied by reduced activation of the associated MAPK 
and other signaling activities. Similar results were observed in other non-MAPK signaling 
cascades (Coffey et al., 2006). Contradictory evidence shows ERK1/2 activation was not different 
after 16 weeks of  training in young men however (Kosek & Bamman, 2008).  
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Mechanotransduction 
 One of many possible mechanism by which exercise activates the MAPK 
proteins is mechanotransduction (Wozniak, Kong, Bock, Pilipowicz, & Anderson, 2005). 
Furthermore mechanotransduction as an upstream activator of ERK1/2 and or p38 would also 
explain why passive stretch can induce some of the same alterations in phosphorylation state of 
the MAPKs as exercise, resistance training, and muscle contractions of various types (Boppart et 
al., 2001; Hanke et al., 2010; Rauch & Loughna, 2005, 2008). Similarly, mechanotransduction 
would help to explain the dose response relationship between amount of tension and the degree of 
change in MAPK and other cellular signaling pathways (Martineau & Gardiner, 2001).  Not all 
studies agree that the MAPK ERK1/2 and p38 are among the downstream targets of 
mechanotransduction (Dentel, Blanchard, Ankrapp, McCabe, & Wiseman, 2005), or that their 
role is essential in muscle hypertrophy (Sasai et al., 2010).  In fact Dentel et al., (2005)  adds 
credence to the idea that p38 responds to the metabolic (cAMP) and not the force producing 
related stimuli of exercise. Kosek & Bamman (2008) propose that the increased p38 
phosphorylation state in older men compared to younger men post resistance training is evidence 
that the decreased hypertrophic response in older men is caused by the elevated p38 
phosphorylation as it is an indicator of “over-stress” to the muscle.  This would indicate the p38 is 
acting as an antagonist to the Distrophin associated protein complex signaling cascade (one of 
many mechanotransduction pathways).  Mechanotransduction is not a single pathway, but instead 
involves multiple different parallel and series signaling components including a variety of 
autocrine signals (Adams & Bamman, 2012).  A complete review of the intricacies of 
mechanotransduction is well beyond the scope of this paper.  Two excellent reviews on the topic 
include Adams and Bamman (2012), and Wang& Thampatty (2006). 
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Timecourse of  ERK1/2 and p38 changes in response to exercise and mechanical 
perturbations 
 Possibly the best direct study of the topic of the timecourse of the alterations of 
the MAPK proteins was performed by Carlson et al. (2001) who performed oblation of the 
gastrocnemius in rats and then sacraficed the  animals after 1, 6, 12, and 24 hours of overload.  
Under these conditions the p38 remained elevated across all timepoints while the ERK 2  was 
increased for the first 12 hours and then returned to baseline (Carlson et al., 2001). This doesn not 
readily  equate the human exercise model however in that the oblation model constitutes a 
continual resistance stimulus that does not end for the durration of the 24 hours.  Studies in 
humans that have used  resistance activity that is intermittenent and finite have demonstrated 
increased ERK1/2 ranging from minutes into the exercise bout (Galpin et al., 2012) and up to two 
hours post exercise (Taylor, Wilborn, Kreider, & Willoughby, 2012). 
NUTRITIONAL INFLUENCES AND DIETARY SUPPLEMENTS 
 Some evidence suggests that there are nutrients and nutraceutical agents that also 
have the ability to alter MAPK phosphorylation (Ulrich-Merzenich, Zeitler, Vetter, & Kraft, 
2009). It is unlikely that the nutritional components can directly affect activity of the MAPKs, but 
instead may alter the cellular status of the various stimuli that MAPKs are sensitive to.  As 
examples, both forskolin and caffeine have been shown to increase cellular cAMP (T. E. Graham, 
Battram, Dela, El-Sohemy, & Thong, 2008; Seamon, Padgett, & Daly, 1981) .  Both of these are 
available in supplement form and marketed to bodybuilders and the fitness minded, but the 
cellular mechanisms of their effectiveness have not been established. Because ERK1/2 and p38 
are implicated in so many cellular signaling pathways these two kinases are also prime targets for 
activation of the various signaling mechanisms that neutraceuticals, phytonutrients, and vitamins 
33 
 
 
activate ultimately leading in many cases to altered protein expression.   Examples of this 
interaction are included here, but an exhaustive list is beyond the scope of this paper.  
Furthermore, a review of this topic does not seem to be available.  
Commercialized multi-ingredient supplements  
 Beyond these isolated compounds nutritional and ergogenic supplements have 
become increasingly common as competitive athletes and recreational exercisers alike seek to 
maximize performance and aesthetic outcomes from their efforts.  A plethora of multi-ingredient 
pre and post workout supplements flood the market advertising dramatic enhancements to the 
exercise program.  As Ormsbee, (2012) notes, the need for double blind placebo controlled trials 
on such supplements to help limit the marketers “misappropriation of the underlying science.” 
After first having identified the concern over these poorly understood multi-ingredient 
concoctions, it is also important to note that multiple previous studies have demonstrated these 
market available supplements do provide significant but modest augments to exercise training 
alone, (Falk, Heelan, Thyfault, & Koch, 2003; Hoffman et al., 2008; Ormsbee et al., 2012). 
 
Amino Acids & Creatine 
 Amino acid supplementation is widely known to affect the mTOR hypertrophyic 
pathway, but much less is known about the effect if that any amino acids have on the MAPK 
pathways.  Karlsson et al.(2004) found BCAA supplementation before exercise had no effect on 
the ERK1/2 or p38 pathways.  Sparse research on the role of creatine yields no effect over 
exercise alone (Deldicque et al., 2008) and a contradictory finding indicating p38 is involved in 
creatine’s hypertrophic properties (Deldicque et al., 2007).    
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Caffeine potentially affects the MAPK cascades 
 There are many studies demonstrating the ergogenic effects of caffeine ingestion 
in skeletal muscle contraction (Reading, Murrant, & Barclay, 2003; Sipido, 2007), lipid 
mobilization (Donsmark, Langfort, Holm, Ploug, & Galbo, 2003), and possibly carbohydrate 
metabolism, but there is a general lack of research into the mechanisms of these actions (T. E. 
Graham et al., 2008) and the results of such studies are far from conclusive as others refute such 
findings, (T. E. Graham, Helge, MacLean, Kiens, & Richter, 2000). There are several possible 
mechanisms by which caffeine could affect muscle signaling and function both directly and 
indirectly. First caffeine can indirectly alter cellular contractile and metabolic functions via 
activity of the adenosine receptor rich CNS. Caffeine ingestion is also associated with increased 
levels of epinephrine and possibly also norepinephrine and thus can cause an increase in beta-
adrenergic receptor signaling (reviewed in T. E. Graham et al., 2008).  The generally accepted 
mechanism of caffeine signaling involves the inhibition of adenosine Gi associated GPCRs  and 
thus the increase of cAMP (T. E. Graham et al., 2008).  A meta-analysis of several smaller (low 
sample number) studies demonstrates that caffeine is most effective at raising cAMP levels when 
combined with exercise (T. E. Graham et al., 2008). Thus the efficacy of caffeine’s cAMP 
increase may also be enhanced by allosteric modifications to either the receptor or some other 
related signaling component.  The contribution of nor-epinephrine, epinephrine, and acetycholine 
have not been adequately studied adequately to determine if they are a cause of the 
exercise/caffeine synergism.   
While the above mentioned association between caffeine and cAMP is well established, very little 
is known about the cellular signaling from that point. There are at least three cellular pathways 
that may be conveying the caffeine signals. These include the protein kinase A pathway (PKA), 
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the protein kinase C pathway (PKC), and calcium calmodulin signaling. Involvement of the 
calcium calmodulin cascade, supported by evidence in cardiomyocytes (Magne, Couchie, Pecker, 
& Pavoine, 2001; Sipido, 2007) and skeletal muscle (Reading et al., 2003), is beyond the scope of 
this paper.   Hormone sensitive lipase activity within skeletal muscle appears to be up-regulated 
following caffeine exposure, but this occurs by a mechanism other than the ERK1/2 related 
changes that occur following exercise (Donsmark et al., 2003).  This may also be related to the 
yet to be determined involvement of the MAPKs.  
Caffeine is a widely utilized stimulant in multi-ingredient sports supplements and as a 
standalone ergogenic aid.  This is particularly true for supplements that are marketed toward 
resistance training athletes of all levels.  Caffeine is known to affect muscle in a couple different 
ways including changes in sarcoplasmic reticulum activity and endocrine activity (Reviewed 
inTarnopolsky, 2008, 2010), but interestingly there is also evidence that caffeine may alter 
cellular signaling in Saccharomyces cerevisiae (Truman, Kim, & Levin, 2009), and in mammals 
is known to affect enzymatic activity regulating glycogen, (Chesley, Howlett, Heigenhauser, 
Hultman, & Spriet, 1998) or not (T. E. Graham et al., 2000). 
It is thought that the majority of caffeine’s muscle specific regulation is due to its role as 
an adenosine receptor antagonist (T. E. Graham et al., 2008).  At least for different adenosine 
receptor types have been identified including type 1 and 2 which has been shown to be expressed 
on the cell membrane of skeletal muscles (Lynge & Hellsten, 2000; Lynge, Schulte, Nordsborg, 
Fredholm, & Hellsten, 2003).  Given the prevalence of adenosine receptors in skeletal muscle 
caffeine should raise cAMP levels and thus result in MAPK phosphorylation changes (Schulte & 
Fredholm, 2003a, 2003b) particularly for p38 though this is contested by (Lynge et al., 2003). 
Graham (2001), has in fact shown that cAMP is elevated following exercise with caffeine 
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compared to exercise alone.  What has not been shown is whether this is also associated with 
changes in the MAPK phosphorylation status or downstream targets of the MAPKinases.  By 
comparing Lynge et al. (2003) and Graham (2008) the co-contributions of exercise and caffeine 
in signaling has not been tested and appears to be different than caffeine alone.   
Two significant confounding variables challenge the elucidation of this information.  
First caffeine in vivo likely increases epinephrine and or norepinephrine levels (T. E. Graham et 
al., 2000).  Thus in vivo, it would be difficult to separate caffeine’s direct action on the skeletal 
muscle with those changes that result by neurological and endocrine interaction.  Based upon the 
work of Napoli  (1998) it is reasonable to assume that such neurological and endocrine 
interactions might contribute to changes in JNK and/or p38 activity, but is unlikely to affect 
ERK1/2 phosphorylation.  The second confounding factor is the role that calcium regulation and 
signaling plays in both exercise, caffeine, and endocrine responses within the cell.  By multiple 
underlying causes Calcium-calmodulin signaling could also result in changes to MAPK 
phosphorylation and activity (T. E. Graham et al., 2008).   
Based upon the complex and multifaceted signaling mechanism that occur when exercise 
is performed with caffeine, it is likely that p38 and other MAPK cascade signaling proteins are in 
fact activated.   Future investigations into the role of long term caffeine supplemented exercise 
should consider the possibility that MAPK signaling cascades are contributing the cellular 
adaptation process.  
 Direct interaction between caffeine and MAPKs has been observed via a novel 
phosphorylation of MAPK analog in budding yeast, (Truman et al., 2009).  No direct interactions 
between MAPK and caffeine have been identified in mammalian cells, however.  
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Vitamins alter MAPK signaling in skeletal muscle 
 Methylcobalamin, an active analog of vitamin B12 in animals, has been shown to 
increase C2C12 cell proliferation and migration in a ERK1/2 dependent manner (Okamoto et al., 
2014).  Furthermore, cells exposed to this form of B12 also demonstrated resistance to apoptosis 
also by a ERK1/2 dependent mechanism (Okamoto et al., 2014).  Vitamin C on the otherhand 
reduced muscular hypertrophy due to overload via synergist oblation and was associated with 
decreased p70s6k phosphorylation as well as reduced ERK1/2 phosphorylation (Makanae et al., 
2013). Though it remains unclear whether the decreased phosphorylation of ERK1/2 was a causal 
or merely a coincidental event in the decreased hypertrophy, the authors proposed that the anti-
oxidant activity of vitamin C may have reduced reactive oxygen species thus reducing ERK1/2 
phosphorylation via that mechanism (Makanae et al., 2013). 
 In addition to vitamin C and B12, there is strong evidence that vitamin D3 affects 
cellular gene expression via the MAPK pathways though vitamin D3 can be syntheysized by 
humans with exposure to UV radiation, it is also listed as an essential dietary nutrient.  
1α(OH)2D3, the active steroid form of vitamin D3 in mammals has been shown to increase 
phosphorylation of  the ERK1/2, p38, and AKT kinases, by a combination of vitamin D receptor 
dependent(Choi, Park, Cho, & Lee, 2013; Ronda et al., 2007), and independent mechanisms(C. 
Buitrago, Pardo, & Boland, 2013).   Some of the findings in this area include the phosphorylation 
ofP38 and ERK1/2 as well as the downstream targets of p38 CREB and Elk-1transcription factors 
following exposure to 1α(OH)2D3 (Ronda et al., 2007). 1α(OH)2D3 also increased Akt 
phosphorylation in a src dependent manner and perhaps via PI3K as well (C. G. Buitrago, 
Arango, & Boland, 2012).  Further study demonstrated that knockdown of the vitamin D receptor 
did no completely eliminate the activation of these signaling cascades and leave open the 
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possibility that there are additional intermediaries, mechanisms, and signaling cascades involved 
including possibly calcium signaling, and protein kinase C (C. Buitrago et al., 2013). It was 
further noted that the 1α(OH)2D3 associated cellular changes were both similar to and synergistic 
with 17β-estradiol (Ronda et al., 2007).  
 In addition to the cellular signaling cascades activated in normal cells, 
1α(OH)2D3 administered by injection to rats normalized markers of inflammation, muscle damage 
following a high intensity muscle damaging exercise protocol (Choi et al., 2013). This indicates 
that the additional vitamin D3 was able to mitigate the muscle damage, possibly by decreasing the 
cytokine and immune cell response following the exercise damage as has been observed in 
humans previously (Barker et al., 2014). The supplementation group had lower creatine kinase 
levels, lower lactate ddgydrogenase levels in the plasma as well as reduced phosphorylation of 
AMPK, p38, ERK1/2, and Akt (Choi et al., 2013). Similarly NF-κB was also reduced in the 
supplement rats(Assy et al., 2011; Choi et al., 2013). While the phosphorylation states of these 
protein kinases was normalized, the effect on the subsequent adaptation was not studied.  Further 
research needs to establish whether this blunted hypertrophic signaling response is also associated 
with reduced adaptive hypertrophy or myosin heavy chain expression compared to the non-D3 
supplement controls. On the other hand Choi et al. points out that this may be one mechanism to 
explain previous research findings that vitamin D3 can reduce muscle soreness in healthy (Barker 
et al., 2013) and diseased populations (Assy et al., 2011). 
Resveratrol 
 The phytonutrient resveratrol is found in high concentrations in grape skin, red 
wine, and Japanese knotweed extracts.  While it’s health benefits have been touted for many 
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years, the mechanisms behind its actions are not yet fully understood.  Previously resverstrol has 
been studied for its effect on vascular endothelium, but there is also evidence that resveratrol 
leads to healthy adaptation in skeletal muscle as well.  Deng et al. demonstrated that resveratrol 
which has a chemical structure similar to estradiol can also bind to the estrogen receptor and 
modulate muscular glucose uptake via improved insulin sensitivity, and by non-insulin dependent 
mechanisms (Deng, Hsieh, Huang, Lu, & Hung, 2008).  It was further demonstrated that ERK1/2 
and p38 were necessary for the early phase response (1 hour) to resveratrol in C2C12 cells, and 
p38 and PI3k were required for adaptations observed at 14hours (Deng et al., 2008). The 
immediate co-activation of ERK1/2 and p38 is highly indicative of that observed in estradiol 
activation of the estrogen receptor (Ronda et al., 2007) .  The late phase p38 activation concurrent 
with PI3k is similarly characteristic of src mediated cross-talk (C. G. Buitrago et al., 2012). 
Forskolin 
 Forskolin, a diterpene extract from the Coleus forskohlii plant native to India, has 
been used in traditional Ayruvedic medicine, traditional Indian healing practice, to treat a variety 
of diseases (Ammon & Muller, 1985). Forskolin is a potent stimulator of adenylyl cyclase 
resulting in dose dependent increased concentrations of cAMP (Ammon & Muller, 1985; Roberts 
& Summers, 1998; Seamon et al., 1981).  This increase in cAMP is both its apparent mechanism 
of action and the reason that the effects of forskolin mimic β-agonists which also increase cAMP 
concentrations within the cell (Ammon & Muller, 1985). 
Forskolin has been shown to produce increased lipolysis (Lynch & Ryall, 2008) , increased 
protein synthesis (Thompson et al., 1996),  and  increased muscle hypertrophy (Godard, Johnson, 
& Richmond, 2005);  again these effects are similar to those observed following B2AR agonist 
40 
 
 
administration. Of primary interest is the study by Goddard and colleagues which demonstrated 
forskolin stimulated increases in lean body mass while simultaneously reducing adiposity when 
supplementation occurred in conjunction with an exercise program (Godard et al., 2005).  This 
increased muscle mass accretion and reduction in body fat  due to forskolin is reminiscent of that 
observed with various B2AR agonists (reviewed in Lynch & Ryall, 2008).  Based upon the 
parallels between the B2AR signaling and that observed in Forskolin signaling, it seems plausible 
that there may be some shared signaling components between them.   
 While it is known that forskolin increases cyclic AMP via activation of adenylyl  
cyclase (Litosch, Hudson, Mills, Li, & Fain, 1982), the signaling pathway that downstream of 
cAMP has not been as well established, especially in skeletal muscle.  Many proteins and 
pathways have been explored as downstream responders to forskolin including the PI3K-AKT 
pathways (Richmond, 2007; Richmond, Touchberry, & Gallagher, 2009), protein kinase C (PKC) 
(Iijima et al., 2002) and the MAPK pathways (Cao, Medvedev, Daniel, & Collins, 2001; Crespo 
et al., 1995; Iijima et al., 2002)  in various cell types. As mentioned above, the strongest evidence 
is for cAMP to affect MAPKs via the PKA pathway, except for possibly ERK1/2.  
 Specific evidence linking p38 MAPK activation following forskolin 
administration comes from a study performed with adipocytes.  Cao and colleagues (Cao et al., 
2001) have been demonstrated that p38 is phosphorylated in response to both forskolin, protein 
kinase A agonist (Isoproterenol), as well as a B3AR agonist (CL316243). Similarly, Zheng and 
colleagues (Zheng et al., 2000), found that cardiomyocytes also increased p38 activity in a protein 
kinase A (PKA) dependent manor.  
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 As mentioned, PKA may not be the only intermediary for cAMP signaling, 
however.  p38 was also temporally associated with protein kinase C (PKC) phosphorylation in 
response to forskolin in cardiomyocytes  (Iijima et al., 2002).  In this same study however ERK, 
and not p38, was identified as the critical kinase leading to phosphorylation of p70/85S6K a 
downstream target associated with protein synthesis (Iijima et al., 2002). Again as mentioned 
above the MAPKs may respond to Gi proteins via PKC, but p38 has not been shown to work by 
this mechanism.    
CONCLUSION 
The purpose of this review has been to examine the stimulatory role of G protein coupled 
receptors, especially β-adrenergic receptors, in cAMP related MAPK signaling. This review 
began by defining the general schema of MAPK activation and examined how the parallel but 
related MAPKs are activated by a complex set of upstream MKKs MKKKs and MKKKKs, 
which allow this set of protein kinases to act as a signaling junction for many different cell 
stimuli. A brief overview of the three key MAPKs in skeletal muscle signaling clearly 
demonstrated the differential activation patterns of the MAPKs in response to key stimuli  
including steroid hormones like estradiol and vitamin D3. The ERK1/2 and p38 changes that are 
observed in response to exercise and nutritional and supplementation were also briefly reviewed.  
This brief glimpse into these ubiquitous, variable, and inherently complicated cellular signaling 
cascades only more emphatically demonstrate the  importance for a cell to tightly regulate these 
proteins and there kinase activity .   
 Though much more research needs to be completed to identify how these two 
proteins and their various isoforms interact with other signaling mechanisms to couple isolated 
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and integrated stimuli with a coherent set of protein modifications and  gene transcription 
adaptations.  Additionally, it is clear that the exact mechanisms of this complex signaling system 
remain undetermined.   Furthermore, there is a need for applied human research demonstrating 
how complex systems of stimuli like resistance exercise training and nutritional supplementation 
might affect both the cellular signaling cascades as well as the adaptive response on a more global 
scale.  
 
 
 
 
 
CHAPTER 3: METHODOLOGY 
STUDY 1.  SKELETAL MUSCLE MAPK ACTIVATION DURING HIGH POWER 
RESISTANCE EXERCISE  
 
STUDY DESIGN 
 The purpose of this study was to determine the MAPK (ERK1/2 and p38) responses to three 
different resistance exercise bouts where the back squat exercise was performed with maximal 
concentric velocity resulting in the greatest  power production possible given the bar’s load. In 
order to elucidate these responses to different resistance exercise loads and different power 
outputs, this study used a repeated measures design in which each of the study volunteers 
completed each of three resistance exercise bouts in a randomized order. A muscle biopsy was 
taken before and within ten minutes after the exercise bout.  These muscle samples were then 
used to determine changes in the MAPK phosphorylation occurring during each exercise bout.  
To ensure complete physical recovery from the previous testing sessions, subjects completed each 
treatment trail no less than one week apart.  Also to prevent muscular fatigue and in order to 
minimize the effect of outside physical activity on the measures of MAPK phosphorylation,   
subjects were asked to refrain from exercise for 36 hours before each testing session.  A timeline 
of the study is shown below (Figure 3.1) to elucidate the data collection points and the 
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organization of the study.  
 
SUBJECTS 
 Nine healthy active collegiate males who had squatted regularly participated in this study.  Prior 
to participation, each volunteer completed a pre study orientation in which informed consent was 
Pre-Testing Session:  
 Study orientation 
 Health history questionnaire & informed consent  
 Training history questionnaire 
 One repetition maximum testing 
 
At least seven days between testing, Subjects report to lab after 8 hour fast, Subjects perform no exercise the 36 
hours before testing 
 
Randomized Trial 1: 
 30 minutes resting in supine position  
 Pre-exercise muscle biopsy and blood draw / Randomly selected High Power Squat exercise bout /Post-exercise 
muscle biopsy and blood draw 
 One of three exercise bouts 
 Post-exercise muscle biopsy and blood draw 
 
 
At least seven days between testing, Subjects report to lab after 8 hour fast, Subjects perform no exercise the 36 
hours before testing 
 
Randomized Trial 2: 
 30 minutes resting in supine position  
 Pre-exercise muscle biopsy and blood draw / Randomly selected High Power Squat exercise bout /Post-exercise 
muscle biopsy and blood draw 
 One of three exercise bouts 
 Post-exercise muscle biopsy and blood draw 
 
 
At least seven days between testing, Subjects report to lab after 8 hour fast, Subjects perform no exercise  the 36 
hours before testing 
 
Randomized Trial 3: 
 30 minutes resting in supine position  
 Pre-exercise muscle biopsy and blood draw / Randomly selected High Power Squat exercise bout /Post-exercise 
muscle biopsy and blood draw 
 One of three exercise bouts 
 Post-exercise muscle biopsy and blood draw 
 
 
Figure 3. Study I Timeline 
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obtained in accordance with the Human Subjects Committee of the University of Kansas, 
Lawrence, KS.  (See Appendices A and B).  A  health history questionnaire to assess the health 
status of the volunteers (See Appendicies C) .  In order to qualify for the study volunteers must 
have had good general health, been physically active, non-obese (BMI less than 28kg/m
2)
 ,  non-
smoker,  normotensive and free of metabolic and cardiovascular disease. A training history 
questionnaire (Appendix D) was used to determine their familiarity with the barbell squat 
exercise and their habitual patterns of lower body resistance exercise.  
 Each participant also performed unloaded squats for evaluation by the researcher 
to ensure the subjects all had safe and consistent squat technique prior to the maximal squat 
protocol. Subjects also had to demonstrate their ability and comfort in achieving the minimum 
parallel squat depth for the study.   All subjects in the study had at least 2 years of resistance 
training experience, though they did not all have 2 consecutive years experience.  All had been 
resistance training consistently for at least 3 months leading up to the study. Finally all subjects 
squatted at least once per week  in the months leading up to the study.      
METHODS 
Anthropometric and Strength Measures. 
 The height and weight of each subject was measured by stadiometer and body composition was 
determined using the Dual Energy X-ray Absorptiometry (DEXA) method.  One repetition 
maximum strength testing was tested. Lastly each subject completed one repetition maximum 
testing for the back squat exercise in accordance with the NSCA protocol published in the 
Essentials of Strength and Conditioning textbook (Baechle & Earle, 2008). The squat maxes were 
carefully monitored for safe and consistent technique.  The required squat depth was parallel as 
 
 
46 
defined by the greater trochanter level with the top of the patella as visually determined by the 
research team.   
DATA COLLECTION. 
  For each of the three exercise conditions the athletes completed a standard relative warm-up 
using a barbell before beginning the measured exercise sets.   Figure 3.2 displays the warm-up 
and the exercise protocols used in this study. The set and repetition scheme of this study was 
intended to typify the recommendations for development of muscular strength and power (90% 
1RM: High Load), muscular Hypertrophy (70% 1RM Load: Moderate Load) and muscular 
endurance (30%1RM : Low Load).  For all indicated loads in the warm-up the actual load was 
rounded up to the nearest loadable 5lb. increment.  For any indicated loads at or below 45lbs. an 
unloaded bar was used.  For the work sets that were measured the bar was loaded to the nearest 
(up or down) loadable 5 lb increment.  A rest interval of two minutes was given between all 
warm-up sets.  For the moderate and low intensity protocols two minutes was enforced between 
all work sets.  The high intensity load protocol utilized a 3 minute rest between work sets, 
however.  All warm-up sets were performed using a standard Olympic style Barbell, while all 
work sets(Jennings, Viljoen, Durandt, & Lambert, 2005) were performed on a ProSpot Fitness® 
Rack (Pompano Beach, CA).  Squat depth was monitored by the research team and a verbal cue 
was given if subjects failed to achieve full depth, but the repetition was not repeated.   
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Table 1. Set, Rep & Load for the Three Protocols 
Exercise Treatment Warm-ups 
Sets x Reps 
 (% target load [TL]) 
Work sets 
Sets x Reps 
(% 1RM) 
90% 1RM 
High Load 
1 x 10 @ 45 lbs 
1 x 5 (~50% TL) 
1 x 3 (~70% TL) 
1 x 2 (~90% TL) 
5 x 3 (90%)  
70% 1RM 
Moderate Load 
1 x 10 @ 45 lbs 
1 x 5 (~50% TL) 
1 x 3 (~70% TL) 
1 x 2 (~90% TL) 
5 x 5 (70%) 
30% 1RM 
Low Load 
1 x 10 @ 45 lbs 
1 x 5 (~50% TL) 
1 x 3 (~70% TL) 
1 x 2 (~90% TL) 
5 x 10  (30%) 
 
 
 Maximal concentric velocity was asked of the subjects on each repetition of the 
experimental sets.  Based upon previous information that type II muscle fibers would respond 
with greater changes in p38 than type I fibers, this method was used to increase the activation of 
type II fibers within the muscle.  Power generated was estimated using a FitroDyne
®
 unit (Slovak 
Republic), which has previously been established as a reliable method of measuring power in 
barbell lifting.  Power estimates were based upon the system mass (bar weight+ body mass of the 
lifter). From these measures set average power and set average of peak power was calculated as 
the arithmetic mean of the repletion average power as mean of the repetition peak power 
respectivey.  
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BIOPSY AND BLOOD DRAW PROCEDURES. 
 In order to obtain muscle samples for analysis, a needle punch biopsy system was used before 
and after each exercise protocol. This system used a spring loaded, mechanical action needle to 
obtain a 15-20 mg of muscle tissue.  To prepare the subjects for the baseline biopsy taken before 
each treatment protocol, subjects arrived at the lab after an 8 hour fast and instructed to relax in a 
reclined position for 30 minutes to return muscle activity to basal levels.  The biopsy site was 
then shaved, sterilized with betadine solution, and anaesthetized with ~3ml of 1% lidocane 
(without epinephrine) by local injection.  After allowing 5 to 10 minutes a sterile needle was used 
to break the skin in preparation for the actual biopsy needle. The biopsy was obtained by needle 
punch method using the Angiotech ProMag system and  14 guage disposable biopsy needles from 
the same company, (Angiotech Medical Device Technologies, Gainsville FL.).  Samples were 
immediately removed from the needles and frozen in liquid nitrogen for further analysis.  
 Following the pre-exercise biopsy sterile and flexible pressure wraps were placed 
over the wound site.  When the bandages where securely in place the volunteers began their 
warm-up and exercise protocol. Immediately following the exercise protocol the subjects returned 
to the supine resting position for the post-exercise biopsy.  The post- exercise biopsy occurred in 
a similar manner to the pre-exercise biopsy, except that the same puncture site was used without 
additional anaesthetization. Additional lidocane was not always administered because the 
exercise protocol for this study was quite short (12-20 minutes in duration).   Subjects who felt 
that they had not retained the anesthetic effects were offered a second injection of lidocane . The 
post exercise biopsy sample (though from the same site) was taken proximally to the pre-exercise 
biopsy as determined by the angle of the biopsy needle over the puncture site.  Post-exercise 
biopsies were completed within 5-10 minutes of the cessation of exercise.  
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  Blood was also drawn from the antecubital vein of the arm.  Approximately 5-
10cc of blood were collected and divided between untreated Vacutainer™ test tubes (for serum) 
and Heparin treated Vacutainer™ test tubes (for plasma). The blood samples were allowed to clot 
in untreated Vacutainer™ test tubes.  The tubes were subsequently centrifuged for 20 minutes at 
2000 RPM). After which the plasma and serum were pipette into eppendorf tubes and stored at -
20° to -70°.  Blood was drawn at the identical six time points as the muscle biopsies.  At the same 
time as Vacutainer™ blood collection, blood Lactate measures were analyzed using the 
Acusport™ Blood lactate analyzer. 
SAMPLE PREPARATION AND ANALYSIS 
  In order to extract the cellular  proteins for analysis, each muscle sample was 
weighed and homogenized in 1:10 (weight: volume) T-per
®
 Tissue Protein Extraction Reagent 
(Thermo Scientific, Rockford, IL) with 10 µl/ml Halt
®™
 phosphatase inhibitor and Halt
™
 protease 
inhibitor  (100x, Thermo Scientific, Rockford, IL) and 3.4 µl/ml of PMSF. The samples where 
then chilled for 30 minutes with intermittent vortexing every ten minutes, then separated in a 
centrifuge at 3000g for 3 minutes at 4°C. The pellet was discarded and the supernatant was stored 
at -80°C until further analyses could be completed.  
Protein concentration of the extracted muscle tissue was determined using the Micro 
BCA
™
 protein assay in triplicate (Thermo Scientific, Rockford, IL was performed. The 
absorbance readings for the samples and standards where read at a wavelength of 562nm using a 
Synergy HT plate reader (Bio-Tek
®
, Winooski, VT).   Upon determination of the protein 
concentration of the samples, an equal volume:concentration of  5X Lane Marker Sample Buffer  
(Thermo Scientific, Rockford, IL) and 2:1 (volume: concentration) of HES buffer was added to 
the samples.   
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 Western Blot analysis was performed by separating the samples in 12% SDS-
Page gels, followed by a transfer to Amersham Hybond-P
™
 PVDF membrane (GE healthcare, 
Little Chalfont, Buckinghamshire UK).  Membranes where then blocked in SuperBlock
®
 
blocking buffer in TBS (Pierce, Rockford, IL) for one hour with gentle rocking.  Primary 
antibodies for total p38 and phospho-p38 (Thr 180/Try 182), (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA) isolated from two different host animals were added to the blocking buffer at the 
manufacturer’s recommended dilutions and incubated at room temperature for two hours with 
gentle shaking.  The membranes where then washed 4x5 minutes in Phosphate buffered Saline 
(PBS) plus 0.1% Tween-20.  Next, IR-Dye
™
 (700 and 800nm wavelengths) linked secondary 
antibodies specific to the two separate host animals of the primary antibody were diluted 1:10,000 
in Superblock
®
 with 0.1% Tween-20 and .02% SDS and incubated for one hour  protected from 
light while gently rocking. Finally membranes where rinsed 4x5 minutes in PBS with Tween, 
followed by PBS alone and dried overnight in preparation for imaging.  Infrared image detection 
of both 800 and 700 nm IR linked secondary antibodies was accomplished with use of the 
Odyssey
®
 Scanner (LI-COR Biotechnology, Lincoln, NE). 
STATISTICAL ANALYSIS 
 First, the total p38 infrared intensities (I.I.) were much lower than the intensities 
for the phosphorylated antibody.  This is a common issue and is merely related to the affinities of 
the antibodies used.  Thus the raw values were expressed as a ratio to the first timepoint.   This 
method corrected for variations in blot intensity .  The mean density and standard deviation (M ± 
SD) was calculated including each of the four subjects.  Three separate repeated measures 
ANOVAs were used to assess differences between the total, phosphorylated and the ratios of total 
to phosphorylated p38.  The alpha level accepted for statistical significance in this study was α ≤ 
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0.05.  Statistical Package for the social Sciences (PASW, Chicago, IL) software was used to 
perform these statistical analyses.    
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STUDY 2.  THE EFFECTS OF RESISTANCE EXERICSE AND A PRE-WORKOUT 
DIETARY SUPPLEMENT ON ERK AND P38 PHORPHORYLATION 
STUDY DESIGN. 
 The purpose of this study was to examine the  acute and training  effects with and 
without a multi-ingredient high caffeine pre-workout supplement on squat and bench press 
power, vertical jump, and the mitogen activated protein kinase  pathways (ERK1/2 and p38).  In 
orders to clearly delineate the contribution of the exercise and the supplement plus exercise a 
double blind placebo controlled training design was utilized.  Subjects were randomly assigned to 
either the experimental (EXP) or the placebo control (CON) group.   
SUBJECTS.   
Thirty recreationally trained men between the ages of 18 and 35 with good health were recruited 
to participate in this study, which was reviewed and approved by the Human Subjects Committee 
of the University of Kansas (Lawrence, KS) (See Appendix E).  The subjects were informed of 
the requirements of the study and their rights as volunteers using the approved informed consent 
documents (appendix F), Health History and caffeine tolerance questionnaire (appendix G), a 
exercise training history questionnaire (Appendix H).  For safety of the volunteers, individuals 
who had health concerns or risk factors listed in the Human Subjects Committee Approved List 
of Exclusionary Criteria (appendix E)  were excluded from participation in the study.  
BASELINE TESTING 
In order to assess changes in body weight and composition  following the exercise training, each 
subject’s height, weight and body composition was determined  by stadiometer, scale, and Dual 
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Energy X-ray absorptiometry (DEXA) (Lunar Protogy; General Eectric, Waukesha, WI),  
respectively.   One repetition Maximum (1RM)  strength testing was also performed for the lifts 
that would make up the first day of exercises for the training program.   These lifts were the 
squat,  bench press, Leg extension, leg curl and lat pull-down exercises.  The 1RM testing was 
done in accordance with the guidelines set forth by the National Strength & Conditioning 
Association (Baechle & Earle, 2008).  Subjects were asked to keep a food log for the three days 
preceding the first day of exercise training as well.   
TESTING AND BIOPSIES. 
 On the first day of the exercise training muscle biopsy and blood samples were 
taken before and after the actual exercise session.  Subjects reported to the lab following an eight 
hour fast.   Subjects were asked to rest comfortably for 30 minutes to return to resting state 
following arrival at the lab. A muscle sample and blood sample was collected from each subject 
before beginning the exercise or consuming the pre-exercise supplement .   
 All muscle biopsies were obtained from the vastus lateralis of  by percutaneous 
needle biopsy by either Dr. Andrew Fry or Dr Philip Gallagher. To prepare the subject’s leg was 
for the muscle biopsy, the thigh was shaved and cleaned with with Betadine solution.. Two to 
Three mL of  2% lidocane solution was injected into the skin and the surrounding tissues of the 
leg. Next, a 1cm incision was made through all lays of the skin and into the adipose and 
connective tissue below.  A Bergstrom needle (Bignel Surgical Inc., Essex, United Kingdom) 
double-chop technique (Staron, 1991) and suction (Evans, Phinney, & Young, 1982) .  The 
incision was closed with adhesive wound closures and covered with sterile and compressive 
dressing  before they proceeded on to the resistance exercise bout.   
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 The same methods were utilized to collect a second muscle and blood sample 
following the exercise bout.   Muscle samples were sectioned, flash frozen and stored in liquid 
nitrogen for later analysis.  Blood samples were allowed to clot, centrifuged for 20 minutes at 
3000G at 4°C.  The blood’s serum was removed and frozen for later analysis.  
Post Exercise Training muscle biopsies and blood samples were collected in the same manner as 
those collected on the first day of exercise training.  The subjects reported to the lab following an 
8 hour fast and samples were collected prior to and just after the last and exercise training bout 
that matched the first training bout in relative (but not absolute) intensity, volume, and allotted 
rest intervals between exercises.   
EXERCISE TRAINING PROTOCOL  
 Following the initial testing day that included exercise, each subject reported to 
the laboratory three times per week for exercise training.  The exercise training was standardized 
for all participants using relative loads based upon the pre-testing strength measures.  Each 
participant worked with one of the research staff for the first part of the study to ensure exercises 
were performed properly.  After the weeks of the study when the participants felt capable, they 
worked with each other and used each other as spotters but with the constant supervision of the 
researchers.  
 The exercise training was designed to be quite challenging such that no 
individual even those who were less well conditioned prior to this experiment would find adapt 
more quickly than the increases in volume and load.    The training program consisted of three 
days per week of total body resistance training.  Each day used a combination of core lifts (major 
multi-joint free weight lifts), accessory lifts (lifts to target smaller quantities of muscle mass), and 
exercises to target the trunk and abdomen. For the core lifts (back squat,  bench press, leg 
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extensions leg curls, incline bench press, deadlift, and bicep curls) the participant completed 
strength testing and load was prescribed relative to their maximal strength in that exercise.  While 
the bicep curl is not typically programmed or considered a core lift, it was in this case because of 
the preferential training of that muscle group/exercise by the subjects.  
 The accessory exercise for this study (standing press, barbell split squat, dips, 
pull-ups, and the abdominal exercises (weighted sit-up, weighted Russian twist, supine leg raise, 
weighted v-ups, weighted twisting crunches, and Supine wipers,  where programmed without 
indicating an appropriate load.  For all of these exercises the subject was to complete two sets of 
12-15 to fatigue/failure recording the weight and repetitions.  The subjects were encouraged to 
increase as they were able adding weight or increasing to the maximum allowable 15 repetitions 
per set, but these exercises where not otherwise programmed for progressive overload.  For the 
pull-up and dip  exercise subjects used an assisted machine (Stairmaster Gravitron assisted 
chin/dip; Vancouver, WA) if they were unable to complete adequate repetitions with body 
weight.  Conversely, subjects added weight via belt or other method of their choosing as they 
were able to accommodate loads higher than body weight. Abdominal exercises were weighted 
with rubberized bumper plates, metal plates, medicine balls as was deemed appropriate and safe 
for the specific accessory exercises.   
 The eight week training program was progressive including fluctuations in both 
volume and  load. Day two of the first week of training consisted of additional 1RM testing for 
lifts used in the training program, but not in the first day of the training program.  After increasing 
linearly for the first four weeks, The end of the fourth week offered a lower volume higher 
intensity training session. Week five of the program began with 1RM re-testing to evaluate any 
progress made in the short phase of exercise training.  The prescribed loads were adjusted to 
match the new strength measures in the following weeks. Week seven, like week 4 has a 
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reduction in volume and an increase in load.  Week 8 has the lowest volume, but contained the 
post training 1RM testing.  The final day of the training program like the first day of the training 
program were identical in volume and relative load (loading relative to the most recent 1RM 
testing), and where testing days in which muscle biopsies were collected.  The exact training 
program is shown in Appendix J where the load indicates the percentage of maximum load.   
SUPPLEMENTATION 
Each subject in this study was randomly assigned to either the EXP or CON group referring to the 
pre-exercise supplementation the individual received prior to each exercise session.  The EXP 
group received a commercially available multi-ingredient workout      supplement called 
Supercharge ,( Labrada Nutrition, Houston, TX).  The nutritional information panel for the 
experimental supplement is shown in a table in appendix K.  The manufacturer proposed that the 
most significant active ingredients for the supplement included charbohydrate in the form of 
maltodextrin, corn syrup, and modified food starch, as well as, Taurine, arginine, caffeine, 
creatine monohydrate, betain, and the amino acids alanine, glutamine, and histidine.  Several 
other ingredients were included and can be seen in appendix K. The CON goup received a low-
glycemic color and flavor matched placeebo that contained polydextrin and/or manitol to match 
the flavor of the EXP drink and silica to match the texture of the drink.  The drink also included 
typical food coloring and flavoring ingredients. 
 The preparation of the EXP and CON pre-exercise supplements was blinded to 
the researchers and the subjects.  The dry powder supplements were measured and placed into 
opaque disposable containers labeled for the specific subjects.  When the subjects arrived at the 
laboratory for their exercise training (or testing as in the case of the first and last days chilled tap 
water was added to the bottles (approximately 12oz.).  The mixture was shaken to dissolve the 
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drink mix completely and then consumed by the subject.   The grouping  was not unblinded until 
the a subject completed the study.  
 Because of the high caffeine content of the EXP supplement, the dosage given to 
the subjects was reduced by half for the first week and a half of training sessions following the 
initial day of training with muscle biopsies. That is to say that the subjects received a serving size 
of  ‘2 scoops’ (32g of powdered supplement)  for the initial day of testing, but the following 
sessions they received only ‘1 scoop’ (16g) dissolved in the same amount of water. This was done 
to allow for some habituation to the caffeine, hoping to avoid serious caffeine related side effects.  
The end of this acclimation period and throughout the remainder of the study the subjects were 
given the full 32g dose of either the  EXP supplement or the CON placebo. To further monitor for 
negative side effects of the supplement, each subject filled out a short questionnaire asking about 
any suspected side effects (appendix I) , and blood pressures were monitored to ensure subjects 
did not develop chronic hypertension.  This monitoring was completed weekly for the duration of 
the study.  
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SAMPLE PREPARATION AND ANALYSIS 
Protein Extraction   
The p38 and ERK protein was extracted from , each muscle sample, weighed and homogenized in 
1:10 (weight: volume) T-per
®
 Tissue Protein Extraction Reagent (Thermo Scientific, Rockford, 
IL) with 10 µl/ml Halt
®™
 phosphatase inhibitor and Halt
™
 protease inhibitor  (100x, Thermo 
Scientific, Rockford, IL) and 3.4 µl/ml of PMSF. The samples where then chilled on ice for 30 
minutes and agitated by vortexing every ten minutes.  The solution was centrifuge at 3000g for 3 
minutes at 4°C. The pellet was discarded and the supernatant was stored at -80°C until further 
analyses could be completed.  
In order to determine the concentration of protein in the extracted muscle tissue, a Micro BCA
™
 
protein assay (Thermo Scientific, Rockford, IL) was performed for each  sample in triplicate 
according to the manufacturer’s instructions. The absorbance readings for the samples and 
standards where read at a wavelength of 562nm using a Synergy HT plate reader (Bio-Tek
®
, 
Winooski, VT).   Upon determination of the protein concentration of the samples, an equal 
volume:concentration of  5X Lane Marker Sample Buffer  (Thermo Scientific, Rockford, IL) and 
2:1 (volume: concentration) of HES buffer was added to the samples and stored at -8o°C until 
further analysis could be performed.   
 Western Blot analysis began by separating the muscle samples in 12% SDS-Page 
gels, followed by a transfer to Amersham Hybond-P
™
 PVDF membrane (GE healthcare, Little 
Chalfont, Buckinghamshire UK).  Membranes where then blocked  in SuperBlock
®
 blocking 
buffer in TBS (Pierce, Rockford, IL) for one hour with gentle rocking.  Primary antibodies for the 
target proteins (total p38 and phos pho-p38 and total and Phospho ERK1/2) isolated from two 
different host animals were diluted in the same blocking buffer at the manufacturer’s 
 
 
59 
recommended dilutions and incubated at room temperature for two hours with gentle shaking.  
The membranes where then washed 4x5 minutes in Phosphate buffered Saline (PBS) plus 0.1% 
Tween-20.  Next, IR-Dye
™
 (700 and 800nm wavelengths) linked secondary antibodies specific to 
the two separate host animals of the primary antibody were diluted 1:10,000 in Superblock
®
 with 
0.1% Tween-20 and .02% SDS and incubated for one hour  protected from light while gently 
rocking. Finally, membranes where rinsed 4x5 minutes in PBS with Tween, followed by PBS 
alone and dried overnight in preparation for imaging.  
 Infrared image detection of both 800 and 700 nm IR linked secondary antibodies was 
accomplished with use of the Odyssey
®
 Scanner (LI-COR Biotechnology, Lincoln, NE) and 
recorded as infrared intensities (I.I.)  which are analogous to optical densities. For all samples 
ratio of  phosphorylated  to total I.I. will be analyzed as an indication of the effect that the 
exercise bout  or the exercise training may have on the phosphorylation state of p38 and ERK.  
STATISTICAL ANALYSIS. 
 Statistical Descriptors of the subjects including average and standard deviation 
for height, weight, body composition, and training history variables were calculated.  For the 
main comparison the I.I. for the total and phosphorylated p38 and ERK were compared between 
pre and post testing  Seperate repeated measures  ANOVAs were run comparing the ratio of 
phosphorylated to total p38 and ERK separately.  For all hypothesis testing the alpha level 
accepted for statistical significance in this study was α ≤ 0.05.  Statistical Package for the Social 
Sciences (SPSS/PASW, Chicago, IL) software was used to perform these statistical analyses.   
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CHAPTER 4: RESULTS 
STUDY 1.  SKELETAL MUSCLE MAPK ACTIVATION DURING HIGH POWER 
RESISTANCE EXERCISE  
 Recall that the purpose of this study was to determine if there was a differential 
response to three different volumes and intensities of maximal concentric velociey (high power) 
back squat protocols.  The three protocols investigated were the High Intensity (5 sets of 3 
repetition at 90% or 1RM load), Moderate Intensity (5 sets if 5 repetitions at 70% of  1RM load, 
and Low Intensity (5 sets of 10 repetitions at 30% of 1RM load.   Nine healthy college aged 
(21.44±0.56 yr.) males participated in the study.  Raw data for their physical characteristics 
including  height (177.80± 5.056cm) and weight (78.68 ± 9.712kg), and their one-repetition 
maximum in the back squat (115.7±40.26 kg)  are reported in appendix L along with the testing 
order for each subject. 
 To determine if the three exercise protocols resulted in significantly different 
blood Lactate response a repeated measures 2x3ANOVA (general linear model) was calculated 
using the Timepoint (pre- vs. Post-exercise) and the three protocols (High, Moderate, and Low 
intensity).  There was a significant effect for timepoint F(1,8) = 93.29, p<0.0001.  There was no 
main effect for the protocol (p >0.05), nor was there a significant interaction, timepoint x 
Protocol, (p >0.05).  Blood lactate values for each subject are included in appendix L along with 
the mean and standard deviation for each timepoint and protocol.  The lactate values are shown in 
Figure 4.   
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Figure 4.  Blood Lactate was significantly and equally increased by each of the three 
protocols. * indicates p < 0.05 compared to associated pre-exercise value. There was no 
difference between protocols. 
 Of major interest in this study was the role that power production might play in 
the physiological response.  As such the power produced while performing the concentric portion 
of the prescribed squats for each protocol was estimated using the Tendo Weightlifting Analyzer.  
An average and peak power was recorded from each repetition.  A set average power was 
calculated by taking an average of the repetitions for each set.  The set peak power is likewise an 
average of the peak power measures from each repetition within a given set.  Lastly a grand mean 
of average power and grand mean of peak power was calculated by finding the mean of the set 
average and peak  values respectively for each protocol.  Appendix L includes set peak and set 
average power by by protocol for each subject.  A mean and standard deviation for set and  the 
grand mean and standard deviation for each  protocol’s peak and average power is also included 
there. Note that missing values are attributable to one of two procedural errors on the part of the 
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research team.  Either the Tendo unit was not attached by the research assistants to the 
weightlifting bar thus no data was collected, or the data file was not saved properly before the 
next trial began.  
 Separate repeated measures ANOVAs was calculated to determine if the set 
average power and  set peak power measures were significantly different between the (grand 
average of average power), F2,16) =11.359,  p = 0.003. Planned contrasts were utilized to 
determine between which protocols the average power differed. The Low Intensity protocol 
(30%1RM) produced average power measures significantly higher than both the High Intensity 
(F(1,8) = 33.169, p < 0.001) or Moderate Intensity (F(1,8) = 10.78, p =0.011) protocols.  There was 
however no difference between the High Intensity and Moderate Intensity protocols (p =0.177).  
The grand mean of peak power was not significantly different between the protocols (F(2,10) 
=0.774, p = 0.487).  
 To determine the impact of power fatigue across the three different protocols  
two separate repeated measures 3x5 ANOVAs (general linear model) were completed for the 
peak and average power measures respectively.  In this statistic the three protocols (High, 
Moderate, and Low Intensity) are compared within and across  the 5 sets. For the set average 
power measures there was a significant main effect for protocol (F2,10) = 10.23, p=0.004), but not 
for set (F4,20) =0.833, p = 0.52).  When the set average power was evaluated by pair wise 
comparisons, it was determined that set averages were significantly lower for the High Intensity 
protocol compared to the Low Intensity protocol (p=0.009),  but no other differences between  
protocols (main effect) were observed. A significant interaction (protocol x set; F(8.40) =4.984, p 
<0.001) was identified and a post hoc analysis showed that the High Intensity protocol alone 
resulted in significantly lower average power measures in the fifth set compared to the first and 
 
 
63 
second sets of that same protocol.  Stated more directly, there was a significant decline in set 
average power by the fifth set, and this pattern was unique to the High Intensity protocol. Figure 
3 below shows demonstrates the set average power decline of 16% that is observed in the High 
Intensity protocol only.  The 3x5 repeated measures  ANOVA for peak power across sets did not 
indicate any significant main effects or interactions (p > 0.05 in all instances). Figure 5 
demonstrates the trend and differences between protocols.  
 
* * * * 
* 
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Figure 5. Set Average Power by Protocol.  A) The set average power declines by 16% in the 
High Intensity (90% protocol) which is significantly different than the trends within the Low and 
Moderate Intensity protocols. * indicates the set average is significantly different from the 90% 
protocol for the same set.  
 Western Blot optical density information for the total and phosphorylated 
versions of ERK1/2 and P38 are given in appendix L.  Statistical analysis of this data was 
performed by first performing separate 3x2 repeated measures ANOVAs  for each protein, where 
the three treatment groups were compared across the pre- and post exercise bout.  For total 
ERK1/2 there was no significant main effect for treatment, but there was a significant main effect 
for the pre-post-timepoint F(1.8) =8.149, p <0.021. The interaction effect was not significant. The 
same pattern was true for the phosphorylated ERK1/2 protein with a significant main effect for 
timepoint (F(1.8) =6.725, p <0.032).  For the pre-Post comparison combined across all treatments 
both the ERK1/2 and the phosphorylated ERK1/2 were significantly lower after exercise 
compared to before. The results of these analyses are shown in Figure 6.  
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Figure 6. The total and phosphorylated ERK1/2 pre- and post exercise for all three exercise 
conditions. There was no significant difference between the protocols for ERK1/2 ( F(2,16) = 
0.585, p=0.528)  or Phospho-ERK1/2 ( F(2,16) = 0.831, p=0.454) . * highlights that ERK1/2 
was significantly lower following exercise (F(2,8) = 8.149, p=0.021) This was a main effect 
thus is the combination of all three protocols.  # Likewise indicates there was a main effect 
for  pre- to post exercise Phospho-ERK1/2( F(1,8) = 6.725, p=0.528) . There was no significant 
interaction (protocol x timepoint) ( F(2,16) = 0.385, p=0.032).   
 To further clarify the findings a set of simple repeated measures ANOVAs were 
also completed using the relative change in total ERK1/2 and the relative change in 
phosphorylated ERK1/2 respectively. This analysis would thus more clearly compare effects of 
the exercise bouts while eliminating any confounding difference in the basal protein expression 
levels. There was no significant difference between treatments for the  relative change in ERK1/2 
(F(2.16) = 0.564, p = 0.58)1  or phosphorylated ERK1/2 (F(2.16) = 1.593, p = 0.234) see Figure 7.  
* * 
* 
# # 
# 
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Figure 7. There is no significant difference in relative change in total or phosphorylated ERK 
1/2  (F(2.16) = 0.564, p = 0.581 & F(2.16) = 1.593, p = 0.234 respectively) 
 Lastly the fold change in the ratio of phosphorylated to total ERK1/2 was 
analyzed by repeated measures ANOVA in the manner as mentioned previously.  There was a 
significant difference in the relative fold change in the ratio of phosphorylated ERK1/2 to total 
ERK1/2 (F(2,16) = 5.514, p=0.015). Planned contrasts identified that there the High Intensity 
protocol resulted in a significantly different change in phosphorylation ratio compared either the 
Moderate Intensity (p =0.026) or Low Intensity (p = 0.017)  power squat protocols (see Figure 8).  
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Figure 8.  There is a significant difference in the relative change in the ratio of phosphorylated 
to total ERK1/2 between protocols. Planned contrasts identified that  the High Intensity protocol 
resulted in a significantly different change in phosphorylation ratio compared either the Moderate 
Intensity (p =0.026) or Low Intensity (p = 0.017)  power squat protocols.  
 The 3x2 ANOVAs for total p38 found no differences between treatment days, the 
pre-post- exercise timepoint, or an interaction of these two variables (p>0.05).  The 
phosphorylated p38 did have a significant main effect for the treatment (F(2.16) = 4.252, p < 0.033). 
But there was not a significant main effect for timepoint (pre-/ post) nor was the interaction 
significant. Planned contrasts further discriminate the significant difference identified between 
the treatments to be a significantly lower values on the High Intensity treatment group than the 
other two treatment days (Figure 9).  
* 
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Figure 9.  Total and phosphorylated p38 by protocol and timepoint. There were no 
significant differences in total p38 by day (F(1.8) = 3.127, p = 0.036) , timepoint (F(1.8) = 252, 
p = 0.622) or interaction (protocol x timepoint)( F(2.16) = 1.537, p = 0.251). * indicates a 
significantly lower phosphor-p38 on the high intensity day F(2.16) = 4.252, p = 0.036. There 
was no significant main effect for timing (pre- post-exercise) (F(1.8) = 2.585, p = 0.147) or for the 
interaction (protocol x timpoint, F(2.16) = 4.252, p = 0.436. 
As was performed for the ERK1/2 proteins, a second set of repeated measures ANOVAs was 
performed using the relative change in the expression of the p38 and phosphor-p38 proteins from 
pre to post exercise bouts in order to more clearly identify the potential differences that might be 
caused by the exercise.  There was no difference in the relative change in total p38 protein 
expression between the exercise bouts (F(2.16) = 0.562, p = 0.581).  Nor was there a significant 
difference between treatments for the relative change in the phosphorylated p38 levels F(2,16) = 
1.974 p = 0.171; See Figure 10). As with the ERK1/2 protein the  fold change in the ratio of 
phosphorylated to total ERK1/2 was analyzed by repeated measures 1x3 ANOVA. There was no 
* 
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significant difference in the relative change in the p38 phosphorylated to total ratio (F(2,16) = 
1.221,  p= 0.32; see Figure 11).   
 
Figure 10. There was no difference in the relative change of total or phosphorylated p38 
between exercise protocols (p >0.05).  
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Figure 11. There is no significant difference between the relative change in the ratio 
(phosphorylated: total) p38 (p>0.05). 
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STUDY 2.  THE EFFECTS OF RESISTANCE EXERICSE AND A PRE-WORKOUT 
DIETARY SUPPLEMENT ON ERK AND P38 PHORPHORYLATION 
 Twenty four subjects completed the study,  (N=14Supplement group N=10 in the 
Placebo Group. Of the six subjects who left the study, five chose do so based due to the time 
commitment and lack of enjoyment, and one was removed from the study after exceeding the 
allowable number of missed training sessions. Descriptive characteristics for the subjects along 
with the raw data for this study are displayed in appendix M.   
 This study was part of a larger investigation and a previously published 
companion study (Moodie, 2008), and a jointly published research abstract (Kudrna et al., 2011) 
have also been published.  Since a number of these findings are important for a complete 
understanding of the current research, a summary of the findings  reported in the dissertation of  
Nicole Moodie is included in appendix N.  Notably, the appendix includes the results for changes 
in body mass, lean body mass, and strength measures.   
 Jointly published (Kudrna et al., 2011),  muscle performance data includes squat 
and bench press power measured by Tendo Weightlifting Analyzer at 70% of 1RM, and vertical 
jump performed at the beginning and end of the 8 week training study. Each of these three 
variables was analyzed by mixed model repeated measures ANOVA (group x time). Squat power 
was significantly increased after training (F (1,23) = 46.178, p <0.001), and the supplement group’s 
response was significantly better than the placebo group (F (1,23) = 6.291, p = 0.02). There was a 
significant increase in bench press power from beginning to end of the study (F (1,23) = 4.855, p = 
0.38) , but no difference was found between the supplement and placebo groups (F (1,23) = 0.903, p 
= 0.352). Vertical Jump was significantly increased after training (F (1,23) = 55.164, p <0.001).  
 
 
72 
There was no significant in vertical jump improvement difference between groups F (1,23) = 0.014, 
p = 0.905. 
 The remainder of the findings are entirely new and have not been previously 
reported. In order to analyze the results of the western blots the raw optical density values which 
varied widely from blot to blot were expressed as a relative or fold change from the initial pre-
training pre-exercise sample.  Repeated Measures 2x2  Mixed Models ANOVA was performed 
for the relative expression of ERK1/2 and phosphorylated ERK1/2 using the group (supplement 
or placebo as categorical factor; data displayed in Figure 12).  For Total ERK1/2 there was no 
significant main effect  or interaction effects among any of the variables. For the relative values 
of phosphorylated ERK1/2 there was a significant main effect for timing (before vs.  after the 
exercise bout; F (1,22) = 4.854, p = 0.38), but there was no main effect for training, and no 
interaction effects associated with the supplement.  Combined analysis  for pre-training and post-
training showed that relative phosphorylation was significantly higher following exercise 
compared to the pre exercise bout levels as seen in (Figure 13).   
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Figure 12. Phosphorylation of ERK1/2 Combined and by group. There is a significant 
main effect for pre-/post-exercise comparison which is more clearly demonstrated in 
Figure 13 below. For the relative values of phosphorylated ERK1/2 there was a significant main 
effect for timing (before vs.  after the exercise bout; F (1,22) = 4.854, p = 0.38), but there was no 
main effect for training, and no interaction effects associated with the supplement. 
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Figure 13. Post Exercie phosphorylation of ERK1/2. For the relative values of 
phosphorylated ERK1/2 there was a significant main effect for timing (before vs.  after the 
exercise bout; F (1,22) = 4.854, p = 0.38).   
 The ratio of phosphorylated to total ERK1/2 for each time point  was calculated 
using the raw score values and also analyzed by a 2x2 mixed model ANOVA. Figure 14 
demonstrates all of the phosphorylated to total ERK1/2 ratio data. For the ratio of phosphorylated 
to total ERK1/2 there was a significant main effect for the combined comparison of pre- to post-
exercise measures (F(1,22) = 5.159, p=0.033) as is shown in Figure 15. There was also a significant 
interaction effect for training status x exercise timing (pre-post training x pre-post exercise ; F(1,22) 
= 6.607, p=0.017) as is highlighted in Figure 16.  
 
 
75 
 
Figure 14. Phospho:Total Ratio of ERK1/2 By group and Combined.  For the ratio of 
phosphorylated to total ERK1/2 there was a significant main effect for the combined comparison 
of pre- to post-exercise measures (F(1,22) = 5.159, p=0.033) as is shown in Figure 15. There was 
also a significant interaction effect for training status x exercise timing (pre-post training x pre-
post exercise ; F(1,22) = 6.607, p=0.017) as is highlighted in Figure 16.  
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Figure 15. The Phosph:Total Ratio of ERK1/2 was significantly increased after exercise 
(p <0.05). 
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Figure 16. The changes in ERK1/2 were significantly reduced after training (p <0.05). 
The * indicates a significant interaction effect demonstrating that the change associated 
with exercise is affected by exercise training. The # indicates a significant post hoc 
analysis showing that ERK1/2 phosphorylation expressed as a ratio was significantly 
altered in the pre-training measures, but not the post-training measures. 
 Repeated Measures 2x2  Mixed Models ANOVA was performed for the relative 
expression of  p38 and phosphorylated p38 using the group (supplement or placebo as categorical 
factor) as was completed for the ERK1/2 protein. For total p38 there was a significant main effect 
for training status F(1,22) = 8.124, p=0.09). This indicates that the combined pre-and post-exercise 
p38 values were higher after training as compared to before.  There was no main effect for 
exercise bout nor was the interaction significant.  The group (placebo vs. supplement) did not 
significantly affect the levels of p38. Figure 17 and 18 show the p38 values by group and 
combined  and the Pre- to Post- training comparison.  The relative phosphorylated p38 values 
# 
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followed the same pattern as the total p38.  There was a significant main effect for training (pre- 
to post-training; F(1,22) = 8.288, p=0.09).  As  with the total p38. These pre- to post training 
analyses should be interpreted with caution since the use of relative expression of the values 
results in a Standard deviation of zero for on set of samples.  As such this leads to an increase in 
the likelihood of a II error. Figure 19 and 20 demonstrate the differences in phosphorylated p38 
by group and combined and show the combined pre- to post training effect respectively.  
 
Figure 17. Total p38 combined and by group. For total p38 there was a significant main 
effecct for training status F(1,22) = 8.124, p=0.09). This indicates that the combined pre-and post-
exercise p38 values were higher after training as compared to before .  There was no main effect 
for exercise bout nor was the interaction significant. Figure 17 and 18 more clearly demonstrate 
these differences.  
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Figure 18. Post Training levels are higher than pre training levels, but should be 
interpreted with caution as the standard deviation is not accurately accounted for.  
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Figure 19. Phosphorylated p38 combined and by group. There was a significant training 
effect which is more clearly shown in figure 20. 
 
Figure 20. Post Training levels of Phosphorylated p38 are higher than pre training levels 
(F(1,22) = 8.288, p=0.09), but should be interpreted with caution as the  standard deviation 
increases the chance of a type II error.  
 The ratio of phosphorylated to total p38 for each timepoint  was caluculated 
using the raw score values and analyzed  by  2x2 mixed model ANOVA. Figure 21 demonstrates 
all of the phosphorylated to total ERK1/2 ratio data. For the ratio of phosphorylated to total p38 
there no significant main effects for training or Exercise (p>0.05). There were also no significant 
interactions between these variables (p>0.05).  The supplement also had no significant impact on 
the ratio of p38 phosphorylation (p >.0.05). 
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Figure 21. Phospho:Total Ratio of p38 combined and by group. No significant 
differences were identified.  
 
 
 
 
 
CHAPTER 5: DISCUSSION 
STUDY 1.  SKELETAL MUSCLE MAPK ACTIVATION DURING HIGH POWER 
RESISTANCE EXERCISE  
 This study sought to determine if there was a difference in the physiological 
response to the three different high power squat exercise bouts.   This study showed that lactates 
were increased following each exercise bout, but that there was no difference in the elevation of 
the lactates between groups.  Since the protocols all consisted of intermittent exercise and rest the 
lactate response was apparently limited. In short there was no distinguishing difference between 
the lactate response based upon the exercise protocol.  
 The power measures taken during the study demonstrated that the low intensity 
protocol produced significantly higher average power in agreement with previous research (Zink, 
Perry, Robertson, Roach, & Signorile, 2006).  There was however no difference between the 
protocols for peak power which was unexpected. The  load appeared to affect power fatigue 
across five sets of resistance exercise.  The heaviest load had the highest power fatigue (13% 
difference from set 1 to set 5). The moderate and light loads did not show any evidence of power 
fatigue. It should also be noted that five sets at 30% 1RM may be indication of a warm-up effect 
an not one of power fatigue. Thus this data indicates that  at the intensities most frequently 
utilized to develop power, there is no evidence of decreased power over 5 sets of speed squats. 
Practitioners attempting to train for power at higher loads (i.e. 90%) should be aware that power 
fatigue may occur in as few as 5 sets.  Also notable is the lack of difference in the average of peak 
power across the 5 sets at dramatically different loads.  
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 This study showed that ERK1/2, Phosphorylated ERK1/2 were found to decrease 
following the exercise bout contradictory to what has been shown previously (Galpin et al., 2012; 
Moore et al., 2011; Ryder et al., 2000). When analyzed further it was determined that the High 
Intensity protocol tended to increase whereas the other two protocols showed a trend  toward 
decrase  resulting in a significant difference from each other. It may be that the decreased total 
ERK1/2 following exercise is due to it’s complexing with larger proteins and lost during 
centrifugation.  That however is only speculator. Against previous research the relative change in 
the  ratio of phosphorylated to total ERK1/2 did not differ between the exercise protocols.  This 
weak response to ERK1/2 might be attributable to an inadequate volume or intensity of exercise.  
The highest intensity protocol did produce the greatest trend toward a ERK1/2 phosphorylation.   
 The p38 and phosphorylated p38 also showed no difference from pre to post 
exercise contrary to what was expected base upon most(Coffey et al., 2006; Galpin et al., 2012; 
Karlsson et al., 2004; Yu, Blomstrand, Chibalin, Wallberg-Henriksson, et al., 2001) but not 
(Williamson et al., 2003) all previous research.  As with the ERK1/2 the volume or intensity of 
the squat exercise may not have been adequate.  It is also possible the timing was not the most 
advantageous to identify the phosphorylation changes, though it is not inconsistent with the 
literature.  It was the intention of this study to examine the relationship between power and the 
ERK1/2 and p38  response but without significant changes in either erk1/2 or p38, it is impossible 
to determine the relationships between these items.   
 There are a number of possible reasons that the MAPK changes in response to 
these exercise bouts were less than hypothesized. Among them, the stimuli may have been 
insufficient to stimulate the muscle.  Most previous research has utilized leg extension as at least 
part of the methodology.  The back squat, while it does typically recruit the vastus lateralis, may 
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not activate that muscle group adequately in this study.  The exercise protocol most close to this 
studies is the use of heavy clean pulls as described in Galpin (2012).  In addition to the mode of 
exercise the volume or the ratio of work to rest may have been a factor. 
 Finally, the prior training of the subjects may have been the reason for the lack of 
MAPK response.  Based upon previous research(Coffey et al., 2006; Yu, Blomstrand, Chibalin, 
Wallberg-Henriksson, et al., 2001) and the second study of this work, it is possible that the 
careful selection of subjects who were competent and practiced in the back squat exercise was 
part of the reason the subjects did not respond to the exercise bouts.  Habitual exercise training 
appears to blunt or eliminate the MAPK response to similar exercise (Coffey et al., 2006), but this 
has not previously been observed in recreationally trained resistance exercisers. . 
Study 2.  The Effects of Resistance Exericse and a Pre-Workout Dietary Supplement on 
ERK and p38 Phorphorylation 
SUBJECT DROPOUT AND SUPPLEMENT TOLERANCE 
 The nutritional supplement utilized in this study seemed to be fairly well 
tolerated by the subjects.  There were no major adverse reactions reported by the subjects.  
Prudent precautions were taken to eliminate caffeine sensitive and caffeine naive subjects from 
the study. Also precautions were taken to help the supplement group adapt to the high caffeine 
loads by increasing the caffeine to the full dose in week two (see methodology).  Such 
precautions are essential to ensuring that a high caffeine supplement such as this one does not 
cause serious adverse reactions.  
   One adverse reaction that was observed in the  supplement, but more so the 
placebo group was stomach upset and vomiting during the exercise training.  Because this was 
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more prevalent in the placebo users it may have contributed to the disproportionate withdrawal of 
subjects selected to the placebo group.  Upset stomach during the exercise training may be 
attributable to the consumption of the supplement or placebo immediately prior to the exercise 
training.  Though the ingredients in the placebo were all generally recognized safe by the FDA, 
there may have been an unexamined factor such as osmolarity of the drinks or there may have 
been different gastric emptying rates due to one or more of the different ingredients within the 
supplement and placebo. Individuals considering the addition of any supplement to their training 
or competition nutritional plan should take into account the possible digestive disturbances.  It is 
recommended that all persons considering this or any pre-exercise supplement consider important 
health, safety, efficacy, and other related nutritional issues as is recommended by the American 
College of Sports medicine and the American Dietetic Association (Rodriguez, Di Marco, & 
Langley, 2009). 
POWER PERFORMANCE MEASURES 
 Both groups increased measures of power in the 70% of maximum back squat, 
the 70% of maximum bench press, and vertical jump.  Increased power performance even at the 
same relative intensity is an expected outcome of resistance exercise training and agrees with the 
previously published literature, (Chtara et al., 2008; Cormie, McBride, & McCaulley, 2009; Pesta 
et al., 2014; Petrella, Kim, Tuggle, & Bamman, 2007). The supplement was associated with 
significantly greater improvements in the squat power than the placebo group, while there was no 
such difference in the other two power measures, bench press and vertical jump.  It remains 
unclear by what mechanism the supplement might disproportionately affect the power 
improvements.  One possible explanation is that the caffeine which has been shown to acutely 
increase muscle power and contraction velocity (Pallares et al., 2013) could have over the course 
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of the 8 weeks of training contributed to a chronic training effect. The dose of caffeine used in 
this study were lower than the effective doses identified in Pallares et al. (2013) given the loads 
prescribed. Nonetheless,  The increase in leg power with a MIPS  (supplement) does agree with 
previous research (Ormsbee et al., 2012), though the methods of  power testing were different.   
 A possible explanation for the vertical jump being unaffected by the supplement 
compared to the 70% of squat power measurement is that the training program which highlighted 
muscle hypertrophy and strength gains was inadequate to cause changes in the vertical jump 
which is a much higher velocity movement (Cormie et al., 2009). It is important to note that the 
training program was not directly designed to increase power and the subjects were not instructed 
to perform the training movements with maximal velocity. Thus the adaptations to the 70% of 
1RM squat power was much more specific to the training undertaken during the 8 week study.  
Finally, the fact that the bench press power test was not different between groups thought the 
force would have been similar to their training loads might be related to the fact that the subjects 
had a greater percent change in their squat maxes compared to their bench press maxes.  Thus 
both the strength and power improvements were greater in the lower body  than in the upper 
body.  
ERK1/2 OBSERVATIONS 
 The results of this study indicate that the levels of phosphorylated ERK1/2 and 
the ratio of phosphorylated to total ERK1/2 increased following a resistance exercise bout  has 
been observed in most previous studies (Galpin et al., 2012; Moore et al., 2011; Ryder et al., 
2000).  One interesting difference between this study and others is that the exercise bout was not 
simply isolated to the muscle specifically being assessed by biopsy (Moore et al., 2011) or to a 
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single exercise  or modality (Galpin et al., 2012; M Gibala, 2009; M. Gibala et al., 2009) or a 
lower body only training program (Kosek & Bamman, 2008).  This study may be the first to show 
that ERK1/2 phosphorylation (and  the ratio of phosphorylation to total) is significantly increased 
following a whole body resistance exercise protocol that is typical of  muscle hypertrophy 
training.  While it may not have been unexpected it does confirm that whole body resistance 
exercise does not preclude the cellular signaling mechanisms that have been observed under more 
tightly controlled and muscle group specific laboratory protocols.  
 One of the most interesting finding of this study is the significant interaction 
between training status and the  response to a single resistance exercise bout.  As was 
demonstrated in Figure16,   when expressed as a ratio of phosphorylaed to total ERK1/2 there 
was a significant diminution of the ERK1/2 response following training.  This is study clearly 
indicates a training effect that may be part of the cellular signaling mechanism associated with the 
ceiling effect of exercise training.  The habitual exposure to similar exercise resulting in  
decreased ERK1/2 phosphorylation has been noted  previously (Coffey et al., 2006; Yu, 
Blomstrand, Chibalin, Wallberg-Henriksson, et al., 2001), but  these studies used previously 
trained individuals and thus do not preclude the possibility that it is a characteristic of successful 
training that the subjects would respond in the manner that they did.  
 One study previously undertook to examine the training response in resistance 
exercise naïve subjects using a stronger pre-post testing design (Kosek & Bamman, 2008).  Kosek 
& Bamman, did not find any training effect for ERK1/2 as has been shown in this study.  A 
second discrepancy with findings with the Bamman study was that they had concluded that young 
but resistance exercise naïve individuals did not demonstrate an  elevated phosphorylation of 
ERK1/2 after training, and had no training associated reduction in the ERK1/2 response. Whereas 
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the current study indicates that regular  recreational resistance exercise is not enough to prevent a 
training associated elimination of the ERK1/2 response.   The most likely reason for the 
discrepancy is that Kosek & Bamman took muscle biopsies a full 24 hours after the exercise 
bouts at the beginning and end of the study.  The current study took biopsies more immediately as 
is more common in the literature.  While the 24 hour time point was useful in identifying aberrant 
signaling in the older men of the Kosek & Bamman study, this study clearly shows acute 
immediate effects on the ERK1/2 pathway.  Thus this study adds clear and important evidence of  
a training effect on ERK1/2 phosphorylation response to an exercise bout . 
P38 OBSERVATIONS 
 Unlike as was observed for ERK1/2, p38 phsophorylation expressed relative to 
the initial pre-training  pre-exercise value or expressed relative to the total p38 did not increase 
following exercise.  Most (Coffey et al., 2006; Galpin et al., 2012; Karlsson et al., 2004; Yu, 
Blomstrand, Chibalin, Wallberg-Henriksson, et al., 2001) but not all previous research 
(Williamson et al., 2003) shows that p38 phosphorylaton is increased following unaccustomed 
resistance exercise in young men.   Reasons this study may differ from the majority of studies 
might include the use of a non-targeted whole body resistance training program that included 
abdominal and not lower body exercise as its final exercises. Thus the timing of the post exercise 
biopsies may not have been ideal to catch the transient increase in p38 phosphorylation.  
 This study di find a significant increase in the amount of p38 and phosphorylated  
p38  and from  pre-training to post training, but should be evaluated with a great deal of caution 
given that expressing the quantities as relative to the initial value while necessary for comparison 
of the Western blots, it does create a standard deviation of 0 for the initial sample set.  Thus there 
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is an increased chance of a type II error in the analysis.  Assuming this information is not 
erroneous,  it  is contradictory to Yu et al., (2001).  A major difference between the studies is that 
Yu et al. compared trained runners to sedentary controls whereas the present study followed 
recreationally active individuals as they became resistance exercise trained to a greater extent 
over the course of 8 weeks.  Tannerstedt et al. (2009) showed that type II fibers phosphorylated 
p38 at a much higher rate than type I muscle fibers following eccentric contractions. While there 
is no other evidence to support the notion, it is possible that there is a fiber type difference 
associated with the amount of p38 present in the muscle.  A hypertrophy based resistance training 
program would selectively increase the volume of type II fibers in proportion to type I in the 
muscle.  This may be an area for future research.  
THE EFFECTS OF THE MIPS SUPPLEMENT 
 The multi-ingredient pre-workout supplement tested in this study did improve in  
some muscle performance variables to a greater extent than the placebo including the 1RM bench 
press, and the 70% of 1RM squat power, but the majority of strength and power measures were 
not improved by consumption of the supplement.  There are several reasons this may have 
occurred. The subjects of this study consumed the supplement only three times per week just 
prior to their resistance training bouts.  The manufacturer does recommend that the product be 
taken daily.  Since one of the ingredients of the supplement is creatine and studies do show that 
daily lower doses of creatine are can be as effective as larger short term doses, the dosing and 
timing used in this study may not have been adequate to observe all of the possible benefits of the 
supplement (Volek & Rawson, 2004).  And as always a longer intervention period may have been 
needed to distinguish a greater difference between the two groups performances.  As for the 
effects of the supplement on the MAPK pathways  it is possible that the effects were simply to 
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small to be detected by western blot and that a truly quantitative method would be necessary to 
distinguish any role that they play. Similarly perhaps the supplement must be consumed daily in 
order to produce observable differences.
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2/2008 HSCL #_____________ 
(to be assigned) 
UNIVERSITY OF KANSAS 
Human Subjects Committee Lawrence 
Application for Project Approval 
 
1. Name of Investigator(s) Dr. Andrew. Fry,  
2. Department Affiliation  Health Sport and Exercise Science 
3.  Campus or Home Mailing Address: 1301 Sunnyside Ave; Robinson Rm101D; Lawrence, KS 
66045 
a. Email address:__acfry@ku.edu________________________ 
Phone Number(s): (a) Campus: ___785-864-0784________________  
(b)________________________;  
5. Name of Faculty Member Responsible for Project: _ Dr. Andrew Fry________________ 
HSCL must receive faculty approval via hard copy signature or email notification before a student 
application may be processed. 
a. Email address of Faculty Member:________________________ 
6. Type of investigator and nature of activity. (Check appropriate categories) 
    Faculty or staff of University of Kansas 
    Project to be submitted for extramural funding; Agency:      
  KU/KUCR project number:   
(HSCL must compare all protocols in grant applications with the protocols in the 
corresponding HSCL application) 
    Project to be submitted for intramural funding; Source:  New Faculty General Research 
Program 
    Project unfunded 
    Other:       
    Student at University of Kansas:  Graduate  Undergraduate  Special 
    Class project (number & title of class):        
    Independent study (name of faculty supervisor):        
    Other (please explain):       
        Investigators not from the Lawrence campus but using subjects obtained  
           through the University of Kansas 
7.a. Title of investigation:  Skeletal Muscle MAPK Activation During High Power Resistance 
Exercise 
7.b. Title of sponsored project, if different from above: N/A 
 
8.   Individuals other than faculty, staff, or students at Kansas University.  
     Please identify investigators and research group:  
None 
 
9. Certifications:  By submitting this application via email or hard copy I am certifying that I have read, understand, 
and will comply with the policies and procedures of the University of Kansas regarding human subjects in research.  
I subscribe to the standards and will adhere to the policies and procedures of the HSCL, and I am familiar with the 
published guidelines for the ethical treatment of subjects associated with my particular field of study. 
 
Date:       Date:        
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Signature:         Signature:        
 First Investigator Faculty Supervisor 
 
Signature:         
 Second Investigator  
 
Principal Investigator: Dr. A. C. Fry HSCL #:  _________ 
 
Project Title:  Skeletal Muscle MAPK Activation During High Power Resistance Exercise 
10.  Please answer the following questions with regard to the research activity proposed:   
        (Please write "Yes" or "No.") 
 
  Does the research involve: 
   
yes a. drugs or other controlled substances? 
 
yes b. payment of subjects for participation? 
 
  no   c. access to subjects through a cooperating institution? 
 
 yes  d. substances taken internally by or applied externally to the subjects? 
 
  no   e. mechanical or electrical devices (e.g., electrodes)  applied to the subjects? 
 
 yes  f. fluids (e.g., blood) or tissues removed from the subjects? 
 
 yes  g. subjects experiencing stress (physiological or psychological)? 
 
  no   h. deception of subjects concerning any aspect of purposes or procedures (misleading or  
    withheld information)?  
 
  no   i. subjects who could be judged to have limited freedom of consent (e.g., minors,  
  developmentally delayed persons, or those institutionalized)? 
 
 yes  j. any procedure or activities that might place the subjects at risk (psychological, physical,  
  or social)? 
 
yes   k. use of interviews, focus groups, X questionnaires, audio or video recordings? 
(check all that apply) 
 
  no   l. data collection over a period greater than one year? 
 
 yes  m. a written consent form will be used?  Note:  HSCL makes the final determination on 
waiver of consent form.   
 
yes n.  will the research involve receiving, accessing, collecting, compiling and/or maintaining           
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   information that relates to the past, present, or future physical or mental health or  
   condition of an individual, the provision of health care to an individual, or the past,  
   present, or future payment for the provision of health care to an individual? 
     
11.  Approximate number of subjects to be involved in the research: 12 
 
 
Complete the following questions on this page.  Please do not use continuation sheets. 
 
This investigation will explore the effects of three different resistance exercise bouts on the Mitogen 
Activated Protein Kinase (MAPK) cellular signaling pathway for musclular hypertrophy. The three 
exercise bouts in this study represent the continuum that exists between resistance training load and the 
velocity with witch the load can be moved.  Maximal power has been shown to occur at approximately 
70% of the repetition maximum (CITE). The effect that power plays in regulating cellular signals of 
hypertrophy such as the MAPK pahway have not been investigated previously.  The purpose of this study 
is to compare changes in the MAPK cellular hypertrophy pathway following three bouts of resistance 
training that generate different levels of muscular power. 
 
12.   Project Purpose(s): 
 
 
Eight (8) young male volunteers (18-30y) will be recruited from KU and the local community for 
participation in our study. The inclusion criteria for all volunteers require: good general health, a history 
of consistent physically activity, non-obese (BMI less than 28kg/m2), non-smoking, normotensive, and 
free of metabolic or cardiovascular diseases. Due to gender differences in hormonal fluctuations and 
typical responses to resistance training only males will be used in this investigation.  
 
13.  Describe the proposed subjects (age, sex, race, or other special characteristics).  If there is a 
physical or mental health condition that characterizes the subjects to be included in the study, 
please indicate this here as well.  
14. Describe how the subjects are to be selected.  Please indicate how you will gain access to, 
and recruit these subjects for participation in the project.  That is, will you recruit participants 
through word-of-mouth, fliers or poster, newspaper ads, public or private membership or 
employee lists, etc.  (If subjects are to be recruited from a cooperating institution, such as a clinic 
or other service organization be aware that subjects' names and other private information, such as 
medical diagnosis, may not be obtained without the subjects' written permission.)   
 
Subjects will be recruited from a current list of potential volunteers that have indicated that they would be 
interested in participating in a research studies in the Applied Physiology Lab. Additional recruiting 
methods will be comprised of word of mouth and flyers posted around the KU campus and throughout the 
Lawrence area. All forms of recruitment will include investigator contact information (laboratory phone 
numbers and e-mail addresses). Potential subjects will be informed of the study design and inclusion 
criteria via phone, e-mail, and/or face to face communication.      
The purpose of this study is to examine changes in the MAPK pathway following resistance training 
designed to utilize different levels of muscular power. The three experimental protocols for the study are 
1) Five sets of 10 repetitions at 30% of  RM; 2) Five sets of five repetitions with 70% of 1RM; 3) Five 
sets of three reptitions at 90% of 1RM. A needle biopsy sample will be taken from the vastus lateralis 
muscle  before and after each of the three exercise protocols. Analysis of the MAPK protein concentration 
and phosphorylation ratios will be accoplished by western imunnoblot analysis.   
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Descriptive data for subject descriptives will be expressed as means and Standard Deviations. MAPK 
protien concentrations will be expressed as a ratio of phoshorylated to total protein and interblot 
comparisons will be made by using a standard control sample on each blot. Repeated measures ANOVA 
will test for statistical differences for percent change following each of the three exercise protocols. 
 
10a. Lidocaine will be used as a local anesthetic during all muscle biopsies. In order to further reduce the 
risk of allergic reaction (very rare), a prebiopsy questionaire will be used to determine if potential subjects 
have had allergic reactions to the anesthetic in previous dental proceedures. 
10b. Subjects will receive a $125 honorarium for their time.  
10d. In addition to the three exercise protocols used in this study subjects will have to complete a one (1) 
repetition maximum (RM) protocol for the squat exercise used in this study. The three experimental 
protocols for the study are 1) Five sets of 10 repetitions at 30% of  RM; 2) Five sets of five repetitions 
with 70% of 1RM; 3) Five sets of three reptitions at 90% of 1RM.  
10f. A total of six (6) muscle biopsies will be performed. 
 A muscle biopsy of the vastus lateralis will be obtained from each subject at  before exercise exercise and 
immediately post exercise for each of the three exercise protocols for quantification of intramuscular 
muscle proteins an cellular signalling activation.  Muscles biopsies will be performed by Philip Gallagher, 
PhD. The sample of muscle to be collected will be about 75-150 mg (the size of a pea) .  Testing sessions 
will be separated by seven days.  
10g. Resistance exercise can be mildly painful lasting a few seconds and occationally muscle sorenesss 
can occur which can last for up to 72 hours. Rarely significant musculoskeletal injuries can occur. The 
use of physically active regular exercisers for our subjects will greatly reduce the risks of injury and 
severe soreness.  
Muscle biopsy – muscle biopsy often causes a dull "cramp-like" pain and delayed soreness.  There may 
also be tenderness at the incission site a few days.  
10j. Muscle biopsy – there is a small risk of bleeding, infection, and scarring of the skin.  Temporary 
numbness of the skin near the biopsy site occurs rarely.  
10k. A health history questionnaire will be used to help in determining the eligibility of subjects. A 
physical activity questionaire establishes recent exercise habbits. A training history questionaire will 
assess long term exercise participation habbits. A pre-biopsy questionaire will be used  to assure the 
subject has not previous alergic reactions to lidocane, a history of abnormal blood clotting, or current 
blood thining medications. Laboratory proceedures exist to protect the subjects health information from 
third parties 
10m. Informed consent will be completed and obtained by each subject for all procedures in accordance 
with the Human Subject Committee – Lawrence of the University of Kansas. 
10n. See item 10k. 
Abstract of the proposed procedures in the project (must be complete on this page).  (The abstract should 
be a succinct overview of the project without jargon, unexplained abbreviations, or technical terminology.  
Here is where you must provide details about Yes answers to items under question 10.a through 10.n 
of the application: drugs, cooperating institutions, medical information requested, security 
measures and post-project plans for tapes, questionnaires, surveys, and other data, and detailed 
debriefing  
 
 
Submit one complete application and  supporting documents with your application. Supporting 
documents may  include consent forms, information statement, oral consent procedures, assent  
procedures, questionnaires/ surveys/research measures, advertisements  recruiting participants 
e.g. flyers, classified ads, debriefing procedures.   You may send  all materials via email 
attachment to dhann@ku.edu; Campus Mail to HSCL Youngberg Hall; or U.S. Mail to HSCL, 
Youngberg Hall, 2385 Irving  Hill Road, Lawrence, KS   66045-7563. 
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TITLE 
Skeletal Muscle MAPK Activation During 
High Power Resistance Exercise 
 
Informed Consent 
 
INTRODUCTION 
You are invited to participate in a research study examining the different physiological responses 
to various resistance exercise protocols in human skeletal muscle. This study will be conducted 
at the University of Kansas, and 8 subjects are being sought to participate. The Department of 
Health, Sports, and Exercise Sciences at the University of Kansas supports the practice of 
protecting human subjects participating in research.  The following information is provided to 
help you make an informed decision on whether or not to participate in the present study. Please 
feel free to ask any questions. 
 
PURPOSE OF THE STUDY 
The purpose of this study is to examine cellular signaling responses following three different 
resistance training bouts; 1)high load low power, 2) moderate load high power or 3) high load 
low power.  Additionally, the hormonal responses to these lifting protocols will also be studied.  
This investigation will help us to understand how exercisers adapt to their various resistance 
exercise programs. It may also help us to understand and develop more effective exercise 
protocols so that exercisers can more easily obtain desired benefits from their exercise programs.   
 
BASIS FOR SUBJECT SELECTION 
You are eligible to participate in this study if you meet the following inclusion criteria: 
Volunteers must be male, between the ages 18-30 years old.  Volunteers must also be in good 
general health, non-obese (body mass index < 28 kg/m
2
), non-smokers, and have normal blood 
pressure.  It is also important that subjects in this study be free of metabolic and cardiovascular 
diseases, a diagnosed bleeding disorder, or abnormal clotting or be taking a blood thinning 
medication or anti-inflammatory (aspirin, ibuprofen, naproxen). Persons with sensitivity to 
scarring, those that cannot exercise because of an orthopedic problem, or those that have been 
treated for a heat related injury will not be eligible for this study as well. Finally, if you are 
allergic to the local anesthetic or to betadine, or have had allergic reactions to other anesthetics 
(e.g., Novacaine), then you will be disqualified from the study. 
 
PROCEDURES 
A time-line of the testing procedures and an overview of the testing sequence for the pre-testing 
and test days are presented below.  All procedures will be conducted in the Applied Physiology 
Laboratory at the University of Kansas and will be supervised by trained personnel. 
 
Timeline of Testing Procedures for all subjects 
Approved by the Human Subjects Committee University of 
Kansas, Lawrence Campus (HSCL).  Approval expires one year 
from 10/16/2008. HSCL #17545 
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Pre-Testing: 
 Health History Questionnaire 
 Pre-Biopsy Screening Questionnaire 
 Age, Height, and Weight Measurements 
 Familiarization with exercise protocols 
 Training History 
1RM Squat Testing 
 
Test-Day 1 (one week after pre testing): 
 Muscle Biopsy #1 & Blood Draw #1 (following an 8 hour fast) 
Resistance Exercise Bout (randomly assigned) 
 Muscle Biopsy #2 Blood Draw #2 within five minutes of exercise completion 
 
Test-Day 2 (One week after previous testing): 
 Muscle Biopsy #3 & Blood Draw #3  (following an 8 hour fast) 
Resistance Exercise Bout (randomly assigned) 
 Muscle Biopsy #4 & Blood Draw #4 within five minutes of exercise completion 
 
Test-Day 3 (One week after previous testing): 
 Muscle Biopsy #5 & Blood Draw #5 (following an 8 hour fast) 
Resistance Exercise Bout (randomly assigned) 
 Muscle Biopsy #6 & Blood Draw #6 within five minutes of exercise completion 
 
Post Biopsy Follow-Up  (24 hrs after each testing day) 
All subjects are to report to the Applied Physiology Laboratory 24 hours after each set of 
biopsies (following each testing day) to ensure the biopsy site is healing normally. 
 
1) Pre-testing Protocol – Health history and pre-biopsy questionnaires, anthropometric data and 
determining appropriate weight for each group will be obtained no later than three (3) days prior 
to Test-Day 1.  These protocols will take approximately 30-40 minutes. 
 
2) Exercise Protocols - For this study the exercise bouts will consist of the two legged squat 
exercise. Each subject will first determine a one repetition maximum (1 RM; i.e., the most 
weight that can be lifted one time) for the squat exercise.  Subsequently each subject will 
complete each one of three squat exercise protocols over the course of the next three weeks. The 
three experimental protocols for the study are 1) Five sets of 10 repetitions at 30% of  RM; 2) Five sets of 
five repetitions with 70% of 1RM; 3) Five sets of three reptitions at 90% of 1RM. The rest intervals 
between exercise sets for the above protocols will be 2 minutes for the low load low power protocol (1),  
2 minutes for the high power protocol (2), and three minutes for the high load low power protocol (3).   
Each protocol will take 20-25 minutes to complete. 
 
3) Muscle Biopsies – You have been informed that the purpose of this study will be to examine 
the difference between a high intensity and a low intensity resistance protocols in regards to 
human skeletal muscle signal pathways and muscular growth.  By obtaining a small sample of 
your muscle tissue (¼ the size of a pea), the different types of proteins in your muscle may be 
determined which will be helpful in the evaluation of health and exercise performance.  All 
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muscle tissue samples (biopsies) will be taken from the outer portion of the front of the thigh 
using a needle biopsy technique.  Andrew Fry, Ph.D. has performed over 400 biopsies over the 
past decade and Philip Gallagher, PhD., Assistant Professor of HSES, has performed over 200 
muscle biopsies over the past year and has assisted on over 1000 biopsies over the past six years 
on various populations (athletes, sedentary people, elderly etc.) with no significant complications 
or nothing more than minimal adverse reactions have occurred. The procedure is being overseen 
by Jeff Burns, M.D. who is on the faculty in the Dept. of Neurology at the KU Medical Center in 
Kansas City, Kansas.  Dr. Burns supervises the procedure, but will not be physically present for 
the biopsies.  The total size of each muscle biopsy will be approximately ¼ the size of a pea (30 
mg or less). You will be placed on an examination table lying down on your back (supine) so 
that the muscles of the leg are relaxed.  The skin will be thoroughly cleaned with antiseptic 
solution (Betadine) using sterile cotton swabs after which a surgical cover will be placed around 
the sampling site. If you are allergic to Betadine, an alternative antiseptic solution will be used to 
clean the skin. A small amount (2ml or 2cc) of a local aesthetic (2% Lidocaine) will be injected 
into the tissue under the skin around the site to be sampled. During this injection you may feel a 
slight burning sensation. Following the injection of the numbing agent into your thigh, a 
minimum of five (5) minutes will be allowed to pass to ensure adequate time for the agent to take 
effect in the area where the biopsy will be taken. A 14 gauge biopsy needle (slightly larger than 
the needle used when donating blood) will be inserted into the middle of the muscle (muscle 
belly) at a depth of 3 cm (about 1 inch). During the time that the sample is being taken (about 5 
seconds) you may feel some deep pressure and cramping that will be moderately painful. You 
have been informed that if you have been previously diagnosed as having a bleeding disorder, a 
blood clotting problem, take blood thinning medication or have sensitivity to scarring, you will 
tell the researcher and not participate in the biopsy procedure.  
Following the biopsy procedure, firm and constant pressure will be placed on the wound to stop 
any bleeding. Since there is not an incision, the biopsy site will simply be covered with a large 
Band-Aid.  The procedure will take about 20 minutes.  
Sterile disposable instruments and sterile gloves will be used for the preparation of the site and 
the sterile biopsy needle will be used only once and then disposed.  Approximately 30 mg (¼ the 
size of a pea) of skeletal muscle tissue will be removed. With this muscle biopsy technique there 
is little possibility of a blood related infection since the needles are sterile in accordance with the 
standards of the American medical Asociation, and are used only once.  A total of six (6) 
biopsies will be performed over the course of this study (see timeline, above). 
 
4) Blood Draws – We will measure the amount of specific hormone and cytokine levels found in 
your blood prior to, after and following the exercise bout.  Six blood draws will be performed 
during this study (see time line above).  In this procedure, a small amount of blood will be taken 
from the antecubital vein (inside of the elbow joint) for each blood draw by a trained 
phlebotomist using a needle and a syringe.  Approximately 10 cc of blood (~ 2 tablespoons) will 
be drawn for each time-point.  The blood draw will take about 5 minutes. 
 
 
RISKS 
Blood Draws – The blood sample has a small risk of infection and bruising of the area, but this is 
rare. The needle stick for the blood draw will be mildly painful and only lasts a couple of 
seconds. 
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Muscle biopsy – The use of local anesthetics will result in a slight burning sensation, lasting 
approximately 5 seconds. There is an extremely low risk of allergic reactions to the local 
injection (1 in 1 million). There is a small chance of bleeding from the biopsy site. The principle 
concern would be prolonged bleeding which would produce a bruise in the area. This would 
extend the muscle soreness, but is adequately treated with rest, ice, a compression bandage, and 
keeping the leg elevated as much as possible. Nausea, dizziness, and fainting can occur in remote 
cases (1 in 100) during the biopsy process. As a result, the subjects will be in a supine position 
during the biopsy procedure. There is a minimal risk of infection (1 in 1000) and irritation 
associated with the biopsy procedure. The use of aseptic techniques, careful cleaning of the skin 
and keeping the area dry will minimize the risk of infection.  There is a minimal risk of bruising 
(1 in 100) from the biopsy procedure. This will be minimized by placing ice over the site 
following the procedure and by applying a compression bandage on the site for the 24 hours 
following the biopsy. In rare instances (1 in 200), some motor nerves may be damaged which 
may cause local muscle atrophy (decrease in the size of muscle fibers, with a small dimple on the 
skin). Since there is no incision, scarring is unlikely. 
 
 
Resistance Exercise: During the strength testing and exercise sessions there is a risk of injury or 
problems even though all subjects are screened for health problems.  The risk and discomforts 
that are associated with this type of test include muscle fatigue, lightheadedness, chest 
discomfort, knee and/or back injury, and very rarely death.  The potential for death during or 
immediately following the test (or any vigorous exercise) is approximately 0.5 per 10,000 tests, 
according to the American College of Sports Medicine.  You will experience muscle soreness 
due to the eccentric component of the resistance exercise.  The determination of your one-
repetition maximum (1 RM) will require maximal exercise. The three exercise bouts in this study 
will consist of  1) Five sets of 10 repetitions at 30% of  RM; 2) Five sets of five repetitions with 70% of 
1RM; 3) Five sets of three reptitions at 90% of 1RM. Each testing session will occur one week apart 
and the exercise bouts will occur in a randomized order.  Laboratory personnel will stay in 
contact with you after a testing/training session to ensure that you are comfortable.  You will be 
given a 24 hr contact number (Applied Physiology Laboratory personnel) to convey any type of 
unusual discomfort. 
 
In all of these procedures, great care will be taken to employ “universal precautions” for the 
handling of blood and infectious materials to ensure your safety. All instruments and bandages 
that will come into contact with broken skin will be sterile.  
 
FOLLOW UP CARE 
Following the procedure you will be provided with a biopsy care sheet, extra bandages and 
contact information for Andrew Fry, Ph.D. and Philip Gallagher, Ph.D. After 24-hrs you must 
report back to the testing coordinator to check the wound.  At this time the bandage will be 
removed and properly disposed of and a new sterile dressing placed over the wound. You will 
again be asked to report to the test coordinator after 3-days and be contacted via phone one week 
after the biopsy or whenever necessary to ensure normal recovery.  The biopsy procedure of this 
type is not likely to result in any scarring at the site, and all post-treatment care will aid in 
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reducing the potential for scarring.  All care will be taken to aid in the healing of the wound. The 
entire biopsy procedure will be performed under sterile conditions. All testing staff and 
associated personnel will be trained in first aid and will be familiar with emergency procedures.   
 
There have been no other major complications reported in the scientific literature as a result of 
taking small tissue samples from the skeletal muscle using the percutaneous needle biopsy 
technique described above. This procedure has been performed on numerous subjects by 
qualified personnel in many institutions worldwide with only slight discomfort being reported. 
During the muscle biopsy it is common to feel a strong cramping sensation in the muscle while 
the biopsy is being performed. However, muscle function is not impaired. In fact, subjects have 
been reported to continue participation in sporting events immediately following a muscle 
biopsy. It is common for subjects to experience mild soreness, moderate pain and bruising near 
the biopsy site, similar to a “Charlie-horse” the day after the procedure. In order to allow the 
biopsy site to heal properly and minimize the risk of infection, you should not get the biopsy site 
wet for 24-hours and avoid prolonged exposure to water for 4-days. Daily showers are 
acceptable (after the first 24-hours), but baths, swimming, sauna’s etc. should be avoided for 4-
days following the biopsy procedure. 
 
BENEFITS 
You will gain an increased understanding of your skeletal muscle function. A copy of all 
personal data from the tests will be provided to you and your data will be completely explained 
to you by a member of the investigation team.   
 
The results of this investigation will provide a greater knowledge of the acute cellular responses 
that exist with different resistance exercise protocols and will aid in understanding  the 
underlying causes of muscle hypertrophy.  These findings will not only have implications on 
those healthy individuals that are trying to gain muscle mass, but also patients that are subject to 
prolonged periods of bed rest or immobilization and the elderly population. 
PAYMENT TO SUBJECTS 
You will receive a $125 honorarium for your participation to compensate for your time and 
effort.  Investigators will ask you to fill out paperwork including your social security number in 
order to comply with federal and state tax and accounting regulations. 
 
 
 
IN CASE OF EMERGENCY CONTACT PROCEDURE 
In the event of a research related injury or adverse reaction, please contact Andrew Fry, Ph.D. at 
785-864-0784 (office), Phil Gallagher, Ph.D. 785-864-0784 (office) or 785-550-6300 (cell), or 
Becky Kudrna at 785-864-0773 (office), 573-694-8871 (cell). 
 
EMERGENCY CARE AND COMPENSATION IN CASE OF INJURY 
In the unlikely event that any injury or illness occurs as a result of this research, the University of 
Kansas, their officers, agents, and employees, do not automatically provide reimbursement for 
medical care or other compensation.  In cases of emergency, consistent with the Kansas Tort 
Claims Act, you would be responsible for payment of expenses related to treatments or 
associated with such complications except in a case where neglect can eventually be proven.  
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The following information is provided in accordance with HEW regulations: “In the event of 
injury, the Kansas Tort Claims Act provides for compensation if it can be demonstrated that the 
injury was caused by the negligent or wrongful act or omission of a state employee acting within 
the scope of his/her employment.”  You have been informed that payment for treatment of any 
injury or illness must be provided by your or your third-party payer, such as a health insurer.  If 
any injury or illness occurs in the course of research, or for more information, you will notify the 
investigator in charge. 
 
INFORMATION TO BE COLLECTED 
To perform this study, researchers will collect information about you. This information will be 
obtained from the health history and physical activity questionnaires, muscle biopsy, and muscle 
function evaluation. Your name will not be associated in any way with the information collected 
about you or with the research findings from this study. The researchers will use a study 
identification number or initials in place of your name. 
 
Dr. Andrew Fry, and his research team will use the information collected about you. The 
researchers will not share information about you with anyone not specified above unless required 
by law or unless you give written permission. 
 
Permission granted on this date to use and disclose your information remains in effect 
indefinitely. By signing this form you give permission for the use and disclosure of your 
information for the purposes of this study at any time in the future. 
 
CONFIDENTIALITY 
Information obtained from this research will be kept confidential, including questionnaires, 
medical history, laboratory findings, or performance data.  Records will be open to FDA 
inspection if deemed necessary, in accordance with FDA regulations.  Records of the research 
may also be subpoenaed by court order or inspected by federal regulatory authorities.  Data from 
this study may be used in reports, presentations, and publications, but the results of each 
individual will be kept confidential.  
 
REFUSAL TO SIGN CONSENT AND AUTHORIZATION 
You are not required to sign this Consent and Authorization form and you may refuse to do so 
without affecting your right to any services you are receiving or may receive from the University 
of Kansas or to participate in any programs or events of the University of Kansas. However, if 
you refuse to sign, you cannot participate in this study. 
 
CANCELLING THIS CONSENT AND AUTHORIZATION 
You may withdraw your consent to participate in this study at any time. You also have the right 
to cancel your permission to use and disclose information collected about you, in writing, at any 
time, by sending your written request to: Andrew Fry, Ph.D., University of Kansas, 1301 
Sunnyside Avenue, Robinson Center Room 101DJ, Lawrence, Kansas 66045. If you cancel 
permission to use your information, the researchers will stop collecting additional information 
about you. However, the research team may use and disclose information that was gathered 
before they received your cancellation, as described above. 
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PARTICIPANT CERTIFICATION 
I have read this Consent and Authorization form. I have had the opportunity to ask, and I have 
received answers to, any questions I had regarding the study and the use and disclosure of 
information about me for the study. I understand that if I have any additional questions about this 
study you may call Dr. Andrew Fry (785-864-0784) or e-mail: acfry@ku.edu.  I understand that 
if I have any additional questions about my rights as a research participant, I may call (785) 864-
7429 or write the Human Subjects Committee Lawrence Campus (HSCL), University of Kansas, 
2385 Irving Hill Road, Lawrence, Kansas 66045-7563, email dhann@ku.edu. 
 
I agree to take part in this study titled ‘Differential cellular response to various resistance 
exercise protocols’ as a research participant. I further agree to the uses and disclosures of my 
information as described above. By my signature I affirm that I am at least 18 years old and that I 
have received a copy of this Consent and Authorization form.  
 
 
___________________________________    ___________________________________ 
Print Subject’s Name          Signature of subject 
 
__________ 
Date 
 
________________________________    ___________________________________ 
Print Name of Person         Signature of Person Obtaining 
Consent 
Obtaining Consent 
 
__________ 
Date 
 
_________________________________    ___________________________________ 
Print Name of Witness       Signature of Witness 
 
__________ 
Date 
 
 
RESEARCHER CONTACT INFORMATION 
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Dr Andrew Fry   
Principle Investigator 
Applied Physiology Lab  
104 Robinson Hall  
University of Kansas  
Lawrence, KS 66045 
785-864-0784 
 
Becky Kudrna 
Graduate Teaching Assistant 
Applied Physiology Lab 
101DC Robinson Hall  
University of Kansas 
Lawrence, KS 66045  
785-864-0773 
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APPENDIX C: MEDICAL HISTORY QUESTIONNAIRE:  SKELETAL MUSCLE MAPK 
ACTIVATION DURING HIGH POWER RESISTANCE EXERCISE 
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 APPENDIX D: EXERCISE TRAINING HISTORY QUESTIONARE: SKELETAL MUSCLE 
MAPK ACTIVATION DURING HIGH POWER RESISTANCE EXERCISE 
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Exercise Training History Questionnaire 
 
TRAINING HISTORY QUESTIONAIRE 
 
1. At what age did you start resistance training?  
 
2. Since then how regular, have you been with resistance training?  
 
a. Have / do you take breaks from resistance training longer than 2 weeks? How frequently? 
 
b. Have / do you take breaks from resistance training longer than 1 month? How frequently? 
 
c. Have / do you take breaks from resistance training longer than 3 months? How frequently? 
 
d. When, and for what reasons did you take such breaks?  
 
3. When you first became serious about resistance training what was you main reason?  
a. Sport(s):   List_____________________level of competition_________________ 
b. Fitness     
c. Competitive Lifting:   (powerlifting, olympic lifting, strongman, other) 
d. Rehabilitation 
e. Other:  Explain____________________________________________________ 
 
4. What is your reason for resistance training now?  
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a. Sport(s):   List_____________________level of competition_________________ 
b. Fitness     
c. Competitive Lifting:   (powerlifting, olympic lifting, body building, strongman, other) 
d. Rehabilitation 
e. Other:  Explain____________________________________________________ 
 
5. In the last 6 months, How many times per week have you typically resistance trained? (Include 
multiple sessions per day separately). 
a. Time per week upper body  ____________ 
b. Times per week lower body  ____________ 
c. Total times per week    _____________ 
 
6. In the last 6 months, How many weeks have you participated in resistance training one time or 
LESS per week? (include vacations, breaks, and schedule conflicts). 
 
7. In the last 6 months, How many weeks have you participated in resistance training three times or 
MORE per week? (Include multiple sessions per day separately). 
 
8. When you lift, do you usually work at a percentage of your known maximum or by what other  
method do you choose a weight for each lift? 
 
9. Estimate your 1RM Max, or provide how much you think that you could lift for a given number of 
repetitions. 
LIFT I have done this 
exercise in 
Predicted Maximum Weight I usually Number of Repetitions I 
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the last 6 
months 
Weight use usually do 
BENCH PRESS Yes     No    
INCLINE BENCH  Yes     No    
PARRALLEL SQUAT Yes     No    
FULL SQUAT  
(below parallel) 
Yes     No    
DEADLIFT Yes     No    
STANDING PRESS Yes     No    
LUNGES (WITH BARBELL) Yes     No    
LEG EXTENSION Yes     No    
LEG CURLS Yes     No    
BICEP CURLS Yes     No    
PULL-UPS Yes     No    
DIPS Yes     No    
 
10. Create in the space below a representation of your TYPICAL exercise session in the last 6 months.  
If you perform lower and upper body movements on separate days list each day separately below.  
 
EXERCISE  SETS AND REPS           POUNDAGES 
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How many times per week do you participate in stretching? _____________ 
11. How many years/months have you been performing cardiovascular exercise?  
 
12. Since you began have / do you take breaks from cardiovascular training longer than 2 weeks? How 
frequently? 
 
13. Since you began, have / do you take breaks from cardiovascular training longer than 1 month? 
How frequently? 
 
14. Have / do you take breaks from cardiovascular  training longer than 3 months? How frequently? 
 
15. When, and for what reasons did you take such breaks?  
 
16. What is your Current reason for participating in cardiovascular training now?  
a. Sport(s):   List_____________________level of competition_________________ 
b. Health / Fitness: Explain ____________________________________________    
c. Rehabilitation 
d. Other:  Explain____________________________________________________ 
 
 
17. In the last 6 months, How many times per week have you typically participated in cardiovascular 
exercise? (Include multiple sessions per day separately).  
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18. In the last 6 months, How many weeks have you participated in cardiovascular exercise one time or 
LESS per week? (include vacations, breaks, and schedule conflicts). 
 
19. In the last 6 months, How many weeks have you participated in cardiovascular exercise training 
three times or MORE per week? (Include multiple sessions per day separately). 
 
20. When you run, row, swim, etc, do you usually work at a percentage of your Heart Rate Maximum, 
aim for a particular time goal, or by what other  method do you choose your intensity? 
 
21. Create a TYPICAL weeks exercise log of cardiovascular exercises below. Use only the last six 
months as a guide. Include type of exercise, the duration, and the intensity or pace at which you 
perform this task.  If you monitor your HR please include that information as well. Provide as much 
detail as possible use additional paper if needed.  
 TYPE OF 
EXERCISE 
DURATION PACE INTENSITY 
MONDAY     
TUESDAY     
WEDNESDAY     
THURSDAY     
FRIDAY     
SATURDAY     
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SUN     
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APPENDIX E: HUMAN SUBJECTS COMMITTEE LAWRENCE APPLICATION FOR PROJECT 
APPROVAL: EFFECTS OF RESISTANCE EXERCISE AND A PRE-WORKOUT DIETARY 
SUPPLEMENT ON PHYSIOLOGICAL ADAPTATIONS 
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HSCL #_____________ 
(to be assigned) 
UNIVERSITY OF KANSAS 
Human Subjects Committee Lawrence 
Application for Project Approval 
 
1. Name of Investigator(s) Philip Gallagher, Andy Fry, Phill Vardiman, Becky Kudrna, Nicole Moodie 
2. Department Affiliation  Health Sport and Exercise Science (HSES) 
3.  Campus or Home Mailing Address: Robinson 101DJ 
a. Email address:philku@ku.edu  
Phone Number(s): (a) Campus: 785.864.0773 (b) Home: 785.550.6300       
5. Name of Faculty Member Responsible for Project: Philip Gallagher, Andy Fry, Phill Vardiman 
HSCL must receive faculty approval via hard copy signature or email notification before a student 
application may be processed. 
a. Email address of Faculty Member: philku@ku.edu 
6. Type of investigator and nature of activity. (Check appropriate categories) 
    Faculty or staff of University of Kansas 
    Project to be submitted for extramural funding; Agency:      
  KU/KUCR project number:   
(HSCL must compare all protocols in grant applications with the protocols in the corresponding 
HSCL application) 
    Project to be submitted for intramural funding; Source:  _____ 
    Project unfunded 
    Other: Funded by Labrada Nutrition Inc. 
    Student at University of Kansas:  Graduate  Undergraduate  Special 
    Class project (number & title of class):        
    Independent study (name of faculty supervisor):        
    Other (please explain):       
       Investigators not from the Lawrence campus but using subjects obtained  
           through the University of Kansas 
7.a. Effects of resistance exercise and a pre-workout dietary supplement on physiological adaptations 
 
7.b. Title of sponsored project, if different from above: N/A 
 
8.   Individuals other than faculty, staff, or students at Kansas University.  
     Please identify investigators and research group:  
N/A 
 
9. Certifications:  By submitting this application via email or hard copy I am certifying that I have read, understand, and 
will comply with the policies and procedures of the University of Kansas regarding human subjects in research.  I subscribe 
to the standards and will adhere to the policies and procedures of the HSCL, and I am familiar with the published guidelines 
for the ethical treatment of subjects associated with my particular field of study. 
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Date:       Date:        
Signature:         Signature:        
 First Investigator Faculty Supervisor 
 
Signature:        Signature:        
 Second Investigator Third Investigator 
 
Principal Investigator: Philip Gallagher HSCL #:  _________ 
 
Project Title:  Effects of Resistance Exercise and a Pre-Workout Dietary Supplement on Physiological 
Adaptations 
 
10.  Please answer the following questions with regard to the research activity proposed:   
        (Please write "Yes" or "No.") 
 
  Does the research involve: 
   
Yes  a. drugs or other controlled substances? 
 
Yes  b. payment of subjects for participation? 
 
No   c. access to subjects through a cooperating institution? 
 
Yes  d. substances taken internally by or applied externally to the subjects? 
 
No   e. mechanical or electrical devices (e.g., electrodes) applied to the subjects? 
 
Yes  f. fluids (e.g., blood) or tissues removed from the subjects? 
 
Yes  g. subjects experiencing stress (physiological or psychological)? 
 
No   h. deception of subjects concerning any aspect of purposes or procedures (misleading or  
    withheld information)?  
 
No   i. subjects who could be judged to have limited freedom of consent (e.g., minors,  
  developmentally delayed persons, or those institutionalized)? 
 
Yes  j. any procedure or activities that might place the subjects at risk (psychological, physical,  
  or social)? 
 
Yes  k. use of interviews, focus groups, questionnaires, audio or video recordings? 
(check all that apply) 
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No   l. data collection over a period greater than one year? 
 
Yes  m. a written consent form will be used?  Note:  HSCL makes the final determination on waiver of 
consent form.   
 
Yes  n.  will the research involve receiving, accessing, collecting, compiling and/or maintaining           
   information that relates to the past, present, or future physical or mental health or  
   condition of an individual, the provision of health care to an individual, or the past,  
   present, or future payment for the provision of health care to an individual? 
     
11.  Approximate number of subjects to be involved in the research: 30 
 
 
 
Complete the following questions on this page.  Please do not use continuation sheets. 
 
12. Project Purpose(s): 
 
The purpose of the present proposal is to examine the effectiveness of a pre-workout dietary 
supplement combined with a supervised resistance exercise program.  Physiological variables of 
interest include lean body mass, body composition, muscle performance, and the accompanying 
endocrine and inflammatory profile.  Psychological variables of interest include body image, effort 
and enjoyment of training, and happiness from pre- to post-study. 
 
Aside from examining the effectiveness of the supplement, the tissue analysis following the 
resistance training component of this study could provide information concerning the role of 
resistance training in preventing and treating various disease states associated with 
inflammation and muscle wasting. 
 
The following hypotheses are postulated; 
 H1: The combination of dietary supplement and resistance exercise will 
result in greater improvements in body composition compared to resistance exercise and a placebo 
supplement. 
 H2: The combination of dietary supplement and resistance exercise will 
result in greater improvements in muscular performance compared to resistance exercise and a placebo 
supplement.  
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13.  Describe the proposed subjects (age, sex, race, or other special characteristics).  If there is a 
physical or mental health condition that characterizes the subjects to be included in the study, please 
indicate this here as well.  
14. Describe how the subjects are to be selected.  Please indicate how you will gain access to, and 
recruit these subjects for participation in the project.  That is, will you recruit participants through 
word-of-mouth, fliers or poster, newspaper ads, public or private membership or employee lists, etc.  
(If subjects are to be recruited from a cooperating institution, such as a clinic or other service 
organization be aware that subjects' names and other private information, such as medical diagnosis, 
may not be obtained without the subjects' written permission.)   
 
Subjects will be recruited from a current list of potential volunteers that have indicated that they 
would be interested in participating in research studies in the Applied Physiology Lab. Additional 
recruiting methods will include word of mouth and flyers posted around the KU campus and 
throughout the Lawrence area. All forms of recruitment will include investigator contact information 
(laboratory phone numbers and e-mail addresses). Potential subjects will be informed of the study 
design and inclusion criteria via phone and/or e-mail.  
 
15. Abstract of the proposed procedures in the project (must be complete on this page).  (The abstract 
should be a succinct overview of the project without jargon, unexplained abbreviations, or technical 
terminology.  Here is where you must provide details about Yes answers to items under question 10.a 
through 10.n of the application: drugs, cooperating institutions, medical information requested, 
security measures and post-project plans for tapes, questionnaires, surveys, and other data, and detailed 
debriefing procedures for deception. 
 
The volunteers will be between the ages of 18 and 35, healthy, non-obese (BMI <28 kg/m
2
), 
non-smoking, normotensive and free of metabolic diseases, cardiovascular diseases, kidney 
diseases, and history of seizures. Subjects will be screened using a health-history questionnaire 
for contraindications to exercise by American College of Sports Medicine (ACSM) guidelines. 
Subjects taking any medications or supplements that could interact with the ingredients in the 
supplement/placebo will be excluded from the study.  If the primary investigator believes a 
medication may pose a risk the information will be forwarded to Dr. Burns for further review.  
Resistance trained subjects (3 or more days / week for at least 1 year) will be selected to mimic 
those who are generally more likely to use a supplement of this kind. In addition, subjects 
currently using drugs that reduce inflammation (aspirin, ibuprofin, NSAIDs, etc.) will be 
excluded from this investigation. Due to gender differences in hormonal fluctuations and 
responses to resistance training, only males will be recruited. Prior to giving their consent to 
participate in this study, the individuals will be fully informed of the risks and benefits 
associated with the using this nutritional supplement or placebo, completing the exercise 
program, as well as muscle biopsies and blood sampling. Written consent will be required in 
accordance with the Institutional Review Board at the University of Kansas. 
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The purpose of this study is to examine the effect of a pre-workout energy drink mix used during an 
eight week strength training exercise program on muscular strength and hypertrophy. Thirty 
physically active, resistance trained, college age (18-35y) males will be recruited from the university 
and local community (Lawrence, Kansas) for this investigation. Subjects will be randomly assigned 
into 2 groups: 1) Experimental group (EXP) (n=15) and 2) control group (CON) (n=15). All subjects 
will report to the laboratory at least one week prior to the beginning of the training protocol in order 
to assess maximal strength and familiarize the subjects with the exercise protocol.  Subjects in the 
EXP will be instructed to drink the supplement 15 minutes before each training session.  Subjects in 
the CON will be instructed to drink a non-caloric placebo mixture at the same times.  Both groups 
will complete an eight week exercise program consisting of three days of strength training per week.  
Each training session will be designed to increase total body muscular strength and hypertrophy.  All 
subjects will complete the same training protocol.  The weights lifted will be assigned relative to 
each individual following their initial maximal strength testing. Subjects will have their blood drawn 
for analysis of plasma markers of the endocrine response (testosterone, growth hormone, cortisol), 
hypertrophy (IGF-1) and systemic inflammation (cytokines) immediately before and after the first 
training bout, and immediately before and after the final training bout. Muscle biopsies will occur 
prior to and immediately following the first and last training bouts. The muscle biopsies will be 
analyzed for markers of skeletal muscle hypertrophy and cytokines. These findings may determine 
the effectiveness of the pre-workout energy drink mix on weight, lean body mass, muscular strength 
and hypertrophy following a resistance training program. 
 
10a. Lidocaine will be used as a local anesthetic during muscle biopsy procedures. 
 
10b. Subjects will receive a $200 honorarium for their time. 
 
10d. An individual associated with the Applied Physiology Laboratory, but not on the research 
team for this particular project will be assigned the task of randomizing the subjects into 
placebo and experimental supplement groups.    This individual will also be responsible for 
preparing the supplement for each subject prior to their exercise sessions.  The supplement and 
placebo mix provided by Labrada Nutrition, Inc. will be labeled ‘A’ or ‘B’ but will not provide 
any information about their contents so that this study can be conducted in a double blind 
fashion.  Only this assigned individual will know the contents of the containers. This individual 
will mix the designated amount of supplement or placebo with a specific amount of water, and 
monitor the participant as they consume the drink 15 minutes prior to exercise.  The subjects 
will be aware that they are consuming either the EXP supplement or the CON placebo, but the 
content of what is ingested will not be revealed until the end of the study.  
 
The placebo drink will consist of a low-glycemic flavor and color matched drink.  The drink will be 
sweetened with polydextrin and/or mannitol.  The drink will also include typical food coloring and 
flavoring ingredients.   The experimental supplement is a blend of several known nutritional 
supplements and ergogenic aids.  The “Nutritional Information Panel” as it is typically included on 
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their commercially available powder supplement has been provided by the company and is also 
attached as a separate documents (super_charge_orange.JPG) .   A “Supplement and Placebo 
Ingredient Information” form is also attached in order to provide further information on these drinks. 
 
10f. Blood Samples:  Blood samples will be obtained by a trained phlebotomist from the antecubital 
vein, using a 22-gauge needle and a 10 cc syringe, when the subject is in a fasted state prior to any 
muscle function tests.  Blood samples will be centrifuged immediately at 3000 g for 20 min at 4°C. 
The plasma and serum will be stored at -80°C until analyses for CK and inflammatory cytokines are 
performed. 
 
 Muscle Biopsies:  Percutaneous needle biopsies will be obtained from the dominate leg.  The biopsy 
will be obtained with the subject in a fasted state prior to muscle function test.  The muscle biopsy 
(~100 mg/sample) will be obtained using manual suction and will be taken from the vastus lateralis 
under local anesthesia (2 % lidocaine) at a depth of ~2 cm.  The sample will be divided into two 
sections (40-50 mg each) and immediately frozen at -80°C for later analysis of stress kinases.  All 
muscle biopsies will be performed in the Applied Physiology Lab at the University of Kansas either 
by Dr. Phil Gallagher or by Dr. Andy Fry.  Dr. Gallagher and Dr. Fry have performed over 200 
muscle biopsies in the last year and assisted on over 1000 over the past eight years with no major 
complications. 
 
10g. Testing – The following tests will be performed at the beginning, middle, and end of the study 
for all subjects.   
 
 Body Weight/Anthropometric testing – Body weight will be measured with a calibrated 
 electronic scale.  Height will be measured by stadiometer.  Limb circumferences will be 
 measured using a measuring tape. 
  
Body Composition – Fat mass, lean body mass, and % fat will be determined using a dual-
energy X-ray absorptiometry (DEXA). 
 
One RM Strength – Maximal strength for the upper and lower body will be determined using 1 
RM tests for the barbell bench press and the barbell high bar parallel squat. 
 
Upper and Lower Body Power and Velocity – Average and peak power and average and peak 
velocity at 70% 1 RM loads for the bench press and barbell squat will be determined using a 
Fitrodyne external dynamometer. This is a simple device attached to the bar or weight stack 
during resistance training.  
 
Vertical Jump Height and Power – Lower body power using body weight for resistance will be 
determined from a standing vertical jump test.  Vertical jump height will be determined, and 
jump power will be calculated using the Harman equation. 
 
120 
 
 
 Rate of Force Development (RFD) – RFD for both the upper body (chest press) and lower body 
(knee extension) will be determined from specially modified resistance exercise machines.  
Force transducers will be placed in-series with the resistance cable to detect isometric force at 
200 HZ sampling rate.  These data will permit determination of maximum isometric force, 
RFD, and the explosive strength deficit as described by Zatsiorsky and Kraemer. 
 
 Dietary Recall – Subjects will be asked to record all food and drink consumption for three days 
prior to their first and last muscle biopsies. 
 
 Psychological & Other Survey Assessments – All subjects participating in the EXP and CON 
groups will complete the following survey assessments at each test time; 
 1 - Task & Ego Orientation in Sport Questionnaire 
 2 - Assessment of exercise enjoyment 
 3 - Assessment of body image 
 4 - Assessments of satiety and palatability 
 5 - Perceptions of training stresses 
  
Exercise Training - EXP and CON groups will perform free weight exercises three days each 
week.  The program will be periodized to provide an optimal stimulus for muscle hypertrophy 
and muscle performance adaptations.  In general, large muscle mass, multi-joint exercises will 
be performed using loads at or near repetition maximum (RM) loads (e.g.,  15 RM, 8-10 RM, 
4-6 RM).  One to two minutes inter-set rests will be used depending on the relative load for the 
exercise.  Examples of exercises include the following:  back squat, bench press, lat pull-down, 
barbell lunges, leg extension and curl, bicep curls, standing shoulder press, pull-ups, and dips 
   
10j. Muscle biopsy – The use of local anesthetics will result in a slight burning sensation, lasting 
approximately 5 seconds. There is an extremely low risk of allergic reactions to the local injection (1 
in 1 million). There is a small chance of bleeding from the biopsy site. The principle concern would 
be prolonged bleeding which would produce a bruise in the area. This would extend the muscle 
soreness, but is adequately treated with rest, ice, a compression bandage, and keeping the leg 
elevated as much as possible. Nausea, dizziness, and fainting can occur in remote cases (1 in 100) 
during the biopsy process. As a result, the subjects will be in a supine position during the biopsy 
procedure. There is a minimal risk of infection (1 in 1000) and irritation associated with the biopsy 
procedure. The use of aseptic techniques and careful cleaning of the skin and keeping the area dry 
will minimize the risk of infection.  There is a minimal risk of bruising (1 in 100) from the biopsy 
procedure. This will be minimized by placing ice over the site following the procedure and by 
applying a compression bandage on the site for the 24 hours following the biopsy. In rare instances 
(1 in 200), some motor nerves may be damaged which may cause local muscle atrophy (decrease in 
the size of muscle fibers, with a small dimple on the skin). There is likely to be a small scar (½-inch 
in length) where the incision for the biopsy is performed. This scar usually dissipates over a period of 
6-12 months at which time the scaring is very modest. 
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Blood Draws – The blood draw has a small risk of infection and bruising of the area, but this is rare. 
The needle stick for the blood draw will be mildly painful and only lasts a couple of seconds. 
 
DEXA Scan- The DEXA scan uses an FDA-approved X-ray absortiometry machine to examine body 
composition (relative amounts of fat mass and lean body mass).  During this test the subject will be 
asked to lie face up, on a padded table, motionless for 7-15 minutes while the scanner arm of the 
DEXA machine passes over the entire body.  The DEXA scan information is being used solely for 
descriptive and comparison purposes and to assess the accuracy of various modes of body 
composition assessment.  This information is not intended to be used as a clinical assessment of any 
medical conditions.  The Applied Physiology Laboratory complies with the University of Kansas 
philosophy of safety that all exposures to radiation, other hazardous materials, and risks from 
physical hazards shall be kept “as low as reasonably achievable.”  The amount of radiation that the 
subject has received in the past year will be evaluated and they will be asked to let us know if they 
have had any other X-rays within the last year.  If they have recently undergone CT (Computed 
Tomography), PET, fluoroscopic, or nuclear medicine studies within the past year, they will be 
excluded from the study. The amount of radiation that each subject will receive from a whole body 
scan is the equivalent to a uniform whole-body exposure of 0.1 mrem.  The DEXA measurements 
will be made by trained personnel who have either received accreditation from the International 
Society for Clinical Densiometry for diagnostic procedures, or who have received formal training by 
the manufacturer following installation of the DEXA for femur/spine/total body scans. 
 
Strength Testing and Training Exercises– The strength training exercises may cause delayed onset 
muscle soreness. This soreness is temporary and is a normal result of this type of contraction. The 
subjects will be informed to expect muscle soreness to peak between 24-48 hours and dissipate 
completely 96 hours following the exercise sessions. 
 
Supplementation-   
 
Placebo – This drink will consist of a low-glycemic flavor and color matched drink.  The drink 
will be sweetened with polydextrin and/or mannitol.  There are no known risks to consuming a 
beverage of this sort except in those who have rare food allergies to the artificial colors or 
flavoring ingredients. No information on the occurrences rate are estimated to be less than 1 per 
100 people, and lower in adults than children. Persons known to be allergic to one of the 
ingredients will be excluded from the study 
 
The Experimental Supplement- The risks associated with each ingredient in the experimental 
pre-exercise supplement are listed in the provided attachment. Safety information for caffeine 
in doses similar to this are also provided in that document.  Questionnaires will be provided 
to all subjects at each exercise session to record any adverse effects (jitters, upset stomach, 
etc.) they might have as a result of taking the placebo or supplement.  If they experience 
any problems that they feel might be related to the placebo or supplement after leaving 
the training session they will be asked to report these to lab personnel immediately..  In 
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addition, blood pressure will be monitored once each week prior to supplementation in 
order to ensure the subject is not having an adverse reaction to the caffeine in the 
supplement.  These questionnaires and blood pressure measures will be reviewed by the 
safety monitoring board.  
 
None of the investigators in this study have consulting agreements, ownership interests or 
receive personal benefit from Labrada Nutrition Inc. Labrada Nutrition Inc. has not 
placed any restrictions on the publication of the effects of this supplement. 
 
   
10k. During the preliminary meeting subjects will be asked to complete medical history, physical 
activity, and biopsy screening questionnaires to determine if they are eligible for participation in this 
study.  At the beginning and end of the study, all participants will complete body image, effort and 
enjoyment of training, and happiness surveys.  All questionnaires are attached.  All documents will 
be stored in a secured file in the Applied Physiology Laboratory.  All subject contact information 
will be saved following the conclusion of the study in the event Labrada Nutrition implements a 
product recall. 
 
10m. Informed consent will be completed and obtained by each subject for all procedures in 
accordance with the Human Subject Committee – Lawrence of the University of Kansas. The 
consent form is attached. 
 
10n. As discussed in 10k, medical history, biopsy screening, and activity questionnaires will be used 
to gain information concerning the individuals past and present health and activity levels.  In addition 
body image, effort and enjoyment of training, and happiness surveys will be completed by 
participants at the beginning and end of the study.   
 
 
Effects of Resistance Exercise and a Pre-Workout Dietary Supplement 
on Physiological Adaptations 
 
Exclusionary Criteria (in no particular order) 
 
 Non-male 
 Under the age of 18 
 Over the age of 35 
 Does not meet activity requirements (exercise 3 or more days per week for at least 1 year) 
 Obese (BMI <28 kg/m2) 
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 Smoker 
 Has adverse effects to caffeine (including but not limited to dizziness, lightheadedness, nausea, 
‘jitters’) 
 Uses anti-inflammatory medications or over-the counter drugs and cannot discontinue for the 
course of the study 
 Uses other nutritional supplements and will not discontinue for the course of the study 
 Takes other medications that may interact with ingredients in the placebo and/or supplement 
(including but not limited to anti-asthmatic medications, anti-hypertensive medications, blood 
thinners, anti-seizure medications, anti-anxiety medications, monoamine oxidase inhibitors-
MAOIs) 
 History of any of the following: myocardial infarction, angiography, coronary surgery, chest 
discomfort, high blood pressure, low blood pressure, shortness of breath upon light exertion, 
pulmonary disease, dizziness upon light exertion, heart palpitation, heart murmur, diabetes (I or 
II), circulation problems, stomach ulcers, kidney problems, metal implants, seizures 
 History of allergies to local anesthetics 
 History of allergies to iodine 
 History of allergies to Band-Aids or other adhesives 
 History of food allergies (including but not limited to ingredients in the placebo such as 
polydextrin or mannitol, or ingredients in the supplement such as caffeine, tyrosine, citrulline, 
malate, arginine, taurine, creatine, betaine, picamilon, niacin, beta-alanine, glutamine, histidine, 
vitamin A or vitamin E) 
 
 
 
Submit one complete application and supporting documents with your application. Supporting 
documents may  include consent forms, information statement, oral consent procedures, assent  
procedures, questionnaires/ surveys/research measures, advertisements  recruiting participants e.g. 
flyers, classified ads, debriefing procedures.   You may send  all materials via email attachment to 
dhann@ku.edu; Campus Mail to HSCL Youngberg Hall; or U.S. Mail to HSCL, Youngberg Hall, 2385 
Irving  Hill Road, Lawrence, KS   66045-7563. 
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HSRC REQUESTED ADDENDUM TO THE APPLICATION 
 
Supplement and Placebo Ingredient Explanation 
 
Placebo: 
 
The placebo drink will consist of a low-glycemic flavor and color matched drink.  The drink will be 
sweetened with polydextrin and/or mannitol.  There are no known risks to consuming a beverage of 
this sort except in those who have rare food allergies to the artificial colors or flavoring ingredients. 
No information on the occurrences rate are estimated to be less than 1 per 100 people, and lower in 
adults than children. Persons known to be allergic to one of the ingredients will be excluded from the 
study.  The health history questionnaire asks potential subjects to identify food allergies so that these 
individuals may be excluded from the study.  
 
Supplement: 
 
Caffeine. The experimental exercise supplement contains 450 mg of caffeine.  The US Food and 
Drug Administration (FDA) has carefully reviewed and deemed caffeine safe and effective. In 1958, 
caffeine was placed on the Food and Drug Administration's generally recognized as safe (GRAS) list. 
The FDA does regulate the amount of caffeine in cola and ‘pepper’ sodas, but not in other foods or 
drinks.   
 
 Caffeine is a known stimulant and diuretic, though its actions as a diuretic have recently 
been questioned in scientific literature. Typical positive effects of caffeine ingestion include 
increased mental concentration, and increased physical work capacity. Ingestion of caffeine can also 
cause ‘jitters’, nervousness, and dizziness or light headedness, and palpitations. These symptoms 
increase with the amount of caffeine consumed. Other common risks of excessive caffeine 
consumption especially in caffeine sensitive individuals include elevated heart rate, anxiety/panic 
disorders, and heart arrhythmias. Caffeine tolerance is highly individualized (A. Graham, Schultz, 
Mayo-Smith, Ries, & Wilford, 2003). Some individuals experience negative side effects with even 
small amounts of caffeine ingested (40mg), while others tolerate doses over 500mg without negative 
side effects. Caffeine sensitivity is decreased in habitual caffeine consumers, such as persons who 
drink coffee or tea daily, but individuals may experience symptoms of caffeine if they consume more 
than their usual amount of caffeine. Body size is also be associated with greater caffeine tolerance 
such that caffeine consumption is often expressed relative to body size. Because the amount of 
caffeine that causes sensitivities is highly individualized, there is no calculatable risk level for these 
side effects. We will be using the Caffeine Questionnaire to attempt to determine individuals who 
would be overtly sensitive to the quantity of caffeine in the study and exclude them from the study.  
 
that caffeine is unlikely to cause adverse events when taken in moderation. 
 
 One cup of brewed or drip coffee has between 80 and 175mg of caffeine per 8oz 
depending on the type of bean, roast, and method of processing,100mg per 8oz is considered the 
average amount. A typical restaurant (McDonalds) serving of coffee is 12 or 16oz. and the typical 
home coffee mug is 11oz, but travel mugs are typically 16oz. The 20oz VENTI® size coffee also 
sold at Starbucks®  has 415mg of caffeine. Nearly the same as in this supplement. These are the 
values of the regular brewed coffees without ‘espresso shots’ or the other coffee drinks like Café 
Americano®.  (http://www.starbucks.com/retail/nutrition_beverage_detail.asp Thus this supplement 
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has caffeine equivalent to 4.5-8oz servings of coffee, or 3.75 McDonalds small coffees, or 2.25 
Large Coffees.   
 A review of caffeine in sports performance has also been sent to you as a separate 
document (L. M. Burke, 2008).  Caffeine is no longer considered an illegal performance enhancer by 
the World Anti-Doping Association (monitor Olympic and International Sports) because they 
deemed caffeine not to be dangerous in quantities that would increase sports performance (L. M. 
Burke, 2008).  Additionally, many studies on caffeine have been performed using the standard 
research doses of 2-6mg/kg bodyweight (a table of studies provided in the article(L. M. Burke, 
2008)). Other evidence suggests doses of caffeine up to 13mg/kg will improve athletic performance, 
(Sokmen et al., 2008). In the above information, I addressed the fact that habitual caffeine users are 
less sensitive (A. Graham et al., 2003) .  Two specific studies have addressed the ergogenic benefits 
in non-habituated athletes ((Jacobson, Weber, Claypool, & Hunt, 1992; Woolf, Bidwell, & Carlson, 
2009).  The first study, (Jacobson et al., 1992) examine caffeine doses of 7mg/kg in individuals 
consuming less than 100mg of caffeine per day and  Woolf et al used a dose of 5mg/kg in individuals 
with less than 50mg caffeine per day in their diet.  Jackobson reported “no side effects” while in 
Woolf et al. some subjects reported jitters, but no other ill effects. I would like to point out once 
again that these studies utilized dosages at more than 1.5 times greater than we are proposing in 
subjects that are similarly or less caffeine habituated than the subjects we will use in our study.  
 
 We understand that caffeine can have serious side effects particularly in sensitive 
individuals. In an attempt to prevent the negative caffeine related side effects in our subjects they 
will answer several questions concerning past and present caffeine consumption.   Subjects will be 
included in this study if they have previously consumed moderate to large amounts of caffeine 
(300mg/day or more) without experiencing any excessively uncomfortable negative side effects. We 
also ask our subjects to refrain from excessive outside caffeine consumption during the study. Our 
informed consent document warns subjects of typical caffeine side effects and asks them to report 
any supplement side effects to us.  A person reporting uncomfortable effects can thus be identified 
and removed from the study via the process described in the IRB application 
 
 
L-Tyrosine. The supplement contains 500 mg of tyrosine.  Tyrosine is a nonessential amino acid 
(meaning the body is capable of producing it from other nutrients) that is made from phenylalanine, 
an essential amino acid.  Tyrosine is a precursor for dopamine and norepinephrine and has been 
associated with improved alertness, regulate appetite, reduced body fat and an antidepressant effect. 
Tyrosine is commonly found in meats and dairy products. A maximum safe dose has not be 
established for tyrosine, but it is suggested that a person should not consume more than 12,000 
mg/day.  Typical tyrosine supplements sold over the counter contain 500-1500mg/dose. Thus, this 
supplement contains less than a typical tyrosine supplement.  Overconsumption of tyrosine (which is 
unforeseeable in this study) can cause gastric upset, diarrhea, and migraine headaches.   
 
L-Citrulline-di-malate. The supplement contains 1000 mg of L-citrulline-di-malate. Citrulline is a 
nonessential amino acid formed from the essential amino acid lysine. Citrulline plays a role in the 
removal of ammonia from the blood via the urea cycle. No clear benefit of citrulline supplementation 
has been determined at this time.  No dosage recommendations currently exist for this supplement. 
However, a published research study reported that 6g/day for 15 days of citrulline supplementation 
did not cause any adverse side effects in men. Because of the small amount in this product, we do not 
anticipate you will experience any side effects due to this ingredient.    
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Arginine Alpha-ketogluterate.  This supplement contains 1742 mg of arginine alpha-ketogluterate. 
This is another naturally occurring amino acid derivative.  Arginine is associated with improved 
growth hormone production leading to reduced body fat and increased muscle mass, improved 
creatine production, and ammonia detoxification.  Previous studies have found that supplementation 
with 6,000-15,000 mg/day of arginine alpha-ketoluterate in healthy young men was well tolerated 
and did not produce negative side effects. Some have suggested a common dose for arginine is 
2,000-3,000 mg taken by mouth three times per day.  Because of the combined amount of ingredients 
that are variations of arginine in this product (arginine alpha-ketogluterate and di-arginine malate) is 
lower than doses used in previous studies, we do not anticipate any risks to due to arginine.  Potential 
side effects associated with high doses of arginine include stomach discomfort, including nausea, 
stomach cramps, or an increased number of stools were common. Other potential side effects include 
low blood pressure and changes in numerous chemicals and electrolytes in the blood. Examples 
include high potassium, high chloride, low sodium, low phosphate, high blood urea nitrogen, and 
high creatinine levels.  
 
Taurine. This supplement contains 1,000mg of taurine.  Taurine is an amino acid derivative found 
naturally in protein rich foods. This nonessential amino acid is associated with the transport of 
electrolytes within the cell as well as with blood pressure regulation. The recommended amount of 
taurine supplementation (beyond food sources) should not exceed 3,000mg per day.   Because of the 
small amount of taurine in this product, we do not anticipate any risks to you due to this ingredient.  
 
Di-arginine malate.  The supplement contains 2242 mg per serving of di-arginine malate.  This is 
another form of the amino acid arginine. Arginine is associated with improved growth hormone 
production leading to reduced body fat and increased muscle mass, improved creatine production, 
and ammonia detoxification.  Previous studies have found that supplementation with 6,000-15,000 
mg/day of arginine alpha-ketoluterate in healthy young men was well tolerated and did not produce 
negative side effects. Some have suggested a common dose for arginine is 2,000-3,000 mg taken by 
mouth three times per day.  Because of the combined amount of ingredients that are variations of 
arginine in this product (arginine alpha-ketogluterate and di-arginine malate) is lower than doses 
used in previous studies, we do not anticipate any risks to due to arginine.  stomach discomfort, 
including nausea, stomach cramps, or an increased number of stools were common. Other potential 
side effects include low blood pressure and changes in numerous chemicals and electrolytes in the 
blood. Examples include high potassium, high chloride, low sodium, low phosphate, high blood urea 
nitrogen, and high creatinine levels.  
 
Creatine monohydrate.  The supplement contains 2750 mg of creatine monohydrate.  Creatine is a 
substance that is produced naturally in the body and stored in the musculature of animals to 
contribute to the production of energy.  Creatine monohydrate is the most common supplemental 
form of creatine. Research has shown that creatine monohydrate supplementation is associated with 
improved muscle strength and power, increases in lean body mass, faster recovery between high 
intensity exercise bouts, and reduced muscular fatigue.  Doses of creatine used to improve training 
intensity and recovery range from 1000 to 24,000 mg per day. Some individuals have used as much 
as 80 to 160 mg per pound of lean body weight (10,000 to 24,000 mg total). Generally creatine is 
used regularly for time periods of two to three months. Large doses of creatine may cause 
dehydration and gastrointestinal distress.  However, because the combined dose of creatine 
monohydrate and di-creatine malate is at the lower end of the typical creatine dose, few side effects 
are anticipated.  No adverse long-term effects have been reported from long-term clinical trials using 
creatine monohydrate. 
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Betaine anhydrous.  The supplement contains 1000 mg of betaine anhydrous.  Betaine consumption 
has been associated with increased creatine consumption in animals.  While studies have examined 
exercise performance changes following betaine supplementation, none have examined if changes 
occur in creatine concentration in humans.  No recommended doses of betaine have been found, 
however a previous study using betain supplementation in humans involved consumption of 1,250 
mg of betaine twice per day for fifteen days.   
 
Di-creatine malate.  This supplement contains 125 mg of di-creatine malate, a form of creatine that 
is bound to malic acid which is also involved in energy production.  As previously mentioned large 
doses of creatine may cause dehydration and gastrointestinal distress. However, because the 
combined dose of creatine monohydrate and di-creatine malate is at the lower end of the typical 
creatine dose, few side effects are anticipated. 
 
Picamilon.  This supplement used in this study contains 50 mg of picamilon.  Picamilon is a 
combination of niacin with γ-Aminobutyric acid (GABA), an inhibitory neurotransmitter in the 
central nervous system. Picamilon is naturally occuring found in particularly high quantities in 
makerel and wheat bran, but also in walnuts and spinach. During digestion niacin and GABA are 
separated and act independently on the body.  Niacin (common vitamin) acts as a vasodilator, 
allowing for relaxation of the smooth muscle that surrounds the vasculature.  Niacin doses of 1500-
6,000 mg/day have been shown to induce side effects including skin flushing and itching, dry skin, as 
well as gastrointestinal complaints. Issues such as liver toxicity, hyperglycemia, orthostasis, and 
cardiac arrhythmias have also been reported in higher doses. The dose of picaminion in this 
supplement is unlikely to cause any side effects except possibly  a niacin induced flushing.  GABA 
could activate its receptors and allow for decreased CNS activity, increasing mental focus and 
increasing sleepiness. Occasionally other side effects such as anxiety and headache have been 
reported as well. There are no dietary recommendations for GABA, but it is found in large quantities 
in organ meats like liver, kidney and brain. Dietary supplements sold in the US contain 50-750mg of 
GABA. A tolerable limit set in some nutrition texts is 500mg/day. With 59mg of picomilon in this 
suplement there appears to be no risk.  
 
Beta-Alanine.  This supplement contains 750 mg of beta-alanine, a naturally occuring amino acid 
derivative of the amino acid alanine.  Beta-alanine has been shown to decrease fatigue and increase 
work production in humans.  No side effects have been reported for beta alanine doses of up to 800 
mg per day. 
 
N-Acetyl-L-Glutamine.  This supplement contains 500 mg of N-Acetyl-L-Glutamine.  L-glutamine 
has been shown to neutralize cortisol, a hormone that is released during high intensity exercise.  This 
could allow for more efficient muscle growth as well as aid in the exercise recovery process.  
Glutamine is also essential for proper brain functioning as well as the immune system.  Glutamine 
supplementation doses have ranged from 500 to over 20,000 mg per day.  Due to the small amount of 
this ingredient in the supplement, no side effects are anticipated due to this ingredient. 
 
L-Histidine. This supplement contains 125 mg of L-histidine.  It has been suggested that this amino 
acid is essential to the growth and repair of tissue which is very important for those participating in 
high intensity activities.  Additionally, histidine has been used as a treatment for arthritis due to its 
anti-inflammatory effects. Exact benefits of the long-term usage of this supplement by athletes are 
unclear.  Typical supplemental doses of L-histidine range from 1,000 to 5,000 mg per day. Due to the 
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small amount of this ingredient in the supplement, no side effects are anticipated due to this 
ingredient. (E. R. Burke & Gastelu, 1999) 
 
Vitamin A.  The experimental supplement contains 4600 IU of Vitamin A.  The recommended daily 
allowance of Vitamin A is 3,000 IU for males over the age of nineteen.  The tolerable upper limit 
intake level for Vitamin A is 10,000 UL.  Recent research has suggested acute toxicity related to this 
vitamin can occur at doses of 25,000 IU/kg of body weight.  Chronic toxicity can also occur if high 
doses of this vitamin are taken on a regular basis.  It has been shown that this will occur when taking 
4,000 IU/kg of body weight daily for 6–15 months.  While the amount of Vitamin A in this 
supplement is higher than the RDA it is also lower than the upper intake level as well as the levels 
shown to cause acute or chronic toxicity.  However, individuals with renal problems will not be 
included in this study as a precaution as high doses of Vitamin A place a large stress on the kidneys. 
 
Vitamin E.  The experimental supplement contains 8 IU of Vitamin E.  The recommended daily 
allowance (RDA) of this vitamin is 22.4 IU for males over the age of fourteen.  This being 
considered we do not see Vitamin E toxicity as a risk for this study considering the relatively low 
dose included in the supplement. 
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APPENDIX F:  INFORMED CONSENT DOCUMENT: THE EFFECTS OF RESISTANCE 
EXERICSE AND A PRE-WORKOUT DIETARY SUPPLEMENT ON ERK AND P38 
PHORPHORYLATION 
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Effects of Resistance Exercise and a Pre-Workout Dietary Supplement 
on Physiological Adaptations 
 
Informed Consent 
 
INTRODUCTION 
You are invited to participate in a research study examining the effectiveness of a pre-workout dietary 
supplement combined with resistance exercise on various physiological variables. Thirty subjects are 
being sought to participate in this study at the University of Kansas. The Department of Health, Sports, 
and Exercise Sciences at the University of Kansas supports the practice of protection for human 
subjects participating in research.  The following information is provided to help you make an 
informed decision on whether or not to participate in the present study. Please feel free to ask any 
questions.  This study was requested and is funded by Labrada Nutrition Inc. 
 
PURPOSE OF THE STUDY 
The purpose of this study is to examine the effectiveness of a pre-workout dietary supplement 
combined with an 8-week resistance training program on physiological measures.  This supplement 
contains large amounts of caffeine (450mg); the equivalent of 4.5 cups of coffee.  The supplement is 
not currently commercially available and is not approved by the Food and Drug administration (FDA), 
as no supplements are approved by the FDA.  Aside from examining the effectiveness of the 
supplement, the resistance training component of this study could provide information concerning the 
role of resistance training in preventing and treating various disease states associated with 
inflammation and muscle wasting. The physiological variables that will be measured include body 
weight, body composition, strength and power, as well as blood and muscle markers of skeletal muscle 
growth (hypertrophy) and the inflammatory response to training.    Psychological variables of interest 
include body image, effort and enjoyment of training, and happiness from pre- to post-study. The 
findings of this study will determine if the use of this pre-workout supplement in addition to an 8-week 
training plan results in changes in weight, lean body mass, muscular strength and hypertrophy that are 
different from the changes in these variables that result from the 8-week training plan alone.   
 
BASIS FOR SUBJECT SELECTION 
In order to participate in this study you must be male, between the ages of 18 and 35, healthy, non-
obese (BMI <28 kg/m
2
), non-smoking, and free of metabolic cardiovascular, kidney diseases, as well 
as free of a history of seizures. You will be screened for participation using a health-history 
questionnaire for contraindications to exercise by American College of Sports Medicine (ACSM) 
guidelines. If you are currently taking any medications or supplements that may interact with 
ingredients in the supplement/placebo involved in this study you will be excluded from the study.  In 
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order to participate in this study you must be recreationally trained (exercise 3 or more days / week for 
at least 1 year) in order to mimic those who are generally more likely to use a supplement of this kind. 
In addition, if you currently use drugs that reduce inflammation (aspirin, ibuprofin, NSAIDs, etc.) on a 
regular basis you will be excluded from this investigation. You will also be asked to refrain from using 
these drugs during the course of this study.  Due to gender differences in hormonal fluctuations and 
responses to resistance training only males will be recruited.  
 
PROCEDURES 
A time-line of the testing procedures and an overview of the training program for the present study are 
presented below.  All procedures will be conducted in the Applied Physiology Laboratory (APL) at the 
University of Kansas and will be supervised by trained personnel.  It is important for you to note that 
this study will require your presence in the Applied Physiology Laboratory for three exercise sessions 
per week (approximately five hours per week) for eight weeks, as well as two testing sessions for one 
week prior to the start of the training program (approximately 2.5 hours). 
 
Timeline of Procedures for Control and Experimental Groups: 
 
Pre-Screening: 
 All subjects 
 Health History Questionnaire 
 Pre-Biopsy Screening Questionnaire 
 Physical Activity Questionnaire 
 Caffeine Intake and Tolerance Questionnaire 
 Body image, effort and enjoyment of training, and happiness surveys 
 Body Weight, Anthropometric Tests, Body Composition Testing using DEXA Scan
  
  
Testing Week 0, Day 1: 
 1-Repetition Maximum (RM) on all exercises in the training protocol 
 
Testing Week 0, Day 2 (3 days after Testing Day 1): 
 Power Testing for Bench Press and Back Squat (70% 1-RM); Vertical Jump Test 
 Rate of Force Development Testing Using an Isometric Bench Press 
  
Training Week 1, Day 1: 
 Report to the APL following an 8 hour fast 
 Turn in 3-day dietary recall 
 30 Minute Rest 
 Blood Draw #1, Biopsy #1 
 Drink Supplement/Placebo 
 Exercise Session 
 15 Minute Rest  
 Blood Draw #2, Biopsy #2 
 
Training Week 5, Day 1: 
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 Body Weight Testing 
 Strength Testing (1-RM) on all exercises in the training protocol will be substituted for 
 normal workout. 
 
Training Week 5, Day 2: 
 Power testing for bench press and back squat (70% 1-RM); vertical jump test 
 Rate of force development testing using an isometric bench press 
 These tests will be incorporated with the bench press and squat sessions within the 
normal  workout. 
 
 
Training Week 8, Day 1: 
 Strength Testing (1-RM) on all exercises in the training protocol will be substituted for 
 normal workout. 
 
Training Week 8, Day 2: 
 Power Testing for bench press and back squat (70% 1-RM); vertical jump test 
 Rate of force development testing using an isometric bench press 
 These tests will be incorporated with the bench press and squat sessions within the 
normal  workout.  
 Body image, effort and enjoyment of training, and happiness surveys 
 
Training Week 8, Day 3: 
 Report to the APL following an 8 hour fast 
 Turn in 3-day dietary recall 
 30 Minute Rest 
 Blood Draw #3, Biopsy #3 
 Drink Supplement/Placebo 
 Exercise Session 
 15 Minute Rest 
 Blood Draw #4, Biopsy #4 
 DEXA Scan 
 
Week 0 1 2 3 4 5 6 7 8 9 
Supplement  
 
        
 
Training 
 
Biopsy 
 
Blood Draw 
 
 
 
 
      
 
      
 
 
 
 
      
 
 
 
      
     
      
Body Weight           
Body 
Composition 
          
1 RM Testing           
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Power Testing           
 
Rate of Force 
Development 
          
 
Psych Surveys 
 
Supplement 
Side Effect 
Survey 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
 
1) Pre-testing Protocol – Health history, physical activity, caffeine intake and tolerance, body 
image, effort and enjoyment of training, and happiness, and pre-biopsy questionnaires, and 
anthropometric data will be obtained approximately 1 week prior to Testing Day 1.  These procedures 
will take approximately 1 hour. The DEXA scan uses an FDA-approved X-ray absortiometry machine 
to examine body composition (relative amounts of fat mass and lean body mass).  During this test you 
will be asked to lie face up and motionless on a padded table for 7-15 minutes while the scanner arm of 
the DEXA machine passes over your entire body.  The scanner will not enclose or touch you, and you 
can wear your regular clothing (no metal or jewelry allowed).  The DEXA scan information is being 
used solely for descriptive and comparison purposes.  This information is not intended to be used as a 
clinical assessment of any medical conditions. 
 
2) Exercise Testing - All strength testing will be done using free weights or weight machines and 
following standard repetition maximum strength testing guidelines. You will be asked to warm-up for 
five minutes using a stationary leg cycle.  Following this you will perform warm-up sets followed by 
maximal effort lifts for each of the following exercises:  back squat, bench press, lat pull-down, barbell 
lunges, leg extension and curl, bicep curls, standing shoulder press, pull-ups, and dips.  Three days 
later you will return to the lab and perform power tests for the bench press and the back squat.  This 
will involve a warm-up, followed by a set of 10 repetitions at 70% of your bench press and back squat 
maximum.  Following this you will perform a rate of force development test for the bench press and 
leg extension exercises. Force transducers will be placed in-series with the resistance cable to detect 
isometric force for these exercises.  For this test you will begin to perform the exercise as normal by 
generating force to move the weight, however the weight will be fixed and will not move.  Following 
this test you will perform three maximal vertical jumps with approximately 3 minutes of rest between 
each.  This will allow for the calculation of lower body power. 
 
3)  Dietary Recall – All subjects will be asked to record food and drink consumption (including 
portion sizes) for three consecutive days prior to their first (training week 1, day 1) and last muscle 
biopsies (training week 8, day 3).  Subjects will be given an explanation of portion sizes prior to 
completion of the dietary recall. 
 
4) Supplementation – All subjects will be asked to consume either a supplement or placebo drink 15 
minutes prior to each exercise session.  The supplement/placebo mix containers will be labeled as 
either A or B, however the experiment will be double blind in nature as neither the research staff or the 
subjects will know which drink is the placebo and which is the supplement.  An individual associated 
with the Applied Physiology Lab, but not directly involved in this research project, will be assigned the 
duty of randomizing subjects into placebo and supplement groups.  They will also be responsible for 
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mixing the supplement drinks, and monitoring the subjects as they consume the supplement.  As this 
experiment is double blind, no other individuals associated with the study (research staff or subjects) 
will know which mix is the supplement and which is the placebo until after the study is completed.   
Questionnaires will be provided to you at each exercise session to record any adverse effects you might 
have as a result of taking the placebo or supplement.   
 
5) Exercise Training – All subjects will report to the lab for training three times per week for a period 
of eight weeks.  These training sessions will be supervised by Applied Physiology Laboratory 
personnel.  All subjects will complete an exercise program consisting of the following exercises:  back 
squat, bench press, lat pull-down, barbell lunges, leg extension and curl, bicep curls, standing shoulder 
press, pull-ups, and dips.  The training program will be relative to each subject and exercise will be 
prescribed as a percentage of their 1-RM on each exercise.  We will also ask you to fill out a pre/post 
exercise survey to asses your anticipation of training, recovery, strength, and muscle pain. These 
surveys will take less than 5 minutes to complete.    Subjects are asked to refrain from exercise other 
than that which is prescribed by this study and takes place during the assigned lab training hours. 
 
6) Muscle Biopsies – You have been informed that one of the purposes of this study is to measure the 
cellular markers of muscle growth and inflammation from the muscle samples that we collect.  By 
obtaining a small sample of your muscle tissue (size of a pencil eraser or small finger nail), the 
different types of proteins in your muscle may be determined which will be helpful in the evaluation of 
health and exercise performance.  All muscle tissue samples (biopsies) will be taken from the outer 
portion of the front of the thigh using a needle biopsy technique by either Philip Gallagher or Andy 
Fry.  Philip Gallagher, PhD., Assistant Professor of HSES, and Andy Fry, PhD., Professor of HSES, 
have performed over 200 muscle biopsies over the past year and have assisted on over 1000 biopsies 
over the past six years on various populations (athletes, sedentary people, elderly etc.) with no 
significant complications and nothing more than minimal adverse reactions. The procedure is being 
overseen by Jeff Burns, M.D., who is a medical doctor in Neurology at the KU Medical Center in 
Kansas City, Kansas.  Dr. Burns supervises the procedure, but will not be physically present for the 
biopsies.  The total size of the muscle biopsy will be approximately the size of a pea. You will be 
placed on an examination table lying down on your back (supine) so that the muscles of the leg are 
relaxed.  The skin will be thoroughly cleaned with antiseptic solution (Betadine) using sterile cotton 
swabs after which a surgical cover will be placed around the sampling site. If you are allergic to 
Betadine, an alternative antiseptic solution will be used to clean the skin. A small amount (2ml or 2cc) 
of a local aesthetic (2% Lidocaine) will be injected into the tissue under the skin around the site to be 
sampled. During this injection you may feel a slight burning sensation. If you are allergic to the local 
anesthetic, or have had allergic reactions to other anesthetics (i.e.: Novocain) then you will be 
disqualified from the study. Following the injection of the numbing agent into your thigh, a minimum 
of five (5) minutes will be allowed to pass to ensure adequate time for the agent to take effect in the 
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area where the incision will be made. A small incision (1 cm) will then be made in the skin overlying 
the muscle and the biopsy needle inserted into the middle of the muscle (muscle belly) at a depth of 3 
cm (about 1 inch). During the time that the sample is being taken (about 5 seconds) you may feel some 
deep pressure and cramping that will be moderately painful. You have been informed that if you have 
been previously diagnosed as having a bleeding disorder, a blood clotting problem, take blood thinning 
medication or have sensitivity to scarring, you will tell the researcher and not participate in the biopsy 
procedure.  
Following the biopsy procedure, firm and constant pressure will be placed on the wound to stop any 
bleeding. The incision site will be closed with a Steri-Strip and covered with a large Band-Aid and the 
site compressed using a 10 cm strip of sterile elastic surgical stocking for a period of 24-hrs.  You have 
been informed that the procedure will take about 20 min.  
Sterile disposable instruments and sterile gloves will be used for the preparation of the site and the 
reusable biopsy needle will be thoroughly sterilized (via steam and heat autoclave) after each biopsy.  
Approximately 100 mg (size of a pencil eraser or small finger nail) of skeletal muscle tissue will be 
removed. With the invasive skeletal muscle biopsy technique there is the possibility of a blood related 
infection (HIV, Hepatitis B), but the reusable needles will be cleaned and sterilized using an autoclave, 
a generally accepted method of cleaning surgical instruments.  
A total of four (4) biopsies will be performed over the course of the study (see timeline, above). 
 
7) Blood Draws – We will measure hormonal markers as well as levels of inflammation found in your 
blood prior to and following the first and last exercise bouts.  Four blood draws will be performed 
during this study (see timeline, above).  In this procedure, a small amount of blood will be taken from a 
vein for each blood draw by a trained phlebotomist using a needle and a syringe.  Approximately 10 cc 
of blood (~ 2 teaspoons) will be drawn for each time-point.  The blood draw will take about 5 minutes. 
 
RISKS 
 
1) DEXA scan – The examination of fat and lean body mass using the DEXA scan involves the use of 
X-rays.    Any time an individual is exposed to radiation there is a potential risk.  The University of 
Kansas has adopted the philosophy of safety that all exposures to radiation, other hazardous materials, 
and risks from physical hazards shall be kept “as low as reasonably achievable.”  There are certain 
limitations placed upon this procedure to achieve that aim.  We also want to evaluate the amount of 
radiation that you have received in the past year, so if you have had other X-rays, let us know.  If you 
have recently undergone CT (Computed Tomography), PET, fluoroscopic, or nuclear medicine studies 
within the past year, you cannot participate in the study.  The parts of your body that will receive the 
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most radiation are the skin, although your whole body will be exposed to the radiation.  The amount of 
radiation that you will receive from a whole body scan is the equivalent to a uniform whole-body 
exposure of 0.1 mrem.  Although you will be receiving a small amount of exposure, the risk from 
radiation exposure of this magnitude is too small to be measured directly and is considered to be 
negligible when compared with other everyday risks.  For example, you would receive radiation 
exposure of approximately 80 mrem on a transatlantic airline flight of 8 hours, or 30-40 mrem during a 
typical chest x-ray.  The Radiation Safety Officer at the University of Kansas can provide you with 
more information about radiation exposure if you are interested.  The DEXA measurements are being 
made by trained personnel who have either received accreditation from the International Society for 
Clinical Densiometry for diagnostic procedures, or who have received formal training by the 
manufacturer following installation of the DEXA for femur/spine/total body scans.  The system is 
equipped with a Class II Laser device.  A Class II rating indicates a low power visible laser that is not 
normally hazardous to eyesight but has the potential to be hazardous if viewed directly for an extended 
period of time.  Because of the potential hazard DO NOT stare directly into the beam while the laser is 
in operation.  The beam should not be pointed directly in the eye of the participant. 
 
2) Muscle biopsies – The use of local anesthetics will result in a slight burning sensation, lasting 
approximately 5 seconds. There is a risk of allergic reactions to the local injection (1 in 1 million). 
There is a small chance of bleeding from the biopsy site. The principle concern would be prolonged 
bleeding which would produce a bruise in the area. This would extend the muscle soreness, but is 
adequately treated with rest, ice, a compression bandage, and keeping the leg elevated as much as 
possible. Nausea, dizziness, and fainting can occur (1 in 100) during the biopsy process. As a result, 
the subjects will be in a supine position during the biopsy procedure. There is a risk of infection (1 in 
1000) and irritation associated with the biopsy procedure. The use of aseptic techniques, careful 
cleaning of the skin and keeping the area dry will minimize the risk of infection.  There is a risk of 
bruising (1 in 100) from the biopsy procedure. This will be minimized by placing ice over the site 
following the procedure and by applying a compression bandage on the site for the 24 hours following 
the biopsy. In some instances (1 in 200), some motor nerves may be damaged which may cause local 
muscle atrophy (decrease in the size of muscle fibers, with a small dimple on the skin). There is likely 
to be a small scar where the biopsy is performed. This scar usually dissipates over a period of 6-12 
months at which time the scaring is very modest. 
 
3) Blood Draws – The blood sample has a small risk of infection and bruising of the area. The needle 
stick for the blood draw will be mildly painful and only lasts a couple of seconds. 
 
4) Supplement/Placebo—You will be asked to ingest a supplement or a placebo drink fifteen minutes 
before each training bout.  This variation of the supplement is not currently available for commercial 
sale and is not approved by the Food and Drug Administration (FDA), as no supplements are approved 
by the FDA.  The ingredients found in this supplement and information concerning the safety of their 
ingestion is listed below.    In addition, blood pressure will be monitored once each week prior to 
supplementation in order to ensure your body is not having an adverse reaction to the caffeine in the 
supplement.  These questionnaires and blood pressure measures will be reviewed by the safety 
monitoring board. Due to the possibility that other supplements may contain similar ingredients that 
might interact with ingredients in the study placebo/supplement and place you at risk or  confound the 
results of this study, you are asked to refrain from using all other nutritional supplements or ergogenic 
aids during the course of this study.  
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Placebo: 
The placebo drink will consist of a low-glycemic flavor and color matched drink sweetened with 
polydextrin and/or mannitol.  Persons known to be allergic to one of the ingredients will be excluded 
from the study 
 
Supplement: 
Caffeine. The experimental exercise supplement contains 450 mg of caffeine.  This amount is the 
equivalent of 4.5 eight-ounce cups of coffee.  Caffeine is a known stimulant and diuretic. Side effects 
of caffeine ingestion can include increased mental concentration, increased physical work capacity, 
‘jitters’, nervousness, and dizziness or light headedness. These symptoms increase with the amount 
of caffeine consumed so we ask that you refrain from consuming more than one additional serving of 
caffeinated beverages per day, (coffee, tea, energy drinks, colas) during the study.  You will be 
included in this study if you have previously consumed moderate amounts of caffeine (300mg/day or 
more) without experiencing any uncomfortable negative side effects.   
 
L-Tyrosine.  The supplement contains 500 mg of L-tyrosine.  Tyrosine a non-essential amino acid 
(meaning the body is capable of producing it from other nutrients) commonly found in meats and 
dairy products.    Doses of 100 to several thousand mg of L-tyrosine are common.  Overconsumption 
of tyrosine (which is unforeseeable in this study) can cause gastric upset, diarrhea, and migraine 
headaches.   
 
L-Citrulline-di-malate. The supplement used in this study contains 1000 mg of L-citrulline-di-
malate, an amino acid derivative. Previous research using citrulline in greater doses than the present 
study did not cause any adverse side effects in men, therefore we do not anticipate any risks to you 
due to this ingredient.  
 
Arginine Alpha-ketogluterate.  The supplement contains 1742 mg of arginine alpha-ketogluterate, 
another naturally occurring amino acid derivative.  Previous research using arginine alpha-
ketogluterate in greater doses than the present study did not cause any adverse side effects in men, 
therefore we do not anticipate any risks to you due to this ingredient.  
 
Taurine. The supplement contains 1,000mg of taurine, an amino acid derivative found naturally in 
protein rich foods. The recommended amount of taurine supplementation (beyond food sources) 
should not exceed 3,000mg per day.  Because of the small amount of taurine in this product, we do 
not anticipate any risks to you due to this ingredient.  
 
Di-arginine malate.  The supplement contains 2242 mg of di-arginine malate, a form of the amino 
acid arginine. Potential side effects include low blood pressure and changes in various chemicals and 
electrolytes in the blood. Examples include high potassium, high chloride, low sodium, low 
phosphate, high blood urea nitrogen, and high creatinine levels.  
  
Creatine monohydrate.  The supplement contains 2750 mg of creatine monohydrate, a substance that 
is produced naturally in the body and stored in the musculature of animals to contribute to the 
production of energy. Doses of creatine used to improve training intensity and recovery range from 
1000 to 24,000 mg per day. Large doses of creatine may cause dehydration and gastrointestinal 
distress.  However, because the combined dose of creatine monohydrate and di-creatine malate is at 
the lower end of the typical creatine dose, few side effects are anticipated. 
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Betaine anhydrous.  The supplement contains 1000 mg of betaine which is associated with increased 
creatine consumption in animals.  Previous studies using higher doses of betaine did not report side 
effects.   
 
Di-creatine malate.  This supplement contains 125 mg of di-creatine malate, a form of creatine that 
is bound to malic acid which is also involved in energy production.  As previously mentioned large 
doses of creatine may cause dehydration and gastrointestinal distress. However, because the 
combined dose of creatine monohydrate and di-creatine malate is at the lower end of the typical 
creatine dose, few side effects are anticipated. 
 
Picamilon.  The supplement contains 50 mg of picamilon, a combination of niacin with γ-
Aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system.  Niacin 
acts as a vasodilator, allowing for relaxation of the smooth muscle that surrounds the vasculature.  
Because of the small amount of picamilon in this product we do not anticipate any risks to you due to 
this ingredient .    
 
Beta-Alanine.  This supplement contains 750 mg of beta-alanine, a naturally occuring amino acid 
derivative.  Beta-alanine has been shown to decrease fatigue and increase work production in 
humans.  No side effects have been reported for beta alanine doses of 800 mg per day. 
 
N-Acetyl-L-Glutamine.  This supplement contains 500 mg of N-Acetyl-L-Glutamine.  L-glutamine 
has been shown to neutralize cortisol, a hormone that is released during high intensity exercise.  This 
could allow for more efficient muscle growth as well as aid in the exercise recovery process.  
Glutamine supplementation doses have ranged from 500 to over 20,000 mg per day.  Due to the 
small amount of this ingredient in the supplement, no side effects are anticipated due to this 
ingredient. 
 
L-Histidine.  This supplement contains 125 mg of L-histidine.  It has been suggested that this amino 
acid is essential to the growth and repair of tissue.  Typical supplemental doses of L-histidine range 
from 1,000 to 5,000 mg per day. Due to the small amount of this ingredient in the supplement, no 
side effects are anticipated due to this ingredient. 
 
Vitamin A.  The experimental supplement contains 4600 IU of Vitamin A. While the amount of 
Vitamin A in this supplement is higher than the RDA (3,000 IU) it is also lower than the upper intake 
level (10,000 IU) as well as the levels shown to cause acute or chronic toxicity (25,000 IU/kg).  
However, individuals with renal problems will not be included in this study as a precaution as high 
doses of Vitamin A place a large stress on the kidneys. 
 
Vitamin E.  The experimental supplement contains 8 IU of Vitamin E.  The recommended daily 
allowance (RDA) of this vitamin is 22.4 IU for males over the age of fourteen.  Because of the small 
amount of Vitamin E in this product we do not anticipate any risks to you due to this ingredient. 
 
5)  Exercise Testing and Training - During the strength testing sessions test there is a risk potential 
even though no health problems exist.  The risk and discomforts that are associated with this type of 
test include muscle fatigue, lightheadedness, chest discomfort, and very rarely death.  The potential for 
death during or immediately following the test (or any vigorous exercise) is approximately 0.5 per 
10,000 tests, according to the American College of Sports Medicine.  Following these tests however 
you will experience muscle soreness due to the eccentric component of the resistance exercise.  This 
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soreness generally referred to as delayed on-set muscle soreness as it is most likely to occur in the days 
following the exercise bout.  All exercise training will be prescribed relative to each subject and the 
principles of proper exercise progression and overload will be applied so as to reduce the risk of injury 
to the subject.  Laboratory personnel will stay in contact with you after a testing/training session to 
ensure that you are comfortable.  You will be given a 24 hr contact number for the Applied Physiology 
Laboratory personnel to convey any type of unusual discomfort. 
 
In all of these procedures, care will be taken to employ “universal precautions” for the handling of blood 
and infectious materials to ensure your safety. 
 
FOLLOW UP CARE 
Following the procedure you will be provided with a biopsy care sheet, extra bandages and contact 
information for Philip Gallagher, Ph.D. After 24-hrs you must report back to the testing coordinator to 
check the wound.  At this time the bandage will be removed and properly disposed of and a new sterile 
dressing placed over the wound. You will again be asked to report to the test coordinator after 3-days 
and be contacted via phone one week after the biopsy or whenever necessary to ensure normal 
recovery.  The biopsy procedure often results in a small fine scar at the site of the incision, however, 
all care post-treatment will aid in reducing the potential for scarring.  All care will be taken to aid in 
the healing of the wound. The entire biopsy procedure will be performed under sterile conditions. All 
testing staff and associated personnel will be trained in first aid and will be familiar with emergency 
procedures.   
 
There have been no other major complications reported in the scientific literature as a result of taking 
small tissue samples from the skeletal muscle using the percutaneous needle biopsy technique 
described above. This procedure has been performed on numerous subjects by qualified personnel in 
many institutions worldwide with only slight discomfort being reported. During the muscle biopsy it is 
common to feel a strong cramping sensation in the muscle while the biopsy is being performed. 
However, muscle function is not impaired. In fact, subjects have been reported to continue 
participation in sporting events immediately following a muscle biopsy. It is common for subjects to 
experience mild soreness, moderate pain and bruising near the biopsy site, similar to a “Charlie-horse” 
the day after the procedure. In order to allow the incisions to heal properly and minimize the risk of 
infection, you should not get the biopsy site wet for 24-hours and avoid prolonged exposure to water 
for 4-days. Daily showers are acceptable (after the first 24-hours), but baths, swimming, sauna’s etc. 
should be avoided for 4-days following the biopsy procedure. 
 
BENEFITS 
Over the course of this study you will receive information concerning your current body composition 
and fitness level as well as a personal exercise prescription.  You will also have trained staff 
monitoring your exercise sessions and tracking your progress through the program. You will also gain 
an increased understanding of resistance training and program design. A copy of all personal data from 
the tests will be provided to you and your data will be completely explained to you by a member of the 
investigation team.   
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The results of this investigation will provide a greater knowledge of the influence of exercise training 
and use of this supplement on body composition, muscular strength and power, as well as blood and 
muscle markers of skeletal muscle growth (hypertrophy) and the inflammatory profile.  These findings 
will not only have implications on those healthy individuals that are trying to gain muscle mass and 
lose body fat but also those whose focus is to improve muscular strength and power. 
 
PAYMENT TO SUBJECTS 
You will receive a $200 honorarium for your participation in this nine week study.  Although not 
anticipated, if you need to discontinue the study due to an adverse event associated with the study, you 
will receive compensation.   In the event that you do not complete the entire nine week study, the 
following payment plan has been devised:  completion of ¼ of the study will result in a payment of 
$25; completion of ½ of the study will result in payment of $50; completion of over ½ of the study will 
result in full payment.  Investigators will ask for your social security number in order to comply with 
federal and state tax and accounting regulations. 
 
COMPENSATION FOR INJURY 
The following information is provided in accordance with HEW regulations: “In the event of injury, 
the Kansas Tort Claims Act provides for compensation if it can be demonstrated that the injury was 
caused by the negligent or wrongful act or omission of a state employee acting within the scope of 
his/her employment.” 
 
IN CASE OF EMERGENCY CONTACT PROCEDURE 
In the event of a research related injury or adverse reaction, please contact Philip Gallagher, Ph.D. at 
785-864-0772 (office) or 785-550-6300 (cell), or the Applied Physiology Laboratory at 785-864-0773. 
 
EMERGENCY CARE AND COMPENSATION IN CASE OF INJURY 
In the unlikely event that any injury or illness occurs as a result of this research, the University of 
Kansas, their officers, agents, and employees, do not automatically provide reimbursement for medical 
care or other compensation.  In cases of emergency, consistent with the Kansas Tort Claims Act, you 
would be responsible for payment of expenses related to treatments or associated with such 
complications except in a case where neglect can eventually be proven.  You have been informed that 
payment for treatment of any injury or illness must be provided by you or your third-party payer, such 
as a health insurer.  If any injury or illness occurs in the course of research, or for more information, 
you will notify the investigator in charge. 
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INFORMATION TO BE COLLECTED 
To perform this study, researchers will collect information about you. This information will be 
obtained from the health history and physical activity questionnaires, muscle biopsy, and muscle 
function evaluation. Your name will not be associated in any way with the information or tissue 
collected from you or with the research findings from this study. The researchers will use a study 
identification number or initials in place of your name.  Any data stored electronically will be stored on 
a password protected laboratory computer (not a laptop).  Any paperwork associated with you will be 
stored in a locked file cabinet secured in the Applied Physiology Laboratory.  All tissue collected will 
be stored securely in the Applied Physiology Laboratory.  All tissue collected will be used to analyze 
markers of inflammation and protein synthesis. 
 
Some persons or groups that receive your information may not be required to comply with the Health 
Insurance Portability and Accountability Act’s privacy regulations, and your information may lose this 
federal protection if those persons or groups disclose it. The researchers will not share information 
about you with anyone outside of the Applied Physiology Laboratory personnel unless required by law 
or unless you give written permission. 
 
Permission granted on this date to use and disclose your information remains in effect indefinitely. By 
signing this form you give permission for the use and disclosure of your information for the purposes 
of this study at any time in the future. 
 
REFUSAL TO SIGN CONSENT AND AUTHORIZATION 
You are not required to sign this Consent and Authorization form and you may refuse to do so without 
affecting your right to any services you are receiving or may receive from the University of Kansas or 
to participate in any programs or events of the University of Kansas. However, if you refuse to sign, 
you cannot participate in this study. 
 
CANCELLING THIS CONSENT AND AUTHORIZATION 
You may withdraw your consent to participate in this study at any time. You also have the right to 
cancel your permission to use and disclose information collected about you, in writing, at any time, by 
sending your written request to: Philip Gallagher, Ph.D., University of Kansas, 1301 Sunnyside 
Avenue, Robinson Center Room 101DJ, Lawrence, Kansas 66045. If you cancel permission to use 
your information, the researchers will stop collecting additional information about you. However, the 
research team may use and disclose information that was gathered before they received your 
cancellation, as described above. 
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PARTICIPANT CERTIFICATION 
I have read this Consent and Authorization form. I have had the opportunity to ask, and I have received 
answers to, any questions I had regarding the study and the use and disclosure of information about me 
for the study. I understand that if I have any additional questions about this study I may call Prof. 
Philip Gallagher (785-864-0772) or e-mail: philku@ku.edu, Becky Kudrna, kudrna@ku.edu or Nicole 
Moodie nicolejg@ku.edu. I understand that if I have any additional questions about my rights as a 
research participant, I may call 785-864-7429 or write the Human Subjects Committee Lawrence 
Campus (HSCL), University of Kansas, 2385 Irving Hill Road, Lawrence, Kansas 66045-7563, email 
dhann@ku.edu. 
 
I agree to take part in this study titled ‘Effects of Resistance Exercise and a Pre-Workout Dietary 
Supplement on Physiological Adaptations’ as a research participant. I further agree to the uses and 
disclosures of my information as described above. By my signature I affirm that I am at least 18 years 
old and that I have received a copy of this Consent and Authorization form.  
 
______________________   ___________________________________ 
Print Subject’s Name        Signature of subject 
 
__________ 
Date 
 
________________________________    ___________________________________ 
Print Name of Person         Signature of Person Obtaining Consent 
Obtaining Consent 
 
__________ 
Date 
 
_________________________________    ___________________________________ 
Print Name of Witness       Signature of Witness 
 
__________ 
Date 
 
 
RESEARCHER CONTACT INFORMATION 
 
Philip Gallagher   Becky Kudrna or Nicole Moodie 
Principle Investigator   Applied Physiology Lab 
Applied Physiology Lab  161D Robinson Hall 
101DJ Robinson Hall   University of Kansas 
University of Kansas   Lawrence, KS 66045  
Lawrence, KS 66045   785-864-0773 
785-864-0772     
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APPLIED PHYSIOLOGY LABORATORY 
UNIVERSITY OF KANSAS 
 
MEDICAL HISTORY FORM WITH CAFFEINE TOLERANCE QUESTIONS 
 
NAME:_  DATE:  
 
AGE:   HEIGHT:   WEIGHT:   
 
A. Have you ever experienced any of the following conditions or procedures? 
 
1. Myocardial Infarction YES NO 
2. Angiography YES NO 
3. Coronary Surgery YES NO 
4. Chest Discomfort YES NO 
5. Hypertension (high blood pressure) YES NO\ 
6. Hypotension (low blood pressure)  YES NO 
Systolic ≤ 100mmHg or Diastolic ≤ 60mmHg 
7. Shortness of breath upon light exertion YES NO 
8. Dizziness upon light exertion YES NO 
9. Pulmonary disease YES NO 
10. Heart palpitation YES NO 
11. Heart murmur YES NO 
12. Diabetes YES NO 
 If “YES”, Type I or Type II 
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13. Extremity discomfort YES NO 
14. Claudication (circulation problems cause leg pain) YES NO 
15. Peptic Ulcers (stomach ulcer) YES NO 
16. Kidney problems YES NO 
17. Metal implants (including pins) YES NO 
18. Seizures YES NO 
19. Have you been told by a doctor that is it not safe or appropriate 
 to exercise?    YES
 NO 
 
20. Does anyone in your family have a history of cardiovascular disease? YES
 NO 
 If “YES”, who?    
 
21. Do you smoke?  YES
 NO 
 
22. Are you currently using any anti-asthmatic medications?  YES
 NO 
 
23. Are you currently using any anti-hypertensive medications?  YES
 NO 
24. Are you currently taking any anti-inflammatory medications?  YES
 NO 
25. Are you currently taking any blood thinners (i.e.: coumadin, aspirin)? YES
 NO 
26. Are you currently taking any anti-seizure or anti-anxiety medication? YES
 NO 
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27. Are you currently taking an MAOI (monoamine oxidase inhibitors)?  YES
 NO 
Common MAOIs include Phenelzine (Nardil), Tranylcypromine (Parnate), Isocarboxazid 
(Marplan), Moclobemide (Aurorix, Manerix, Moclodura), Selegiline (Selegiline, Eldepryl, 
Emsam), Nialamide, Iproniazid (Marsilid, Iporzid, Ipronid, Rivivol, Propilniazida), Iproclozide, 
and Toloxatone 
 
28. Are you currently taking any other kind of medication? NO YES
  
i. If “YES”, please list below: 
__________________________________ 
__________________________________ 
           __________________________________ 
 
29. Are you currently taking any vitamin, mineral, or performance enhancing supplements? Please 
list them, with the dosage. 
__________________________________ 
__________________________________ 
__________________________________ 
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30. Are you allergic local anesthetics (such as Novocain or lidocaine)? YES NO 
31. Are you allergic to iodine (Betadine, tincture of Iodine)? YES NO 
32. Are you allergic to Band-Aids or any other adhesive? YES NO 
33. Have you ever been treated for a heat related illness  
(heat exhaustion, heat stroke)? YES NO 
 
34. Do you have any food allergies? YES NO 
 
35. Are you allergic to any of the following?  
(If you are unsure what the ingredient is, please ask for more information and you can also refer 
to ingredient explanations in the consent form) 
 
Natrual Food flavaorings (corn syrup solids, modified food starch, medium chain                   
                triglycerides, talin, or di-alpha tocopherol) YES NO 
     Silica YES NO 
     The Artificial Sweetener Sucralose  YES NO 
      Citric Acid YES NO 
      Natural  Food Colors (beta-carotein) YES  NO 
      Polydextrin YES NO 
      Mannitol YES NO 
      Caffeine YES NO 
      L-Tyrosine YES NO 
      L-Citrulline-di-malate YES NO 
      Arginine Alpha-ketogluterate YES NO 
      Taurine YES NO 
148 
 
 
      Di-arginine malate YES NO 
      Creatine monohydrate YES NO 
      Betaine anhydrous YES NO 
      Di-creatine malate YES NO 
      Picamilon YES NO 
      Beta-Alanine YES NO 
      N-Acetyl-L-Glutamine YES NO 
      L-Histidine YES NO 
      Vitamin A YES NO 
      Vitamin E YES  NO 
     Any other Artificial Food Colors (such as yellow 5)  YES  NO 
     Any artificial food flavorings  YES  NO 
                   
  
36. What is your current Cholesterol level? (If known)   
 
37.What is your current Blood-Pressure? (must be measured by APL staff)  
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Caffeine Questionnaire 
1. How many cups of caffeinated coffee, tea, soda, and energy drinks (red bull, full throttle etc. ) 
do you consume on a typical weekday?  
 
 
2. How many cups of caffeinated coffee, tea, soda, and energy drinks (red bull, full throttle etc. ) 
do you consume on a typical weekend day? 
  
 
 
3. Do you consider yourself addicted to caffeine? YES  NO 
 
 
4. Do you ever get headaches or feel unwell because you  
did not get caffeine or coffee at your usual time?   YES  NO 
 
 
5. Do you feel that you need a caffeinated beverage  
to wake up in the morning?   YES  NO 
 
 
6. If you take part in this study will you be able 
 to reduce or eliminate caffeine from your diet?  YES  NO 
 
 
7. Have you ever had too much caffeine such that 
 it caused negative side effects like rapid heart rate, 
 anxiety, rapid breathing, or jitters?    YES  NO 
 
a. IF yes, approximately how much caffeine (or how much soda, coffee, tea) did you 
consume?  (you will find caffeine amounts for common foods on the next page) 
 
_________________________________________________________________ 
 
__________________________________________________________________ 
 
b. If NO, What is the most caffeine you have ever consumed in a 3 hour period? ( or how 
much soda, coffee, tea) did you consume? (you will find caffeine amounts for common 
foods on the next page) 
 
_________________________________________________________________ 
 
__________________________________________________________________ 
 
 
Caffeine Content of Popular Drinks 
12-ounce beverage milligrams 
Red Bull (8.2 oz)  80.0 
Jolt  71.2 
Pepsi One 55.5 
Mountain Dew / Diet Mountain Dew / Code Red 55.0 
Mellow Yellow / Surge 52.8 
Tab / RC Cola / Diet RC 46.8 
Diet Coke  45.6 
Dr. Pepper/ Diet Dr. Pepper / Mr. Pibb 41.0 
Pepsi-Cola / Diet Pepsi / Wild Cherry Pepsi 37.5 
Coca-Cola Classic  34.0 
Snapple Flavored Teas (Reg. or Diet)  31.5 
Nestea Sweet Iced Tea 26.5 
Nestea Unsweetened Iced Tea 26.0 
Lipton Diet Green Tea with Citrus (16.9 oz) 23.0 
Barq's Root Beer  23.0 
Lipton Brisk, All Varieties 9 
Diet Rite Cola 0 
Sprite /7-Up / Slice / Sierra Mist / Fresca 0 
Mug / Diet Barq's Root Beer /A&W Root Beer 0 
Sundrop Orange / Minute Maid Orange 0 
8 Ounce Beverage milligrams 
Coffee, Drip  115-175  
Coffee, Brewed  80-135 
Coffee, Espresso (2 ounces) 100 
Tea, iced  47 
Tea, brewed, imported brands (avg.) 50 
Tea, instant  30 
Tea, green  15 
Hot cocoa 14 
Coffee, Decaf,  3-4 
                            Dark Chocolate      10-30 mg per ounce         Milk Chocolate 5-10mg / oz 
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Exercise Training History Questionnaire 
22. At what age did you start resistance training?  
 
23. Since then how regular, have you been with resistance training?  
 
a. Have / do you take breaks from resistance training longer than 2 weeks? How frequently? 
 
b. Have / do you take breaks from resistance training longer than 1 month? How frequently? 
 
c. Have / do you take breaks from resistance training longer than 3 months? How frequently? 
 
d. When, and for what reasons did you take such breaks?  
 
24. When you first became serious about resistance training what was you main reason?  
a. Sport(s):   List_____________________level of competition_________________ 
b. Fitness     
c. Competitive Lifting:   (powerlifting, olympic lifting, strongman, other) 
d. Rehabilitation 
e. Other:  Explain____________________________________________________ 
 
25. What is your reason for resistance training now?  
a. Sport(s):   List_____________________level of competition_________________ 
b. Fitness     
c. Competitive Lifting:   (powerlifting, olympic lifting, body building, strongman, 
other) 
d. Rehabilitation 
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e. Other:  Explain____________________________________________________ 
 
26. In the last 6 months, How many times per week have you typically resistance trained? 
(Include multiple sessions per day separately). 
a. Time per week upper body  ____________ 
b. Times per week lower body  ____________ 
c. Total times per week    _____________ 
 
27. In the last 6 months, How many weeks have you participated in resistance training one time 
or LESS per week? (include vacations, breaks, and schedule conflicts). 
 
28. In the last 6 months, How many weeks have you participated in resistance training three 
times or MORE per week? (Include multiple sessions per day separately). 
 
29. When you lift, do you usually work at a percentage of your known maximum or by what 
other  method do you choose a weight for each lift? 
 
30. Estimate your 1RM Max, or provide how much you think that you could lift for a given 
number of repetitions. 
LIFT I have done this 
exercise in 
the last 6 
months 
Predicted Maximum 
Weight 
Weight I usually 
use 
Number of Repetitions I 
usually do 
BENCH PRESS Yes     No    
INCLINE BENCH  Yes     No    
PARRALLEL SQUAT Yes     No    
FULL SQUAT  
(below parallel) 
Yes     No    
DEADLIFT Yes     No    
STANDING PRESS Yes     No    
LUNGES (WITH BARBELL) Yes     No    
LEG EXTENSION Yes     No    
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LEG CURLS Yes     No    
BICEP CURLS Yes     No    
PULL-UPS Yes     No    
DIPS Yes     No    
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31. Create in the space below a representation of your TYPICAL exercise session in the last 6 
months.  If you perform lower and upper body movements on separate days list each day 
separately below.  
 
EXERCISE SETS AND REPS    POUNDAGE 
 
 
 
 
 
 
 
 
 
32. How many times per week do you participate in stretching? _____________ 
33. How many years/months have you been performing cardiovascular exercise?  
 
34. Since you began have / do you take breaks from cardiovascular training longer than 2 
weeks? How frequently? 
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35. Since you began, have / do you take breaks from cardiovascular training longer than 1 
month? How frequently? 
 
36. Have / do you take breaks from cardiovascular  training longer than 3 months? How 
frequently? 
 
37. When, and for what reasons did you take such breaks?  
 
38. What is your Current reason for participating in cardiovascular training now?  
a. Sport(s):   List_____________________level of competition_________________ 
b. Health / Fitness: Explain ____________________________________________    
c. Rehabilitation 
d. Other:  Explain____________________________________________________ 
 
 
39. In the last 6 months, How many times per week have you typically participated in 
cardiovascular exercise? (Include multiple sessions per day separately).  
 
40. In the last 6 months, How many weeks have you participated in cardiovascular exercise one 
time or LESS per week? (include vacations, breaks, and schedule conflicts). 
 
41. In the last 6 months, How many weeks have you participated in cardiovascular exercise 
training three times or MORE per week? (Include multiple sessions per day separately). 
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42. When you run, row, swim, etc, do you usually work at a percentage of your Heart Rate 
Maximum, aim for a particular time goal, or by what other  method do you choose your 
intensity? 
 
43.  Create a TYPICAL weeks exercise log of cardiovascular exercises below. Use only the last 
six months as a guide. Include type of exercise, the duration, and the intensity or pace at which 
you perform this task.  If you monitor your HR please include that information as well. Provide 
as much detail as possible use additional paper if needed.  
 
APPENDIX I: SUPPLEMENT SIDE EFFECTS QUESTIONAIRE 
 TYPE OF 
EXERCISE 
DURATION PACE  INTENSITY 
MONDAY     
TUESDAY     
WEDNESDAY     
THURSDAY     
FRIDAY     
SATURDAY     
SUN     
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Supplement Side Effects Questionnaire 
 
Have you experienced any of the following since your last training session? 
 
 Dizziness or light headedness    
 YES NO   
 Nervousness or ‘jitters’    
 YES NO 
 Indigestion     
  YES NO 
 Stomach discomfort    
  YES NO 
 Other: (please explain)     
 
If so, when did this occur? 
 
If you circled “yes” for any of the above, answer the next question according to the following 
scale: 
 1 = some, but no influence on normal functioning 
 2 = moderate, but minor influence on normal functioning 
 3 = severe; inability to maintain normal functioning 
 
How would you rate the supplement side effects that you have experienced since your last 
training session? 
  
     1 
 2  3 
 
 
Have you experienced any of the following since you ingested the supplement/placebo drink 
today? 
  
 Dizziness or light headedness    
 YES NO  
 Nervousness or ‘jitters’    
 YES NO 
 Indigestion     
  YES NO  
 Stomach discomfort    
  YES NO 
 Other: (please explain)     
 
If so, when did this occur? Circle all that apply. 
 Immediately (prior to workout) 
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 During my workout 
 Immediately following my workout 
 
If you circled “yes” for any of the above, answer the next question according to the following 
scale: 
 1 = some, but no influence on normal functioning 
 2 = moderate, but minor influence on normal functioning 
 3 = severe, inability to maintain normal functioning 
How would you rate the supplement side effects that you have experienced since your last 
training session? 
  
     1 
 2  3 
 
Are you experiencing any joint or muscle pain that has stemmed from the exercise program? 
YES NO 
 
If so, please explain. 
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APPENDIX J: EIGHT WEEK EXERCISE TRAINING PROGRAM 
 
 161 
DAY 1 
wt bar 45 65 65 65
reps 10 10 10 10 10
wt bar 45 65 65 65
reps 10 10 10 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt
12-15 reps
wt
12-15 reps
DAY 2 Date: 
wt Max
reps
wt Max
reps
wt Max
reps
wt
12-15 reps
wt
12-15 reps
wt
12-15 reps
wt wt
12-15 reps
Day 3 Date: 
wt bar 45 65 65 65
reps 10 10 10 10 10
wt bar 45 65 65 65
reps 10 10 10 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt
12-15 reps
wt wt
12-15 reps
Weighted V-ups
Squat
Bench Press
staff initials: 
Pull-ups
Weighted Supine Leg Raise
12-15
12-15
Lat Pulldown
Upright Row
Wtd Twist Cruch/Elev. Legs
staff initials: 
staff initials: 
Leg Extensions
Leg Curl
Wtd Supine Wipers
BB Split Squat
Deadlift
Incline Bench
Bicep Curls
Dips
reps
NOTES:
W
e
e
k
 1
Weighted Sit-up
N
a
m
e
:
Wted Russian Twist (BH) wt
reps12-15
reps
Leg Curl
Lat Pulldown
Standing Press
Jo
e
se
p
h
 A
. 
E
xa
m
p
le
Date: 
Squat
Bench Press
Leg Extensions
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DAY 1 
wt bar 45 65 65 65 65
reps 10 10 10 10 10 10
wt bar 45 65 65 65 65
reps 10 10 10 10 10 10
wt 70 70 70
reps 10 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt
12-15 reps
wt
12-15 reps
DAY 2 Date: 
wt bar 45 65 65 65 65
reps 10 10 10 10 10 10
wt 95 45 65 65 65 65
reps 10 10 10 10 10 10
wt 70 70 70
reps 10 10 10
wt
12-15 reps
wt
12-15 reps
wt
12-15 reps
wt wt
12-15 reps
Day 3 Date: 
wt bar 45 65 65 65 65
reps 10 10 10 10 10 10
wt bar 45 65 65 65 65
reps 10 10 10 10 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt
12-15 reps
wt wt
12-15 reps
12-15
reps
Leg Curl
Lat Pulldown
Standing Press
Jo
e
se
p
h
 A
. 
E
xa
m
p
le
Date: 
Squat
Bench Press
Leg Extensions
Bicep Curls
Dips
reps
NOTES:
W
e
e
k
 2
Weighted Sit-up
N
a
m
e
:
Wted Russian Twist (BH) wt
reps
Pull-ups
Weighted Supine Leg Raise
staff initials: 
staff initials: 
Leg Extensions
Leg Curl
Wtd Supine Wipers
BB Split Squat
Deadlift
Incline Bench
12-15
12-15
Lat Pulldown
Upright Row
Wtd Twist Cruch/Elev. Legs Weighted V-ups
Squat
Bench Press
staff initials: 
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DAY 1 
wt bar 45 65 65 65 65 65
reps 10 10 10 10 10 10 10
wt bar 45 65 65 65 65 65
reps 10 10 10 10 10 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt
12-15 reps
wt
12-15 reps
DAY 2 Date: 
wt bar 45 65 65 65 65 65
reps 10 10 10 10 10 10 10
wt 95 45 65 65 65 65 65
reps 10 10 10 10 10 10 10
wt 70 70 70
reps 10 10 10
wt
12-15 reps
wt
12-15 reps
wt
12-15 reps
wt wt
12-15 reps
Day 3 Date: 
wt bar 45 65 65 65 65 65
reps 10 10 10 10 10 10 10
wt bar 45 65 65 65 65 65
reps 10 10 10 10 10 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt
12-15 reps
wt wt
12-15 reps 12-15
12-15
Lat Pulldown
Upright Row
Wtd Twist Cruch/Elev. Legs Weighted V-ups
Squat
Bench Press
staff initials: 
Leg Extensions
Dips
Pull-ups
Weighted Supine Leg Raise
staff initials: 
staff initials: 
Incline Bench
Leg Curl
Lat Pulldown
Standing Press
NOTES:
W
e
e
k
 3
Weighted Sit-up
N
a
m
e
:
Wted Russian Twist (BH) wt
reps12-15
reps
Leg Curl
J
o
e
s
e
p
h
 A
. 
E
x
a
m
p
le
Date: 
Squat
Bench Press
Leg Extensions
reps
Wtd Supine Wipers
BB Split Squat
Deadlift
Bicep Curls
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DAY 1 
wt bar 45 65 70 70 70
reps 10 10 8 8 8 8
wt bar 45 65 70 70 70
reps 10 10 8 8 8 8
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt
12-15 reps
wt
12-15 reps
DAY 2 Date: 
wt bar 45 65 70 70 70
reps 10 10 8 8 8 8
wt 95 45 65 70 70 70
reps 10 10 8 8 8 8
wt 70 70 70
reps 10 10 10
wt
12-15 reps
wt
12-15 reps
wt
12-15 reps
wt wt
12-15 reps
Day 3 Date: 
wt bar 45 65 75 75 75
reps 10 10 6 6 6 6
wt bar 45 65 75 75 75
reps 10 10 6 6 6 6
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt 70 70
reps 10 10
wt
12-15 reps
wt wt
12-15 reps
J
o
e
s
e
p
h
 A
. 
E
x
a
m
p
le
Date: 
Squat
Bench Press
Leg Extensions
reps
NOTES:
W
e
e
k
 4
Weighted Sit-up
N
a
m
e
:
Wted Russian Twist (BH) wt
reps12-15
reps
Leg Curl
Wtd Supine Wipers
BB Split Squat
Deadlift
Bicep Curls
Dips
Pull-ups
Weighted Supine Leg Raise
staff initials: 
staff initials: 
Incline Bench
Leg Curl
Lat Pulldown
Standing Press
12-15
12-15
Lat Pulldown
Upright Row
Wtd Twist Cruch/Elev. Legs Weighted V-ups
Squat
Bench Press
staff initials: 
Leg Extensions
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DAY 1 
wt max
reps
wt Max
reps
wt Max
reps
wt Max
reps
wt Max
reps
wt
12-15 reps
wt
12-15 reps
DAY 2 Date: 
wt bar 50 75 75 75
reps 10 10 10 10 10
wt 95 50 75 75 75
reps 10 10 10 10 10
wt 80 80 80
reps 10 10 10
wt
12-15 reps
wt
12-15 reps
wt
12-15 reps
wt wt
12-15 reps
Day 3 Date: 
wt bar 50 75 75 75
reps 10 10 10 10 10
wt bar 50 75 75 75
reps 10 10 10 10 10
wt 80 80
reps 10 10
wt 80 80
reps 10 10
wt 80 80
reps 10 10
wt
12-15 reps
wt wt
12-15 reps
12-15
reps
Leg Curl
Lat Pulldown
Standing Press
Jo
e
se
p
h
 A
. 
E
xa
m
p
le
Date: 
Squat
Bench Press
Leg Extensions
Bicep Curls
Dips
reps
NOTES:
W
e
e
k
 5
Weighted Sit-up
N
a
m
e
:
Wted Russian Twist (BH) wt
reps
Pull-ups
Weighted Supine Leg Raise
staff initials: 
staff initials: 
Leg Extensions
Leg Curl
Wtd Supine Wipers
BB Split Squat
Deadlift
Incline Bench
12-15
12-15
Lat Pulldown
Upright Row
Wtd Twist Cruch/Elev. Legs Weighted V-ups
Squat
Bench Press
staff initials: 
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DAY 1 
wt bar 50 75 75 75 75
reps 10 10 10 10 10 10
wt bar 50 75 75 75 75
reps 10 10 10 10 10 10
wt 80 80
reps 10 10
wt 80 80
reps 10 10
wt 80 80
reps 10 10
wt
12-15 reps
wt
12-15 reps
DAY 2 Date: 
wt bar 50 75 75 75
reps 10 10 10 10 10
wt 95 50 75 75 75
reps 10 10 10 10 10
wt 80 80 80
reps 10 10 10
wt
12-15 reps
wt
12-15 reps
wt
12-15 reps
wt wt
12-15 reps
Day 3 Date: 
wt bar 50 75 75 75 75
reps 10 10 10 10 10 10
wt bar 50 75 75 75 75
reps 10 10 10 10 10 10
wt 80 80
reps 10 10
wt 80 80
reps 10 10
wt 80 80
reps 10 10
wt
12-15 reps
wt wt
12-15 reps 12-15
12-15
Lat Pulldown
Upright Row
Wtd Twist Cruch/Elev. Legs Weighted V-ups
Squat
Bench Press
staff initials: 
Leg Extensions
Dips
Pull-ups
Weighted Supine Leg Raise
staff initials: 
staff initials: 
Incline Bench
Leg Curl
Lat Pulldown
Standing Press
NOTES:
W
e
e
k
 6
Weighted Sit-up
N
a
m
e
:
Wted Russian Twist (BH) wt
reps12-15
reps
Leg Curl
J
o
e
s
e
p
h
 A
. 
E
x
a
m
p
le
Date: 
Squat
Bench Press
Leg Extensions
reps
Wtd Supine Wipers
BB Split Squat
Deadlift
Bicep Curls
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DAY 1 
wt bar 50 70 80 80 80
reps 10 10 8 8 8 8
wt bar 50 70 80 80 80
reps 10 10 8 8 8 8
wt 80 80
reps 10 10
wt 80 80
reps 10 10
wt 80 80
reps 10 10
wt
12-15 reps
wt
12-15 reps
DAY 2 Date: 
wt bar 50 70 80 80 80
reps 10 10 8 8 8 8
wt 95 50 70 80 80 80
reps 10 10 8 8 8 8
wt 80 80 80
reps 10 10 10
wt
12-15 reps
wt
12-15 reps
wt
12-15 reps
wt wt
12-15 reps
Day 3 Date: 
wt bar 50 70 85 85 85
reps 10 10 6 6 6 6
wt bar 50 70 85 85 85
reps 10 10 6 6 6 6
wt 80 80
reps 10 10
wt 80 80
reps 10 10
wt 80 80
reps 10 10
wt
12-15 reps
wt wt
12-15 reps 12-15
12-15
Lat Pulldown
Upright Row
Wtd Twist Cruch/Elev. Legs Weighted V-ups
Squat
Bench Press
staff initials: 
Leg Extensions
Dips
Pull-ups
Weighted Supine Leg Raise
staff initials: 
staff initials: 
Incline Bench
Leg Curl
Lat Pulldown
Standing Press
NOTES:
W
e
e
k
 7
Weighted Sit-up
N
a
m
e
:
Wted Russian Twist (BH) wt
reps12-15
reps
Leg Curl
J
o
e
s
e
p
h
 A
. 
E
x
a
m
p
le
Date: 
Squat
Bench Press
Leg Extensions
reps
Wtd Supine Wipers
BB Split Squat
Deadlift
Bicep Curls
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DAY 1 
wt max
reps
wt max
reps
wt max
reps
wt max
reps
wt max
reps
wt
12-15 reps
wt
12-15 reps
DAY 2 Date: 
wt Max
reps
wt Max
reps
wt Max
reps
wt
12-15 reps
wt
12-15 reps
wt
12-15 reps
wt wt
12-15 reps
Day 3 Date: 
wt bar 55 75 75 75
reps 10 10 10 10 10
wt bar 55 75 75 75
reps 10 10 10 10 10
wt 85 85 85
reps 10 10 10
wt 85 85
reps 10 10
wt 85 70
reps 10 10
wt
12-15 reps
wt wt
12-15 reps
12-15
reps
Leg Curl
Lat Pulldown
Standing Press
J
o
e
s
e
p
h
 A
. 
E
x
a
m
p
le
Date: 
Squat
Bench Press
Leg Extensions
Isometric ROFD tests
Dips
reps
NOTES:
W
e
e
k
 8
Weighted Sit-up
N
a
m
e
:
Wted Russian Twist (BH) wt
reps
Pull-ups
Weighted Supine Leg Raise
staff initials: 
staff initials: 
Leg Extensions
Leg Curl
Wtd Supine Wipers
Bicep curls
Vertical jump
Squat Power test
12-15
12-15
Lat Pulldown
Standing Press
Wtd Twist Cruch/Elev. Legs Weighted V-ups
Squat
Bench Press
staff initials: 
Duplicates the initial tested 
workout with same relative but 
different absolute loads to reflect 
strength improvements 
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APPENDIX K: EXERCISE SUPER CHARGE NUTRITIONAL INFORMATION 
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 Amount 
Calories 64 
Total Carbohydrate 16 
      Sugar 2g 
Vitamin A 4600IU (92%) 
 Vitamin E 8IU (26%) 
“Super Charge Proprietary Blend” 
      
2242mg 
     Nitrous Mallage (di-arginine malate)  
     Taurine 2000mg 
     Arginine Alpha-Ketogluterate 1742mg 
     L-Citruline-di-malate 1000mg 
     L-Tyrosine 500mg 
     Caffeine 450mg 
Phase 2 Strength & Endurance Complex  
     CreaPure™ (creatine monohydrate) 2750mg 
     BetaPure™ (Betaine anhydrous) 1000mg 
     2CM™ (di-creatine malate) 250mg 
     Picatropin™ (picamilion) 50mg 
Phase 3  Post Workout Recovery Complex  
     Beta-Alanine 1500mg 
     N-Acetyl-L-Glutamine 1000mg 
     L-Histadine 250mg 
Other ingredients: Maltodextrin, Natural Flavor (Corn Syrup Solids, Modified 
Food Starch, Medium Chain Triglycerides, Talin, di-Alpha tocopherol, Silica, Beta-
carotene (color), Sucralose, Citric Acid.  
 
Nutritional Information Label for Supper Charge Supplement, as provided by the manufacturer; 
(Labrada nutrition, Houston TX.). 
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APPENDIX L: STUDY 1 DATA 
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STUDY 1  
SUBJECT DESCRIPTIVE DATA AND TESTING ORDER 
 
Subject Age Height  Weight %BF Max Squat Testing Order 
1 19 73.3 205.5 19.1 275 H-L-M 
2 21 70.0 206.2 24.8 315 L-H-M 
3 21 70.2 173.7 9.9 315 H-L-M 
4 22 74.0 173.4 8.6 255 M-H-L 
5 22 73.2 210.9 21.0 295 M-L-H 
6 20 72.5 200.3 21.0 295 M-L-H 
7 22 70.3 204.5 20.2 405 L-H-M 
8 25 75.2 245.8 23.8  330 M-H-L 
9 21 70.0 206.3 12.4 545 H-M-L 
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BLOOD LACTATE CONCENTRATIONS (MMOL/L) 
 
Subject 
High 
Intensity 
High 
Intensity 
Moderate 
Intensity 
Moderate 
Intensity 
Low 
Intensity 
Low 
Intensity 
 
PRE Post Pre Post Pre Post 
1 1.5 4.5 2.4 7.2 4.9 8 
2 1.8 2.9 1.3 2.1 1.5 6.6 
3 1.3 3 2.4 2.7 1.1 2.9 
4 0.9 3.5 1.2 4.3 1.4 2.2 
5 1.8 4.1 1.6 6.5 2.6 3.1 
6 1.3 2.3 0.9 5.6 1 6.1 
7 1.1 6.7 1.5 4.1 1.4 3.7 
8 1.7 4.1 4.2 5.5 1.7 3.8 
9 0.9 4.8 1.3 3.9 1.5 4.1 
 
 
 
 
 AVERAGE AND STANDARD DEVIATION (N=9) FOR BLOOD LACTATE 
CONCENTRATIONS (MMOL/L) 
 
High 
Intensity 
High 
Intensity 
Moderate 
Intensity 
Moderate 
Intensity 
Low 
Intensity 
Low 
Intensity 
 
PRE Post Pre Post Pre Post 
Average 1.37 3.99 1.87 4.66 1.90 4.50 
Standard Deviation 0.36 1.30 1.01 1.69 1.21 1.95 
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 POWER DATA  
AVERAGE POWER HIGH INTENSITY (90% 1RM)  EXERCISE BOUT 
 
Subject Number Set 1 Set 2 Set3 Set 4 Set 5 
Average of 
Sets 
1 916.0 788.3 673.3 653.3 653.3 736.9 
2 1334.3 1246.7 1356.3 1217.7 1174.3 1265.9 
3 1047.3 1108.7 1006.7 1027.0 952.0 1028.3 
4 1271.0 1260.7 1343.3 1157.3 1126.3 1231.7 
5 1010.0 1010.3 1017.0 960.7 1024.0 1004.4 
6 1235.0 1152.0 1159.0 1104.0 1021.3 1134.3 
7 1189.7 1189.7 1198.0 1122.0 1096.3 1159.1 
8 1386.0 1162.0 1201.7 1089.7 1113.7 1190.6 
9 999.3 909.7 879.7 849.7 832.0 894.1 
 
 
 
 
MEAN AND STANDARD DEVIATION FOR THE AVERAGE POWER MEASURES FOR HIGH INTENSITY 
(90% 1RM) BOUT 
 
Set 1 Set 2 Set3 Set 4 Set 5 Grand Mean 
Average  1154.3 1092.0 1092.8 1020.1 999.3 1071.7 
Standard Deviation 166.0 159.2 221.9 175.8 165.9 172.9 
 
 
 
 
 175 
 
  
AVERAGE POWER MODERATE INTENSITY (70% 1RM)  EXERCISE BOUT 
 
Subject 
Number Set 1 Set 2 Set3 Set 4 Set 5 
Average of 
Sets 
1 1207.4 1179.0 1172.1 1157.8 1161.4 1175.6 
2 1131.9 1108.4 1123.1 1036.5 1107.5 1101.5 
3 1362.0 1239.8 1190.8 1208.4 1194.0 1239.0 
4 1130.2 1123.6 1177.0 1167.6 1183.4 1156.4 
5 779.2 800.2 813.3 769.0 803.1 793.0 
6 1361.2 1408.0 1321.4 1350.4 1317.8 1351.8 
7 1537.6 1472.2 1472.2 1567.8 1520.0 1514.0 
8 1131.9 1108.4 1123.1 1036.5 1107.5 1101.5 
 
 
 
 
 
MEAN AND STANDARD DEVIATION FOR THE AVERAGE POWER MEASURES FOR MODERATE 
INTENSITY (70% 1RM) BOUT 
 
 
Set 1 Set 2 Set3 Set 4 Set 5 
Grand 
Mean 
Average 1238.8 1234.3 1217.0 1217.6 1233.9 1228.3 
Standard Deviation 234.2 252.8 217.5 276.7 260.6 245.4 
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AVERAGE POWER LOW INTENSITY (30% 1RM)  EXERCISE BOUT 
 
Subject 
Number Set 1 Set 2 Set3 Set 4 Set 5 
Average of 
Sets 
1 1234.0 1241.8 1286.2 1189.0 1234.0 1237.0 
2 1559.1 1588.5 1556.3 1544.2 1511.9 1552.0 
3 1382.3 1283.1 1270.0 1151.4 1285.4 1274.4 
4 1591.6 1656.7 1656.7 1715.8 1639.6 1652.1 
5   1182.1 1216.7 1244.9 1190.0 1208.4 
6 1254.0   1469.4 1207.4 1593.7 1381.1 
7 1377.8 1491.0 1544.0 1621.3 1635.7 1534.0 
8 1533.5 1619.6 1673.9 1669.3 1664.6 1632.2 
9 1697.8 1765.8 1793.9 1858.3 1790.6 1781.3 
 
** Missing Values reflect data that was either not collected or nor not saved properly as a result 
of assistant error.   
 
 
 
 
 
MEAN AND STANDARD DEVIATION FOR THE AVERAGE POWER MEASURES 
 FOR LOW INTENSITY (30% 1RM) BOUT 
 
 
Set 1 Set 2 Set3 Set 4 Set 5 
Grand 
Mean 
Average  1453.8 1478.6 1496.3 1466.8 1505.1 1472.5 
Standard Deviation 166.9 216.6 201.9 269.1 215.4 204.9 
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 PEAK POWER FOR THE HIGH INTENSITY (90% 1RM)  EXERCISE BOUT 
 
Subject 
Number Set 1 Set 2 Set3 Set 4 Set 5 
Average of 
Sets 
1 1381.0 1219.3 1098.0 1017.3 1017.3 1146.6 
2 2486.7 2384.7 2450.3 2333.7 2224.0 2375.9 
3 2095.0 2272.0 1986.0 2081.3 2061.0 2099.1 
4 2521.3 2325.0 2449.0 2004.7 2077.0 2275.4 
5 1511.3 1483.3 1441.0 1398.7 1462.3 1459.3 
6 2360.0 2483.7 2498.0 2449.0 2380.3 2434.2 
7 2193.7 2075.3 2244.0 2227.3 2362.3 2220.5 
8 2667.7 2403.3 2291.3 2475.7 2523.7 2472.3 
9 1903.0 1819.0 1831.3 1885.0 1837.0 1855.1 
 
 
 
 
 
MEAN AND STANDARD DEVIATION FOR THE PEAK POWER MEASURES  FOR HIGH INTENSITY (90% 
1RM) BOUT 
 
 
Set 1 Set 2 Set3 Set 4 Set 5 
Grand 
Mean 
Average  2124.4 2051.7 2032.1 1985.9 1993.9 2037.6 
Standard Deviation 450.4 449.3 492.7 492.0 486.2 463.2 
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PEAK POWER FOR THE MODERATE INTENSITY (70% 1RM)  EXERCISE BOUT 
 
 
 
Subject 
Number Set 1 Set 2 Set3 Set 4 Set 5 
Average of 
Sets 
1 
      2 2585.2 2585.2 2564.0 2546.8 2623.2 2580.9 
3 2105.8 1868.4 1780.8 1816.2 1756.8 1865.6 
4 1688.8 1751.6 1883.4 1783.2 1773.4 1776.1 
5 2397.2 2469.4 2353.8 2389.8 2401.0 2402.2 
6 2317.4 2247.6 2247.6 2256.2 2243.2 2262.4 
7 2585.2 2585.2 2564.0 2546.8 2623.2 2580.9 
8 2585.2 2585.2 2564.0 2546.8 2623.2 2580.9 
9 2184.0 2480.4 2470.0 2589.6 2704.0 2485.6 
 
** Missing Values reflect data that was either not collected or nor not saved properly as a result 
of assistant error.   
 
 
 
 
 
 
MEAN AND STANDARD DEVIATION FOR THE PEAK POWER MEASURES FOR MODERATE INTENSITY 
(70% 1RM) BOUT 
 
Set 1 Set 2 Set3 Set 4 Set 5 
Grand 
Mean 
Average  2306.1 2321.6 2303.5 2309.4 2343.5 2316.8 
Standard Deviation 311.3 336.2 313.2 333.2 386.8 326.0 
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PEAK POWER FOR THE LOW INTENSITY (30% 1RM)  EXERCISE BOUT 
 
Subject 
Number Set 1 Set 2 Set3 Set 4 Set 5 
Average of 
Sets 
1 2190.7 2273.8 2241.8 2189.3 2136.9 2206.5 
2 1986.7 1848.9 1792.6 1627.7 1801.3 1811.4 
3 2318.5 2355.8 2386.7 2416.3 2337.1 2362.9 
4 
 
1496.9 1529.0 1571.6 1458.5 1514.0 
5 
      6 1856.4 2338.8 2337.3 2502.1 2316.0 2270.1 
7 2140.6 2314.4 2394.5 2438.3 2397.5 2337.1 
8 2339.1 2483.5 2538.0 2581.4 2475.2 2483.4 
9 
       
** Missing Values reflect data that was either not collected or nor not saved properly as a result 
of assistant error.   
 
 
 
 
MEAN AND STANDARD DEVIATION FOR THE PEAK POWER MEASURES  FOR LOW INTENSITY (30% 
1RM) BOUT 
 
 
Set 1 Set 2 Set3 Set 4 Set 5 
Grand 
Mean 
Average  2138.7 2158.9 2174.3 2189.5 2131.8 2140.8 
Standard Deviation 188.7 353.1 369.5 420.7 371.3 348.2 
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Study 1  
WESTERN BLOT RAW OD VALUES FOR TOTAL ERK1/2 (ARBITRARY UNITS) 
 
Subject 
Number 
High 
Intensity 
Pre 
High 
Intensity 
Post 
Moderate 
Intensity 
Pre 
Moderate 
Intensity 
Post 
Low 
Intensity 
Pre 
Low 
Intensity 
Post 
1 9.25 9.73 11.07 13.00 11.17 9.49 
2 8.73 4.06 7.07 7.07 4.87 5.62 
3 17.72 16.80 16.48 15.71 16.56 17.37 
4 21.25 20.35 14.34 15.03 18.91 12.67 
5 12.12 8.61 10.19 8.81 10.40 7.78 
6 18.73 17.75 19.53 19.55 19.43 19.55 
7 5.29 7.68 13.12 12.42 9.06 5.52 
8 8.26 12.33 12.92 10.20 10.06 8.43 
9 5.74 6.89 11.57 6.25 9.86 10.79 
 
 
 
 
WESTERN BLOT RAW OD VALUES FOR PHOSPHO-ERK1/2 (ARBITRARY UNITS) 
 
Subject 
Number 
High 
Intensity 
Pre 
High 
Intensity 
Post 
Moderate 
Intensity 
Pre 
Moderate 
Intensity 
Post 
Low 
Intensity 
Pre 
Low 
Intensity 
Post 
1 19.67 23.40 27.18 32.20 28.69 24.44 
2 27.51 13.12 22.19 23.31 16.49 18.12 
3 49.84 56.26 54.93 48.70 54.72 58.89 
4 80.76 78.85 56.20 59.02 63.40 43.31 
5 46.23 37.61 41.20 36.34 44.23 29.79 
6 69.21 67.21 83.11 78.06 76.65 68.64 
7 14.50 23.25 41.13 38.60 28.91 18.56 
8 32.23 47.75 50.81 41.51 40.18 31.98 
9 15.16 17.33 32.24 14.37 28.99 30.22 
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Study 1. 
  
WESTERN BLOT RAW OD VALUES FOR TOTAL P38 (ARBITRARY UNITS) 
 
Subject 
Number 
High 
Intensity 
Pre 
High 
Intensity 
Post 
Moderate 
Intensity Pre 
Moderate 
Intensity 
Post 
Low 
Intensity 
Pre 
Low 
Intensity 
Post 
1.00 21.11 19.42 22.13 17.75 23.76 19.92 
2.00 31.82 18.66 30.37 35.77 27.30 25.67 
3.00 9.42 10.73 12.17 9.62 8.46 6.25 
4.00 29.82 39.95 38.45 34.89 41.30 30.26 
5.00 31.14 28.32 29.35 36.48 31.89 27.87 
6.00 25.27 27.98 31.59 37.98 34.99 24.72 
7.00 59.48 36.92 67.53 100.89 67.28 42.96 
8.00 17.69 23.80 31.26 43.98 38.73 45.87 
9.00 15.55 15.46 19.22 10.52 13.44 20.31 
 
 
 
 
WESTERN BLOT RAW OD VALUES FOR PHOSPHO-ERK1/2 (ARBITRARY UNITS) 
 
Subject 
Number 
High 
Intensity 
Pre 
High 
Intensity 
Post 
Moderate 
Intensity Pre 
Moderate 
Intensity 
Post 
Low 
Intensity 
Pre 
Low 
Intensity 
Post 
1 134.29 119.36 145.71 112.32 161.10 132.32 
2 67.11 39.01 74.06 74.06 61.14 54.89 
3 41.90 49.32 39.97 38.41 37.95 28.91 
4 67.64 95.18 93.09 84.72 96.02 76.29 
5 81.00 73.73 79.32 101.99 96.89 71.15 
6 80.15 84.34 91.59 109.71 101.90 70.83 
7 77.41 50.35 99.04 147.02 98.12 70.90 
8 22.51 28.40 31.26 52.96 49.40 57.39 
9 110.72 111.07 158.49 93.42 145.25 154.98 
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APPENDIX M: STUDY 2. DATA 
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MUSCLE SAMPLE AND PROTEIN CONCENTRATION DATA FOR STUDY 2 
PRE-TRAINING VALUES 
Subject  Time Point*   
Muscle Sample 
Size (mg) Mean BSA(μg/ml) CV 
1 PRE 1 19.4 26.598 8.4438 
1 PRE 2 16.21 20.070 3.8280 
2 PRE 1 13.88 21.365 1.1586 
2 PRE 2 14.05 20.066 3.1056 
3 PRE 1 16.31 23.726 6.2521 
3 PRE 2 17.52 18.200 2.3923 
4 PRE 1 15.79 22.628 0.7813 
4 PRE 2 17.73 23.103 1.6163 
5 PRE 1 12.4 36.312 0.6929 
5 PRE 2 14.5 24.549 1.5212 
6 PRE 1 15.75 24.219 1.9795 
6 PRE 2 17.03 19.536 1.5479 
7 PRE 1 17.26 28.793 1.2492 
7 PRE 2 16.13 23.487 1.8885 
8 PRE 1 16.73 24.164 1.1434 
8 PRE 2 18.9 24.567 4.1379 
9 PRE 1 13.78 24.183 1.4892 
9 PRE 2 15.44 26.488 0.9499 
10 PRE 1 17.81 14.596 5.0075 
10 PRE 2 20.15 23.982 3.5908 
11 PRE 1 13.89 19.737 2.7816 
11 PRE 2 20.06 27.585 1.8978 
12 PRE 1 16.27 27.439 9.5734 
12 PRE 2 20.33 31.153 4.3052 
13 PRE 1 16.8 23.067 2.2869 
13 PRE 2 16.84 26.836 4.3736 
14 PRE 1 16.5 22.577 2.8487 
14 PRE 2 16.4 28.052 1.6247 
15 PRE 1 13.38 25.176 3.0667 
15 PRE 2 17.04 25.176 3.0667 
16 PRE 1 13.92 25.101 0.2211 
16 PRE 2 17.49 25.120 1.2210 
17 PRE 1 15.41 30.687 3.0421 
17 PRE 2 19.52 39.743 7.0418 
18 PRE 1 16.65 33.174 1.4238 
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18 PRE 2 16.53 25.899 5.4043 
19 PRE 1 20.1 31.633 1.2742 
19 PRE 2 15.21 27.440 1.7675 
20 PRE 1 18.7 25.992 0.5664 
20 PRE 2 14.62 25.640 11.9074 
21 PRE 1 16.08 27.681 5.1137 
21 PRE 2 19.14 31.763 0.8643 
22 PRE 1 16.55 29.425 0.7652 
22 PRE 2 19.98 22.206 1.9923 
23 PRE 1 15.21 20.481 7.7676 
23 PRE 2 13.99 24.842 3.5013 
24 PRE 1 19.22 32.432 8.3077 
24 PRE 2 14.77 30.669 5.4544 
 
 
* Timepoint of muscle biopsy.  Pre indicates the biopsy was taken at the beginning of the study 
before the 8 weeks of exercise training.  Post would indicate biopsies taken after the 8 weeks of 
training.  The number 1 indicates that the sample was taken before the exercise session for that 
testing day.  The numeral 2 indicates it is the second biopsy taken on that given testing day, after 
the exercise session for the day.   
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Muscle Sample and Protein Concentration Data for Study 2 
POST -TRAINING VALUES 
 
Subject 
Number Timepoint* Musle Sample Size  Mean BSA(μg/ml) CV 
1 Post 1 17.05 33.062 5.420 
1 Post 2 18.96 27.885 1.830 
2 Post 1 16.35 27.941 6.561 
2 Post 2 16.7 27.347 5.529 
3 Post 1 20.87 27.565 1.609 
3 Post 2 19.75 23.803 0.269 
4 Post 1 17.89 32.985 0.897 
4 Post 2 18.96 33.711 1.599 
5 Post 1 16.03 32.724 1.422 
5 Post 2 18.45 27.230 1.086 
6 Post 1 12.79 27.267 1.706 
6 Post 2 20.66 38.330 0.366 
7 Post 1 19.06 27.453 0.538 
7 Post 2 17.61 27.062 1.801 
8 Post 1 17.17 22.332 1.665 
8 Post 2 17.02 25.330 2.884 
9 Post 1 19.32 31.886 0.789 
9 Post 2 17.37 23.244 0.773 
10 Post 1 15.11 20.655 4.202 
10 Post 2 14.82 23.021 1.222 
11 Post 1 17.55 29.334 1.586 
11 Post 2 14.48 23.486 1.647 
12 Post 1 17.83 25.516 4.140 
12 Post 2 18.48 33.916 4.329 
13 Post 1 15.32 20.003 3.645 
13 Post 2 18.33 22.890 1.798 
14 Post 1 15.66 24.231 1.920 
14 Post 2 16.31 27.416 1.850 
15 Post 1 20.65 33.357 5.041 
15 Post 2 17.58 26.820 1.357 
16 Post 1 16.63 26.045 2.428 
16 Post 2 19.5 33.076 0.782 
17 Post 1 17.57 30.756 0.308 
17 Post 2 17.32 25.899 1.274 
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18 Post 1 15.57 21.826 2.421 
18 Post 2 92 25.880 8.802 
19 Post 1 15.71 27.305 0.875 
19 Post 2 17.05 30.775 2.725 
20 Post 1 16.41 30.556 0.746 
20 Post 2 16.65 27.871 0.299 
21 Post 1 19.88 37.624 0.445 
21 Post 2 18.99 27.798 2.422 
22 Post 1 14.5 23.141 6.169 
22 Post 2 16.56 26.227 1.052 
23 Post 1 18.35 32.017 2.532 
23 Post 2 18.05 30.738 2.066 
24 Post 1 15.37 25.625 0.326 
24 Post 2 17.54 34.044 1.004 
 
* Timepoint of muscle biopsy.  Pre indicates the biopsy was taken at the beginning of the study 
before the 8 weeks of exercise training.  Post would indicate biopsies taken after the 8 weeks of 
training.  The number 1 indicates that the sample was taken before the exercise session for that 
testing day.  The numeral 2 indicates it is the second biopsy taken on that given testing day, after 
the exercise session for the day.   
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WESTERN BLOT RAW OPTICAL DENSITY VALUES FOR TOTAL ERK1/2 (ARBITRARY 
UNITS) 
 
      Subject Number Group* Pre 1 Pre 2  Post 1 Post 2 
1 1 0.96 0.98 0.50 0.98 
2 1 0.97 0.73 0.73 0.59 
3 1 1.56 1.57 1.17 1.27 
4 1 1.43 0.94 0.77 1.48 
5 2 1.15 2.04 1.05 1.63 
6 2 1.58 1.89 1.58 1.92 
7 2 1.65 2.07 1.85 1.16 
8 2 2.10 2.60 1.75 2.49 
9 2 0.77 0.81 1.15 1.18 
10 2 0.92 1.09 0.83 1.13 
11 2 2.85 0.89 1.40 0.72 
12 2 1.17 0.65 1.05 0.69 
13 2 1.86 1.16 0.93 1.56 
14 2 2.72 2.91 2.12 2.54 
15 2 1.77 2.97 1.92 3.28 
16 1 2.91 2.62 3.17 1.81 
17 2 3.74 5.47 4.18 4.60 
18 1 4.35 1.75 3.92 2.27 
19 1 1.89 2.27 2.14 2.04 
20 2 0.20 1.02 0.92 81.00 
21 1 0.53 0.16 1.32 0.72 
22 2 0.20 0.76 0.50 1.04 
23 1 1.67 1.99 1.88 1.80 
24 1 2.49 1.14 2.22 1.22 
 
 
*Group: 1= Placebo/control group; . 2= Supplement/experimental group 
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WESTERN BLOT RAW OPTICAL DENSITY VALUES FOR PHOSPHO- ERK1/2 
(ARBITRARY UNITS) 
 
Subject Number Group* Pre 1 Pre 2  Post 1 Post 2 
1 1 2.97 6.57 1.23 2.53 
2 1 0.50 1.53 2.53 0.92 
3 1 1.31 1.50 1.13 1.11 
4 1 2.00 3.43 1.16 3.73 
5 2 1.18 3.65 1.91 2.70 
6 2 1.61 5.66 1.63 4.10 
7 2 19.11 3.91 1.89 1.73 
8 2 1.20 1.70 1.28 1.82 
9 2 0.74 1.72 0.98 1.30 
10 2 0.80 2.01 0.87 1.88 
11 2 1.20 0.56 9.21 0.51 
12 2 10.63 0.79 73.00 0.56 
13 2 2.43 0.73 0.81 2.19 
14 2 0.41 0.47 0.39 0.50 
15 2 0.40 0.65 0.38 0.62 
16 1 2.87 4.61 4.61 2.47 
17 2 0.72 1.12 0.87 0.87 
18 1 6.53 3.47 3.22 3.77 
19 1 1.80 5.31 2.36 2.39 
20 2 0.30 3.54 1.44 1.20 
21 1 0.69 4.92 1.37 1.17 
22 2 0.14 2.22 0.51 1.69 
23 1 1.03 1.35 0.95 0.99 
24 1 2.01 1.10 1.55 1.38 
 
 
*Group: 1= Placebo/control group; . 2= Supplement/experimental group 
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WESTERN BLOT RAW OPTICAL DENSITY VALUES FOR TOTAL P38 (ARBITRARY 
UNITS) 
 
Subject 
Number Group* Pre 1 Pre 2  Post 1 Post 2 
1 1 52.44 43.29 58.06 80.13 
2 1 70.86 104.96 82.57 74.23 
3 1 20.89 27.41 18.90 25.97 
4 1 82.37 86.03 72.21 65.44 
5 2 2.33 4.28 3.39 5.03 
6 2 4.33 3.70 3.01 3.94 
7 2 7.27 8.70 12.30 11.39 
8 2 20.42 21.90 29.49 21.01 
9 2 28.02 28.99 29.79 36.25 
10 2 2.68 7.20 8.53 5.56 
11 2 6.51 8.04 7.09 7.70 
12 2 6.80 11.14 6.66 9.92 
13 2 9.53 3.14 12.36 10.08 
14 2 36.37 13.31 33.93 26.67 
15 2 30.43 19.35 29.65 16.07 
16 1 8.02 5.73 7.27 7.85 
17 2 31.09 17.34 14.80 16.78 
18 1 27.22 26.94 29.92 26.08 
19 1 25.46 28.69 30.94 30.32 
20 2 21.48 23.55 36.72 14.26 
21 1 18.69 12.65 10.43 24.46 
22 2 16.30 18.58 27.38 32.83 
23 1 7.21 22.20 16.95 20.94 
24 1 11.92 15.24 21.28 16.55 
 
 
 
*Group: 1= Placebo/control group; . 2= Supplement/experimental group 
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WESTERN BLOT RAW OPTICAL DENSITY VALUES FOR TOTAL P38 (ARBITRARY 
UNITS) 
 
Subject 
Number Group* Pre 1 Pre 2  Post 1 Post 2 
1 1 104.45 74.40 120.59 179.60 
2 1 161.08 256.17 203.45 189.41 
3 1 57.27 74.60 49.75 63.30 
4 1 205.11 201.61 166.09 143.21 
5 2 4.72 9.63 7.30 11.47 
6 2 11.20 8.07 7.62 6.24 
7 2 4.12 2.62 3.55 3.55 
8 2 17.86 19.91 23.81 18.48 
9 2 22.10 21.50 22.90 27.79 
10 2 7.96 21.95 25.01 20.41 
11 2 19.77 31.25 29.53 26.22 
12 2 26.17 41.72 25.47 39.66 
13 2 41.35 12.01 50.78 42.21 
14 2 67.47 21.65 58.74 45.61 
15 2 52.90 29.64 51.07 23.92 
16 1 22.89 16.48 21.47 21.78 
17 2 53.79 34.61 48.20 59.12 
18 1 268.82 268.74 287.42 277.68 
19 1 242.89 275.38 298.26 237.80 
20 2 117.96 113.95 197.38 89.51 
21 1 121.59 84.84 74.29 162.02 
22 2 107.56 113.40 153.58 198.53 
23 1 17.60 65.22 46.40 56.50 
24 1 32.53 39.93 56.71 44.18 
 
 
 
*Group: 1= Placebo/control group; . 2= Supplement/experimental group 
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APPENDIX N: SUMMARY OF FINDINGS PREVIOUSLY PUBLISHED BY NICOLE 
MOODIE 
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STUDY 2. FINDINGS PREVIOUSLY PRESENTED AND PUBLISHED IN DISSERTATION 
FORMAT:  
 
 
Moodie, Nicole Jayne, (2008). The effects of a pre-workout supplement and eight weeks of 
resistance training on markers of inflammation. University of Kansas 
 
 
 
 
Anthropometric Findings 
 Body Mass Significantly increased over the eight weeks of training (F(1,22)=23.29, p<0.01) ,but 
there was no significant difference in body mass gains between the supplement and placebo 
groups (p>0.05). 
 Lean Body Mass increased significantly following the 8 weeks of resistance training, 
(F(1,22)=220.320, p<0.01).  Again there was no significant difference between the supplement and 
placebo groups. 
 
Strength Measures 
 Significant improvements were observed in the 1-repetition maximum of the back squat, bench 
press, leg extension, leg curl, and lat pull-down exercises (all p>0.05). 
 Non-significant improvements were observed in the dead lift, incline press, and bicep curl 
exercises. 
 The supplement group was not different than the placebo for all strength measures except bench 
press F(1/22 )=4.843, p=0.039 (Kudrna et al., 2011). 
 
Inflammation Markers 
 Significant differences in the Skeletal muscle IL-6 was observed across the four time points (pre-
& post-training and pre-& post exercise; F(3,69)=14.641, p<0.01 was lower pre- and Post Exercise 
in the post-training samples compared to the initial pre-exercise pre-training time point. 
 No significant differences were observed in serum cytokine levels for:  IL-1-α, IL-1β, IL-2, IL-4, 
IL-6, IL-8, IL-10, IFN-γ, or TNF-α. 
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